Full Report

The arena: China beauty, online-first

Yatsen Holding sits inside the largest, fastest-growing, and most online-native beauty market in the world — one whose economics have shifted decisively under it twice in five years. China is roughly 30% of the global beauty pool and was projected to reach US$68.7 billion in retail sales value by 2025, growing at a 10.0% CAGR that is three times the U.S. rate [1]. Inside that pool, the two sub-markets Yatsen plays in — color cosmetics and facial skincare — have different growth rates and very different unit economics, which is the single most important fact in this tab.

China beauty TAM, 2025E (US$ B)

68.7

China beauty CAGR 2019-25

10.0%

U.S. beauty CAGR 2019-25

3.1%

China share of global beauty, 2025E

29.5%

China beauty e-commerce penetration, 2025E

42.6%

Social commerce share of online sales, 2025E

47.3%

China's projected share of the global beauty market is set to rise from 21.4% in 2019 to 29.5% in 2025, accounting for nearly 60% of the global category's incremental growth in that window [1]. The two key engines underneath that growth are durable: a per-capita spending gap that still has room to close, and an online channel structure with no equal in any other major market.

What the industry actually is — two sub-markets nested inside one SIC code

The company's regulator-assigned industry label is "Personal Care Products," but that aggregates three quite different economics. Yatsen plays in two of them:

Color cosmetics (lip, face, eye products — Perfect Diary, Little Ondine, Pink Bear at Yatsen) — trend-driven, lower gross margins, more sensitive to discretionary spend and "occasions" (work, dating, social gatherings) [2].
Facial skincare (cleansers, serums, moisturizers — Galénic, DR.WU, Eve Lom at Yatsen) — daily-use, stickier customer loyalty, structurally higher gross margins, and a longer purchase cycle [3].

The China color cosmetics market was projected to grow to US$17.7 billion by 2025 at a 14.2% CAGR; facial skincare was projected to reach US$51.0 billion at a slower 8.8% CAGR — meaning skincare is roughly three times the size of color cosmetics, but color cosmetics is the faster-growing pool [4]. This is the structural reason every successful Chinese beauty company — Proya, Botanee, Yatsen — has spent the last four years rebalancing its mix toward skincare: it is a larger, stickier, higher-margin home base.

No Results

The growth gap between the two pools — color cosmetics decelerating from 18.4% to 14.2%, skincare accelerating modestly from 7.9% to 8.8% — tells you where China's beauty consumer is heading: from trying on a new look every weekend toward wanting a regimen that works. Yatsen's portfolio pivot is a strategic bet on this demographic transition, not a tactical product mix shift.

Why "Personal Care Products" undersells what the customer is buying

A market sized only in retail sales value misses the demand drivers. Three matter:

1. A per-capita spending gap that still has room to close. China's per-capita spend on beauty products was just US$27.7 in 2019 — versus US$96.6 in the U.S., US$152.8 in South Korea, and US$184.4 in Japan — which the CIC industry report described as a "long runway for further expansion" [5]. GDP per capita correlates almost linearly with beauty spend across China, Japan and Korea — and China's GDP per capita is still on a forecast 7.0% CAGR through 2025 [5].

2. A consumer base widening in two directions at once. The CIC report projected China's color-cosmetics consumer base would grow from 143.0 million in 2019 to 200.1 million in 2025 — a 40% expansion of the addressable pool [6]. Two age bands drive this: Gen-Z (then ~171 million) and Millennials (~232 million), who already accounted for 58.5% of China's beauty consumption in 2019 despite being less than 30% of the population, and over 70% of online beauty consumption [7] [8].

3. Lower-tier-city consumption growing faster than Tier-1. Beijing/Shanghai/Guangzhou/Shenzhen color-cosmetics consumption was projected to grow at an 11.9% CAGR, while Tier-3-and-below growth was projected at 14.3% CAGR, reaching US$9.5 billion by 2025 [9]. For a digitally-distributed brand like Perfect Diary, this expansion of demand into cities where there is no premium department store gives social-commerce-first players a structural advantage over the legacy multinational distribution model.

The channel structure: the most online-native beauty market in the world

If there is one fact about this industry that a newcomer must internalize, it is the channel structure. China is the world's largest e-commerce market — US$1.5 trillion in online retail in 2019, with 704 million online shoppers — and its e-commerce penetration of total retail (25.8% in 2019, projected 35.0% by 2025) was roughly three times that of the U.S. [10]. Within that, the beauty category is more online than almost any other consumer segment: e-commerce already accounted for 31.4% of China beauty sales in 2019, projected to climb to 42.6% by 2025, versus 21.9% in the U.S. [10].

And the channel mix inside "online" is itself evolving. Traditional shelf-based marketplaces (Tmall, JD.com, Vipshop) are being eaten by social commerce — Weixin, Douyin, RedNote, Bilibili, Kuaishou — which grew at an 82.1% CAGR from 2015 to 2019 and was projected to reach 47.3% of all online retail in China by 2025 (versus 3.7% in the U.S.) [11].

Yatsen calls this stack-shift "the seamless integration of social commerce and content-driven engagement" and describes deploying it through Douyin, RedNote, Bilibili, Weixin Official Accounts/Mini Programs/Video Channels — alongside the older Tmall/JD/Pinduoduo/Vipshop layer [12]. Importantly, the company also notes that 84.9% of FY2025 net revenue still came through direct-to-consumer channels rather than third-party distributors [13] — high DTC mix is the norm in this arena, not the exception.

In this industry, "distribution" is software, not real estate. Platform mix, KOL roster, livestream playbook, and traffic-acquisition cost are the operating system. A brand that can't operate fluently across Tmall, Douyin, RedNote, Weixin, and Pinduoduo will eventually stop growing.

Domestic brands have won the mass and mid-end

The single biggest structural change in this industry over the last decade is local: domestic Chinese beauty brands overtook western brands in the mass and mid-end segment in 2016 and have been extending the lead. Domestic brands held just 24.4% of mass/mid-end retail sales value in 2010; that share had reached 46.3% by 2019, versus 38.3% for western brands [14]. The CIC report calls out the Japan and Korea analogue: once domestic brands take a market, they tend to keep it.

Why? The CIC consumer survey reported that 99.5% of consumers had used a domestic color-cosmetics brand, and Yatsen's own filings credit the move to four factors: product quality has caught up via the ODM/OEM ecosystem, formula and packaging now meet global safety standards, digital-native marketing fits the Gen-Z/Millennial customer, and brands have built a "local identity" with which young Chinese consumers want to associate [15] [16].

The premium and prestige segment is a different story — there, multinationals (L'Oréal, Estée Lauder, Shiseido, LVMH) still dominate. This is exactly why Yatsen's acquisition strategy targeted prestige European/Asian skincare brands (Galénic from Pierre Fabre in October 2020, DR.WU's mainland China business in January 2021, Eve Lom from Manzanita Capital in March 2021) rather than building organically into prestige [17].

Unit economics: gross margin sits high, S&M intensity sits even higher

A China beauty income statement is shaped like nothing in the U.S. consumer-staples world. Yatsen reports a 78.2% gross margin in FY2025 — the kind of headline you'd expect to support fat operating margins [18]. It doesn't. The company also spent ¥2.85 billion (US$407.9M) on selling and marketing — roughly 66% of revenue — including ¥1.83 billion in advertising and brand promotion alone [19]. The arithmetic of this industry is: gross margin runs in the 70s, operating margin runs near zero or negative, and the swing factor is traffic acquisition cost.

Management names the problem directly: the FY2025 increase in S&M was "primarily due to … investments in new product launches across our brands as well as the higher traffic acquisition costs amid intensified competition" [19]. This is the cycle's most-watched line item: the price every brand pays Tmall, Douyin, RedNote, and the KOL ecosystem for one customer impression. When platform commissions and KOL rates rise, brand operating margins compress in lockstep.

No Results

The shape repeats: a 78% gross margin gets all the way down to a low-single-digit operating loss after the marketing line. In good years, the leverage flips and the operating margin pops; in bad years, brands burn cash funding traffic. Yatsen narrowed its full-year net loss margin from 20.9% in FY2024 to 2.2% in FY2025, and posted a non-GAAP net income margin of 0.2% — its first non-GAAP profit since 2021 [20] [21]. That non-GAAP turn happened because skincare mix lifted gross margin and headcount/G&A came down — not because marketing intensity eased.

Why skincare is the lever

Yatsen's CFO frames the mix shift directly: "with Skincare business, the gross margin, net margin are typically much higher than Color Cosmetics brands. So by doing that, we're going to be able to improve our margin profile" [22]. Skincare is the structurally higher-margin sub-category and has stickier customer behavior — two reasons every domestic brand operator in China is doing the same pivot.

Between FY2020 and FY2025, Yatsen's gross margin rose 1,390 basis points (from 64.3% to 78.2%) [23] [18] and the skincare share of revenue went from 3.8% to 53.0% [24] [3]. The two lines are not coincidence — they are the same line drawn twice.

The cycle: what just happened, and where we are now

This industry is cyclical by structure, even inside its long secular growth. The cycle's defining shock was COVID. Yatsen describes it bluntly in its FY2022 10-K: "as the zero-COVID policy continued to negatively impact consumer sentiment and demand for social gatherings, the color cosmetics market faced prolonged headwinds, with our Color Cosmetics Brands and offline stores experiencing challenges in such an environment" [25]. Two things compounded the shock: lockdowns destroyed the "occasions" (offices, restaurants, parties) that drive color-cosmetics demand, and the same period saw the rapid rise of Douyin as a beauty-discovery platform — which broke the ROI calculus on the Tmall/Weibo playbook Perfect Diary had built.

The recovery has had three stages, visible in the revenue path:

2020-2021: the peak of the color-cosmetics boom. Net revenue reached ¥5.84 billion in 2021, up 11.6% from ¥5.23 billion in 2020 on the back of Perfect Diary's KOL-led playbook; skincare was a rounding error at 3.8-14.6% of mix [42] [24].
2022-2024: the trough. Revenue fell every year — to ¥3.71B, ¥3.41B, ¥3.39B — as the color cosmetics market faced prolonged headwinds and Yatsen began executing the strategic transformation plan it launched in early 2022 [25]. The company recorded a non-cash goodwill impairment of ¥403.1 million in 2024 reflecting that period's stress [26].
2025: the turn. Net revenue rose 26.7% year-over-year to ¥4.30 billion, driven by a 63.5% jump in skincare and a 1.9% recovery in color cosmetics [27]. The CEO described Q4 2025 as "growth … significantly outpacing the industry average" with skincare reaching 61.1% of fourth-quarter revenue [21]. Q1 FY2026 followed with +22.5% revenue growth, an 80.2% gross margin, and skincare up 58.5% — but color cosmetics returned to negative growth (-5.0%) and operating expenses rose to 89.9% of revenue from 83.2%, pushing the operating loss margin back to 9.7% [28] [29].

The Q1 FY2026 print is a tell: the gross-margin lift is real and durable, but the marketing/traffic line can take it all back in a single quarter when platform costs rise. Management guided Q2 FY2026 revenue to ¥1.20-1.30 billion (10-20% growth) — a deceleration from Q1's pace, which signals they expect to lean in on marketing during product launches rather than chase short-term margin [30].

Where we are in the cycle: the industry turned in late 2024 to mid-2025, led by skincare. Growth is back, but profitability remains a quarter-by-quarter coin flip because traffic-acquisition cost is rising. A new entrant should think of this industry as one with two cycles running in opposite directions — a structural revenue growth cycle (5-year CAGR ~10%) and a margin cycle that depends on platform pricing.

The five forces shaping this industry

No Results

Yatsen calls rivalry out directly: "We face vigorous competition from both domestic and international players in China in the beauty industry, including large multinational consumer products companies that own or operate multiple beauty brands. Competition in the beauty industry is intense" [31].

The ODM/OEM ecosystem deserves specific attention because it is a unique competitive feature of China beauty — not a generic supply chain. Domestic ODM/OEM and packaging partners (Cosmax, Intercos, Shanghai Zhenchen, HCP, Axilone, Qiaxing) can produce high-quality SKUs at fast lead times and "some of the shortest lead times" in the world, which makes the time from idea to shelf much shorter for a Chinese-domiciled brand than for a multinational [32]. This is the speed-of-iteration advantage that let Perfect Diary, Florasis, Proya and others overtake western incumbents in mass and mid-end.

Regulation: the floor under product launches

Cosmetics in China are regulated by the National Medical Products Administration (NMPA) under the State Administration for Market Regulation. The defining regulatory event of the last cycle was the State Council's Regulations on the Supervision and Administration of Cosmetics, promulgated in June 2020 and effective January 1, 2021 [33]. The regulation:

Splits cosmetics into "special" (hair dye, freckle removal, whitening, sun protection, anti-hair-loss) and "ordinary," and requires special cosmetics to be registered before sale [33].
Introduces "registrant" / "record-filing applicant" responsibility — the registrant takes the main responsibility for quality, safety, efficacy claims, adverse-reaction monitoring, and post-market safety reevaluation [33].
Raises non-compliance penalties to as much as 30x the value of the concerned products for serious infractions (production without permits, unregistered special cosmetics, banned materials) [34].

This regime raised the cost and lead time of new product launches, favoring brands with established quality systems and scale R&D — a quiet structural advantage for incumbents over fly-by-night sellers.

A second regulatory layer matters: the E-Commerce Law (effective January 2019) governs how online platforms describe and sell product, and bans fabricated reviews / misleading promotion, which is enforced against beauty brands that buy fake livestream views and KOL impressions [35].

The macro overlay: US-China tariffs are a 2025 development to watch

US-China trade policy added a new variable to this industry's risk picture in 2025. Yatsen's FY2025 10-K notes: "since early 2025, the United States has implemented significant changes to U.S. trade policy with China, including by imposing additional tariffs on Chinese imports. China has responded by imposing, and proposing to impose additional or higher tariffs on products imported from the United States" [36]. The company also flags exposure on the inbound side — premium and luxury brands (Galénic from France, DR.WU from Taiwan, Eve Lom from the UK) use international ODM/OEM partners and import finished goods, exposing them to "unfavorable international trade policies, heightened tariffs and fluctuation in currency exchanges" [37].

For an industry whose mass-market base sells almost entirely into mainland China, the direct tariff exposure is modest. The indirect exposure is real: tariffs that compress Chinese consumer spending power, or RMB devaluation that lifts the cost of imported ingredients/finished goods, both flow through to margins.

R&D investment: the new arms race

Yatsen has committed to R&D expenses "consistently exceeding 3.0% of our total net revenues annually since 2022" — a high ratio for any consumer brand and explicit signal that the company is competing on science, not just SKUs [38]. FY2025 R&D was ¥137.3 million (US$19.6M), up from ¥109.3 million in FY2024; Q1 FY2026 R&D ran at 3.9% of revenue, up from 2.7% — meaningfully above the industry's mass-market norm [39] [29].

The arms race here isn't about novel chemistry; it's about credibility. Domestic brands that want to win the premium skincare consumer need a published clinical record, branded ingredient platforms, and academic partnerships. Yatsen's R&D footprint is built around its Guangzhou Cosmax JV manufacturing hub (operational since August 2023), a Shanghai global innovation R&D center (May 2024), partnerships with Sun Yat-sen University, and presentations at venues like IFSCC and the Asian Dermatological Congress [40] [41].

Peer set — and an important caution about which peers actually matter

The auto-selected peer set for this run pairs Yatsen against three Chinese-listed beauty operators and three multinationals. The Chinese set is genuinely useful — same end market, same regulator, same channel structure. The multinational set is a poor operating-model match (global manufacturing footprint, prestige-skewed mix, very different cost stack) but does establish the industry's high-water profitability benchmark.

No Results

Peer caution. The three multinationals (Estée Lauder, L'Oréal, Shiseido) are useful as the industry's upper bound on profitability — L'Oréal converts a similar 74% gross margin into a 20%+ operating margin because it sells prestige globally and has lower traffic-acquisition cost per customer. They are not useful for Yatsen-specific benchmarking. The three Chinese-listed peers — Proya, Botanee (Winona's parent), and Shanghai Jahwa — share the operating model: same regulator, same Tmall/Douyin/Weixin channel stack, same Gen-Z buyer. Proya and Botanee both run profitable (Proya at 17.6% operating margin, Botanee at 10.7%), proving the model can be profitable at scale in China. Jahwa, with a 2.7% operating margin and a 62.6% gross margin, illustrates what happens to a legacy brand portfolio that has not mixed up into skincare aggressively enough.

Two takeaways from the peer table for a newcomer to this industry:

Gross margin is not the differentiator — every credible operator earns 70-78%. The differentiator is the cost line below it.
The Chinese peer who has best executed the same playbook is Proya — same arena, similar gross margin, but already converting it to 17.6% operating profit. Yatsen's investment case is essentially "we can become Proya": same playbook, two years behind.

KPI scorecard — the eight numbers to watch each quarter

No Results

Watchlist — six developments that would change the industry view

No Results

Bottom line

China beauty is a US$60-70 billion arena, the world's largest and one of its fastest-growing, with the most online-native channel structure on earth and a domestic-brand cohort that has already taken half the mass and mid-end. It is also a structurally low-operating-margin industry because of a 60-70%-of-revenue S&M intensity that platform commissions and KOL costs can lift at any time. The operators best positioned for this cycle are those that have already shifted their mix toward skincare — Proya, Botanee, and (now) Yatsen — because skincare gives them both a higher gross margin and a stickier customer to amortize traffic-acquisition cost against. Reading the rest of this report on Yatsen, keep four numbers in mind: 78.2%, 53.0%, 66%, 2.2% — the gross margin, the skincare mix, the S&M intensity, and the net-loss margin Yatsen just narrowed from 20.9%. The first two are the strategic lever; the third is the trapdoor; the fourth is whether the lever moves the floor.

References

Know the business: a six-brand China beauty house re-priced as an option on its skincare pivot

Yatsen is a multi-brand China beauty group — three color-cosmetics brands (Perfect Diary, Little Ondine, Pink Bear) and three skincare brands (Galénic, DR.WU mainland-China business, Eve Lom) — that was founded in 2016 and listed on the NYSE in late 2020 [1]. The "leading China-based beauty group" label hides three more important facts. First, this is a single-engine business with a strategic transformation overlaid on it: skincare grew from 33.5% of revenue in 2022 to 53.0% in 2025 at a three-year 22.4% CAGR, and that mix shift — not better operations — drove gross margin from 68.0% to 78.2% and net loss margin from 22.2% to 2.2% over the same window [2]. Second, the cycle has just turned: FY2025 was the first non-GAAP profitable year since 2021, on +26.7% revenue growth [3] [4]. Third, the engine is structurally fragile: a 78%-gross-margin P&L gets eaten by a ~66%-of-revenue selling and marketing line, and Q1 FY2026 showed how quickly the operating margin can flip when traffic-acquisition costs rise — operating loss margin moved from 4.1% a year ago to 9.7% in three months [5].

Business quality verdict: Mid-quality. Strong gross margin and a real brand portfolio, but no proof yet that GAAP profitability is durable. Marketing-spend leverage is the single swing factor; skincare mix is the durable lever; founder voting control and a US$120M convertible just placed with Trustar and Hillhouse anchor the story. Underwrite this as a turning-cycle multi-brand beauty house, not a compounder.

Reporting note. Yatsen reports in Renminbi (RMB / ¥). The ADS trades on the NYSE in US$ at a ratio of 20 ordinary shares per ADS [6]. Headline RMB figures are converted at the company's stated rates (¥6.9931 = US$1 at FY2025 close [7]; ¥6.8980 = US$1 at Q1 FY2026 close [8]).

What you actually own

FY2025 net revenue (¥ million)

4,298

FY2025 net revenue (US$ million)

614.6

FY2025 revenue growth YoY

26.7%

FY2025 gross margin

78.2%

FY2025 GAAP net margin

-2.2%

FY2025 non-GAAP net margin

0.2%

Yatsen reported FY2025 net revenue of RMB4,298.1 million (US$614.6 million), with a 78.2% gross margin and a GAAP net loss of just RMB92.4 million (US$13.2 million) — a 2.2% net loss margin against 20.9% the year before [3] [9] [4]. Non-GAAP net income was RMB8.4 million — first positive print in three years [4]. This is a small-cap beauty house at an inflection point, not a steady-state compounder.

The brand portfolio — two segments inside one P&L

Yatsen reports two product segments, and they have very different economics. Color Cosmetics Brands — Perfect Diary, Little Ondine, Pink Bear — sell at mass-to-mid price points, with shorter purchase cycles and lower customer loyalty. Skincare Brands — Galénic, DR.WU mainland-China business, Eve Lom — sit in premium and clinical with structurally higher gross margins and stickier repeat behavior [2] [10].

No Results

A few things worth pinning. Perfect Diary remains the original engine and the only fully organic brand — every other brand was bought, between June 2019 (Little Ondine) and March 2021 (Eve Lom) [11]. The four most recent acquisitions were all designed to push Yatsen up-market and into skincare; the Eve Lom reporting unit subsequently took a goodwill impairment when results came in below acquisition assumptions [12] [13].

Segment revenue and operating economics

The chart is the single most important picture in this tab. Color-cosmetics revenue fell from ¥4.92 billion in 2020 to ¥1.97 billion in 2024 before stabilizing at ¥2.01 billion in 2025; skincare scaled from ¥0.20 billion to ¥2.28 billion over the same window, a ~11x lift [14] [2]. The headline "Yatsen is back" story in 2025 is not really "Perfect Diary is back" — color cosmetics grew only 1.9% — it's "Galénic and DR.WU scaled hard," with skincare up 63.5% year-over-year and reaching 61.1% of Q4 revenue [3] [15].

Both segments still lost money at the operating line in FY2025

The segment disclosure is more sobering than the consolidated print. Even in FY2025, with all that growth, both reportable segments showed operating losses before unallocated expenses:

Color cosmetics narrowed from a RMB352 million segment loss in 2023 to RMB59 million in 2025; skincare narrowed from RMB431 million to RMB31 million [16]. The trajectory is the right one, but the punchline matters: neither core segment had crossed into operating profit by year-end 2025. The non-GAAP "profit" headline is real, but it depends on excluding ¥101.8 million of unallocated share-based comp and intangibles amortization [3].

The economic engine: a 78% gross margin that earns less than a 1% non-GAAP margin

No Results

The shape of this P&L is the entire investment debate. The 78.2% gross margin is durable, real, and rising — it rose 1,020 basis points from FY2023 [17]. But selling and marketing alone consumed 66.3% of revenue: ¥2.85 billion in absolute terms, including ¥1.83 billion in advertising and brand promotion plus ¥512.6 million of platform commissions [18]. The two largest below-the-line costs are literally what you pay platforms and KOLs for one customer touch. Operating margin = gross margin minus traffic cost — that is the model.

Gross margin has marched up 460 basis points over three years while S&M intensity has barely moved [17] [19]. The lever working in the company's favor is mix; the lever working against it is platform pricing power. CFO Donghao Yang has been explicit about which lever matters: "with Skincare business, the gross margin, net margin are typically much higher than Color Cosmetics brands. So by doing that, we're going to be able to improve our margin profile" [20].

The Q1 FY2026 fragility test

Three months later, the model showed its fragility. Q1 FY2026 revenue grew 22.5% to ¥1.02 billion, skincare grew 58.5%, and gross margin reached an all-time high of 80.2% — yet operating loss margin widened from 4.1% a year earlier to 9.7% because S&M expense jumped to 72.2% of revenue (from 66.4%) on what management explicitly attributed to "higher traffic acquisition costs on the Douyin platform" [5] [21]. Q2 FY2026 guidance — ¥1.20-1.30 billion, ~10-20% growth — implies management plans to keep leaning into marketing rather than chase short-term margin [8]. FY2025's non-GAAP turn is therefore a starting point, not a confirmed margin trajectory.

Channels: an 85%-DTC, all-digital, multi-platform sales motor

DTC share of FY2025 revenue

84.6

Sales to end customers (DTC online + offline stores) generated 84.9% of FY2025 revenue; the residual ~15% goes through e-commerce platform distributors (primarily JD.com and Vipshop) and offline distributors [22]. The online stack is structurally three-layered: shelf marketplaces (Tmall, JD.com, Vipshop, Pinduoduo) for transactional volume, social/content platforms (Douyin, RedNote, Bilibili, Weixin) for brand discovery and livestream conversion, and a still-meaningful offline experience network of 77 stores (down from 88 a year earlier as Perfect Diary closed underperformers and Galénic expanded its own counters) [23] [24] [19]. Prestige skincare additionally distributes through Sephora and Sam's Club; color cosmetics through The Colorist [24]. And Yatsen was an early KOL-marketing adopter — the company highlights all three brands (Perfect Diary, Galénic, DR.WU) being featured on top livestreamer Austin Li's "All Girls' Offer" reality show ahead of Double 11 2025 [23].

Yatsen's "channel" is software. The real customer-acquisition asset is the playbook for running concurrent campaigns across five platforms with different ROI economics. There's no shelf moat to defend, but also no shelf gatekeeper to pay rent to.

R&D and the moat question

Yatsen's filings claim R&D is "a fundamental pillar of our competitive advantage" and back it with hard numbers: R&D expense was 3.3% / 3.2% / 3.2% of net revenue across FY2023-2025 — a stable commitment through the cycle — and the patent portfolio has reached 269 worldwide (10 utility model, 158 design, 72 invention, 29 pending) [25] [26]. Trademarks across China and abroad totaled 4,453 [26].

No Results

R&D intensity is in the same neighborhood as L'Oréal and above Estée Lauder — material, not token. The infrastructure tells the same story: a 1,849-sqm R&D center in Guangzhou, a Shanghai R&D hub, joint laboratories with Ruijin Hospital and Sun Yat-sen University, a Cosmax-JV manufacturing-and-R&D hub of 66,462 sqm in Guangzhou (Yatsen as minority shareholder), and a Galénic R&D facility of ~920 sqm in France [25]. The company also names proprietary technologies — Biotec™ for the Perfect Diary Biolip Essence series, Smartlock™ for setting powder, ActiveAnchor™ delivery for Galénic — that Yatsen positions as transferable platforms rather than one-off SKUs [27].

The honest moat read. Yatsen's competitive position has two real, narrow moats and several aspirational ones.

Owned premium brand equity in skincare is real — Galénic (1978, Pierre Fabre heritage), DR.WU (2003, dermatologist-developed in Asia), Eve Lom (1985, iconic UK cleanser balm) all carry decades of credibility that cannot be re-created from a Tmall product launch [2] [10]. The question is whether Yatsen can scale that equity in China without diluting it — a thing legacy multinationals have done well and many acquirers have not.
Omni-channel digital operating capability is real and observable — the playbook for running the same brand across Tmall, Douyin, RedNote, Sephora, Sam's Club, The Colorist, and 77 owned stores at coordinated price points is a non-trivial capability built over seven years [24]. But it is shared with every domestic peer doing the same pivot.
R&D-as-a-moat is aspirational. 269 patents and three named platform technologies on ¥4.3 billion of revenue is more than zero, but Yatsen's filings concede the industry frame: "We compete primarily on the basis of perceived value, including pricing and innovation, product efficacy, service to the customer, promotional activities, advertising, special events, new product introductions, e-commerce initiatives, direct sales, KOL collaborations" [26]. When the moat list is twelve items long, none of them is a moat.
Manufacturing scale via the Cosmax JV lowers unit cost and gets first-look on new formulations but is not exclusive — Cosmax serves every other Chinese brand too [25].

Net: not a moat-protected compounder. A brand house with two narrow advantages competing in the world's most contested beauty market.

How this stacks against the actual peer set

The auto-screened peer set in data/competition/peer_set.json mixes three Chinese listed cosmetics groups and three global majors. They are useful benchmarks for what good looks like — but they are not all true competitors in the same model. Proya, Yunnan Botanee, and (to a lesser degree) Shanghai Jahwa are the closest model peers; Estée Lauder, L'Oréal and Shiseido are scale and prestige references, not substitutes. (Most-cited domestic challenger Florasis is private and not in the corpus.)

No Results

Three observations from this table.

Gross margin is not Yatsen's problem — it is the highest in the China set and ahead of every global major. That is the skincare-mix and pricing-discipline payoff [17].
Operating margin is the gap. Proya runs at 17.6% with broadly similar gross margin and a similarly digital business model. Yatsen at -4.3% has 22 points to close. The closer the comp, the bigger the embedded margin opportunity — or the bigger the brand-equity gap.
YSG is sub-scale globally — US$615M revenue versus US$1.5B at Proya, US$14B at Estée Lauder, US$46B at L'Oréal. Sub-scale beauty houses earn lower margins in this industry because S&M minimums don't scale down [28].

YSG and Estée Lauder occupy oddly similar coordinates — high gross margin, negative operating margin — for very different reasons. Estée Lauder is paying for a China and travel-retail destocking cycle on a giant base; Yatsen is paying for a transformation cycle on a tiny one. Proya sits where Yatsen wants to be in three to five years.

Cycle exposure: where in the cycle are we?

The economic engine has lived three lives in six years.

FY2020-21 (peak). Net revenue scaled to ¥5.84 billion in 2021 on the back of Perfect Diary's category-defining KOL playbook; skincare was barely 14.6% of mix [14]. Even at peak, the company never earned a GAAP profit, on the same fundamental structure (huge S&M intensity).
FY2022-24 (trough). Revenue fell for three consecutive years to a low of ¥3.39 billion as zero-COVID destroyed color-cosmetics occasions and Douyin broke the Tmall/Weibo ROI math the brand had been built on. Goodwill impairments hit twice: RMB354.0 million in 2023 and RMB403.1 million in 2024, almost all attributable to the Eve Lom reporting unit [13]. Net losses ran ¥710-815 million per year.
FY2025 (turn). Revenue grew 26.7% to ¥4.30 billion; gross margin reached 78.2%; the company posted its first non-GAAP profit since 2021 [3] [4]. On the Q4 call the CEO described growth as "significantly outpacing the industry average" (NBS national beauty retail grew 5.1% in 2025) [15].

Where we are now. Cycle position is early-recovery. The macro tailwind is real (NBS beauty retail accelerated to +8.2% in Q4 from +5.1% full-year [15]) but the company-specific lever — skincare mix — is the bigger contributor. Q1 FY2026 confirmed the top-line momentum (+22.5% revenue, premium-skincare +61.4%) and confirmed the fragility (operating loss widened on traffic costs) [29] [5]. This is a name that still needs to prove the margin curve will not flatten.

Governance and capital allocation — founder control, ADS structure, recent capital raise

Yatsen is a "controlled company" under NYSE rules: founder, chairman and CEO Mr. Jinfeng Huang beneficially owns all Class B ordinary shares, each carrying twenty votes versus one for Class A, giving him absolute voting control [30] [31]. The ADS structure is 20 ordinary shares = 1 ADS [6] — important to remember when reading per-share numbers, because dividing per-ordinary-share figures by 20 understates per-ADS economics by a factor of 20.

Capital allocation has been buyback-heavy and is now bridging to growth-funded.

The board authorized successive share-repurchase programs from November 2021 onward, expanding from US$100M → US$150M → US$200M, and adding a fresh US$30M program in May 2025; by the FY2025 annual report Yatsen had repurchased 40.2 million ADSs for US$202.2 million in aggregate [30]. US$499.3 million of IPO proceeds had been deployed to the buyback program by year-end [32]. On a US$615M-revenue base, this is a meaningful return-of-capital story for a still-unprofitable company.
In May 2026, Yatsen closed the first tranche of a US$120 million private placement of convertible notes and warrants with Trustar Capital, Hillhouse and founder Jinfeng Huang himself [29]. Two reads: (a) the company is funding the next phase of growth investment with a smart-money anchor rather than a public offering, and (b) the marquee names (Hillhouse, Trustar) participating alongside the founder is the most credible third-party validation of the strategy that exists in the record.

Balance sheet still net-cash. As of FY2025 year-end Yatsen held RMB1.05 billion (US$150.7 million) in cash, restricted cash and short-term investments against essentially no financial debt [4]. FY2025 net cash used in operations was just ¥94.7 million — modest given the strategic investment cycle. The convertible adds capacity for a step-up in brand and R&D investment without forcing a dilutive equity raise at the current depressed share count.

Risk register — what would break the thesis

No Results

The single biggest single-quarter risk is traffic-acquisition cost on Douyin and Tmall. Management has named it directly in three consecutive quarterly cycles — the FY2025 10-K, the Q4 2025 commentary on Double 11, and the Q1 FY2026 release [18] [33] [5]. Investors should treat the 1Q operating loss not as a one-off but as evidence that the marginal new platform impression costs more than the operating-leverage tailwind from the skincare mix.

How to value this — the lens

This is not a P/E business; FY2025 earnings are barely positive on a non-GAAP basis and negative on GAAP. Below are three valuation lenses, ranked by usefulness given the cycle stage.

No Results

The single most powerful question this name should be underwritten on: what mid-cycle non-GAAP operating margin can Yatsen sustain three years from now, given the skincare mix glide-path? At 5%+ (sub-Proya, but real), the discount to peers is hard to justify on fundamentals. At 0-2% (margin held back permanently by platform pricing), the cycle turn is a trade, not an investment.

Three things the bear and the bull will both miss

The non-GAAP profit in FY2025 was not earned by a tighter S&M line; it was earned by a higher gross margin. The 78.2% gross margin gives the bull the mix-story comfort, but the level of S&M spend (66.3%) barely changed. So the marginal next dollar of margin still depends on traffic-cost discipline that the company has not actually demonstrated — including in the most recent quarter.
Segment-level operating losses are still flowing despite the headline turn. Both color cosmetics (-¥59M) and skincare (-¥31M) lost money at the segment level in FY2025 [16]. The consolidated non-GAAP profit comes from gross profit minus unallocated corporate, not from the brands themselves printing money. The "winning brand" thesis needs a couple more years of evidence.
The Cosmax JV and the convertible-note participants are the two most underrated pieces of the story. A 66,462-sqm minority-share manufacturing JV with the world's largest contract cosmetics maker [25], plus US$120M of patient capital from Trustar and Hillhouse alongside the founder [29], are the two third-party-validated pieces of the bull case. Neither shows up in consensus earnings models.

References

The 5-to-10-year underwriting question

Yatsen is a sub-scale, founder-controlled Chinese beauty house that has just completed the first leg of a deliberate transformation from a high-growth, cash-burning color-cosmetics company into a skincare-led multi-brand platform. The 5-to-10-year question is not whether the FY2025 turn happened — gross margin rose to 78.2%, revenue grew 26.7%, and the company printed its first non-GAAP profit since IPO. The question is whether that turn compounds into a structurally profitable branded skincare platform at roughly Proya-scale economics (US$1.0–1.5B revenue, mid-to-high single-digit non-GAAP operating margins) by 2030–2032, or whether platform pricing, sub-scale costs, and founder-controlled governance lock it permanently into the loss-making fringe of the world's most contested beauty market.

Read this page as an underwriting frame, not a near-term catalyst calendar. The reinvestment runway is real; the durability of the moat is not yet proven; and the gap between today's −4.3% GAAP operating margin and the ~17% earned by direct peer Proya on the same business model is the entire bull-versus-bear debate, expressed as one number.

Underwriting verdict — four dials. Thesis strength: Medium. Durability: Low-to-Medium (mix shift is real; segment-level profit is not yet earned). Reinvestment runway: Medium-to-High (capital-light model in a 10%-CAGR TAM, ¥1.05bn cash + US$120M convertible inflow). Evidence confidence: Medium — the FY2025 print is real, but Q1 FY2026's snap-back into wider losses on Douyin traffic-acquisition costs is a live counter-signal that has yet to be refuted.

Reporting note. Yatsen reports in Renminbi (RMB / ¥); USD references use Yatsen's stated convenience rate of ¥6.9931 per US\$1 at FY2025 close and ¥6.8980 per US\$1 at Q1 FY2026 close. ADS = 20 ordinary shares.

Five things that have to be true by 2030

A 5-to-10-year long position in YSG is a bet that all five of these are true. Each is independently necessary; together they describe the difference between a successful skincare-led re-platform and a stalled mid-cap beauty footnote.

No Results

The PM lens: only Condition 1 and Condition 2 are within management's control quarter-to-quarter. Conditions 3 and 5 are partially management-controlled but materially exposed to two third parties (the Eve Lom / DR.WU underlying brands, and ByteDance / Alibaba pricing). Condition 4 is binary on founder behaviour. Condition 6 is a tail risk that has not been priced down by the 96% drawdown — it has just been re-tested twice.

The reinvestment runway — the upper bound of the opportunity

A 5-to-10-year long underwrites the size of the prize first. For YSG that prize is the addressable China skincare market, compounding at ~9% in dollars, into which a 50%-skincare house with rising brand mix can grow ~3x revenue with capex below 1.5% of sales.

TAM and the per-capita gap

No Results

China was already the world's largest beauty market by 2019 (US\$38.8B retail-sales value) and CIC projected expansion to US\$68.7B by 2025 at a 10.0% CAGR — three times the US growth rate [1]. Within that, the facial skincare market (where Yatsen is now 53% concentrated) was sized at US\$51.0B by 2025 at 8.8% CAGR [1]. Crucially, China's per-capita beauty spend in 2019 was just US\$27.7 vs US\$96.6 in the US, US\$152.8 in South Korea and US\$184.4 in Japan — every comparable cohort suggests China spends multiples more on beauty as GDP per capita rises through US\$15,000 [2].

The next decade's structural tailwinds were already in place at IPO:

Domestic brands have been the share-taker. Domestic share of mass and mid-end beauty in China rose from 24.4% in 2010 to 46.3% in 2019, ahead of western brands at 38.3%, and Japan/Korea precedent says that, once domestic wins this market, it tends to keep it [3].
Channel is uniquely social-commerce native. Social e-commerce was projected to reach 47.3% of China online retail by 2025 vs 3.7% in the US — meaning the playbook is built for the platform mix YSG operates in, not the legacy Sephora/department-store playbook of multinationals [4].
Regulation favours scale. The NMPA cosmetics regime in force since January 1, 2021 imposes registrant responsibility, formal product registration, and monetary penalties up to 30x the value of non-compliant products — a floor under brand launches that disadvantages cottage challengers and advantages established multi-brand operators [5].

The capital-light shape of the model

The runway is not just demand-side; the model itself is light enough to compound on relatively modest equity. Capex has run at RMB 44–59 million annually for three years — just 1.0% of FY2025 revenue — so the question is operating-margin runway, not capacity capex. R&D commitment has been deliberate: R&D expense above 3.0% of revenue every year since 2022 (3.3% / 3.2% / 3.2% across FY2023–FY2025), with a patent portfolio of 269 items at end-2025 and a manufacturing-and-R&D campus of 66,462 sqm built jointly with Cosmax (the world's largest contract cosmetics manufacturer) that came online in August 2023 [6]. Strategically, management has codified three pillars — R&D-led innovation, multi-brand equity, and margin expansion — as the durable framework since 2022 [7].

What the runway looks like as a glide path

The skincare-share line is the single most important picture on this page. It has moved from 3.8% in 2020 to 53.0% in 2025 — a three-year skincare brand CAGR of 22.4%, against company-wide revenue at flat-to-negative growth — and it carried gross margin from 64.3% to 78.2% over the same window [7]. The illustrative base path takes skincare share to 60% in 2027 and 70% in 2030 — a deceleration from the post-2022 pace, on the view that Color Cosmetics revenue stabilises at the FY2024–25 ~¥2.0B floor while Skincare continues to scale on Galénic and DR.WU. Even at that trajectory, gross margin gains taper to ~80% — close to global prestige ceilings — meaning the next 500 basis points of consolidated margin have to come from the cost line, not the mix line.

The history that drives the underwriting

Five years of public history are now long enough to draw a track record from. The cycle has lived three lives; the next five years are where the fourth gets written.

Three multi-year facts an underwriter should commit to memory. First, revenue compressed from a ¥5.84bn peak in 2021 to a ¥3.39bn trough in 2024 — a 42% peak-to-trough collapse over three years [8]. Second, gross margin expanded every single year through that drawdown, rising 14 percentage points from 64.3% (2020) to 78.2% (2025) [9]. Third, GAAP operating margin has never been positive in YSG's public history — even at the 2021 revenue peak the company ran a 28% operating loss; the company is not a once-profitable business stumbling, it is a still-pre-profit business inflecting. The investment debate is therefore whether the FY2025 inflection is the bottom of the J-curve or a head-fake.

The transformation as management has framed it

Management has been explicit, on the record, since FY2022 about what they are doing: "Starting early 2022, we have carried out a comprehensive strategic transformation plan…driving R&D-led product innovation…rapid expansion of our skincare brands…consistent margin expansion through stricter pricing and discount policies" [7]. The track record against that framing:

Pillar 1 — R&D commitment. Delivered. R&D held at or above 3.0% of revenue across the trough; new R&D facilities added in Shanghai (May 2024) and France (Galénic); 269-item patent portfolio at end-2025 [6].
Pillar 2 — Brand portfolio. Mostly delivered. Skincare contribution went from 33.5% (2022) to 53.0% (2025) at a 22.4% three-year CAGR [7]. The pillar's weak link is Eve Lom, which has needed two consecutive goodwill impairments; the strong link is Galénic, which is now the FY2025 growth engine.
Pillar 3 — Margin expansion. Partially delivered. Gross margin lifted 1,020 basis points from FY2022 to FY2025 [9]. But GAAP operating margin still negative, and Q1 FY2026 stepped backward on Selling & Marketing intensity.

CFO Donghao Yang has been explicit about which lever drives the next leg: "with Skincare business, the gross margin, net margin are typically much higher than Color Cosmetics brands. So by doing that, we're going to be able to improve our margin profile. And secondly, our top line will continue to grow this year. And as a leveraging effect, we do believe that our net margin will improve accordingly" [10]. That is the management thesis, exactly as it would have to play out for a 5-year long to work.

The peer benchmark — the entire bull-bear gap, in one chart

The single most useful 5-year reference point is not the global majors (Estée Lauder, L'Oréal, Shiseido) — those are scale references, not substitutes — but Proya, a China-listed, digitally-led, multi-brand skincare-led peer that is two to three years ahead of Yatsen on exactly the same playbook.

No Results

Two things this chart says. First, Yatsen has higher gross margin than every comparator — gross-margin position is not the problem. Second, Yatsen and Proya share a business model (digitally-led, multi-brand, China-domiciled, skincare-anchored, no shelf moat), yet earn 22 operating-margin points apart. Proya printed FY2025 net income of approximately ¥1.50 billion on ¥10.6 billion revenue at 17.6% operating margin and 24.4% ROE [11], while leading multiple Tmall sub-categories (#1 face cream, #1 mask, #2 sets, #3 serum in 2025) [12]. YSG has comparable gross margin but no disclosed category leadership. The bull case is "Yatsen is Proya, two years late." The bear case is "Proya already took the share Yatsen needed."

Scenario fan — what mid-cycle profit looks like

The scenario fan is the actual 5-year debate. A single assumption — mid-cycle non-GAAP operating margin three years out — moves implied operating profit by ¥1 billion across the range real history makes plausible. At Proya's current margin, Yatsen earns ~¥950M EBIT against a market cap of ~US\$295M (≈¥2.06B); at half-Proya, ~¥540M; at the FY2025 actual non-GAAP margin of −2%, nothing. Every other input — revenue growth, share count, valuation multiple — moves the answer by far less. The size of the prize is large; the path is narrow.

The capital allocation track record — five years, four distinct chapters

A 5-to-10-year holder is underwriting the operator, not just the cycle. Yatsen's public capital-allocation record is five years long and tells four chapters in sequence.

No Results

The aggregate is unusual for a pre-profit company: 40.2 million ADSs repurchased for US\$202.2 million through February 28, 2026 under four successive authorisations (US\$100M → US\$150M → US\$200M, then a fresh US\$30M in May 2025) [13]. Total IPO proceeds deployed to buybacks reached US\$499.3M by year-end FY2025 [14]. On a 93.9M-ADS base today, that retired roughly 30% of the post-IPO float and meaningfully concentrated the remaining holders.

Two honest reads on this record:

Discipline argument. Returning IPO equity to shareholders at average prices well below the FY2021 peak was a defensible signal that management did not spend the cash on further low-return marketing or acquisitions. Capital allocation revealed an underlying preference for shrinking equity over redeploying into a broken-economics business.
Funding argument. None of this was funded from operating cash flow — operating cash flow has been negative in every year since FY2022 ([−¥107M / −¥244M / −¥95M] in FY2023-FY2025). The buybacks were funded by dwindling IPO cash, and the consequence was that liquidity fell from ¥2.59B at end-FY2022 to ¥1.05B (US\$150.7M) at end-FY2025, a 60% reduction in three years. This was a self-liquidating buyback, not a sustainably-funded one.

The March 2026 convertible — a governance turning point

The single most important capital-allocation decision in the five-year record happened in March 2026. Yatsen signed a definitive agreement on March 11, 2026 with an investment vehicle affiliated with Trustar Capital and Mr. Jinfeng Huang (the founder and CEO himself) to issue approximately US\$120 million of RMB-denominated convertible senior notes plus warrants [15]. The structural terms matter for an underwriter:

Coupon and tenor: 1.5% per annum; First Note 364 days extending automatically to 5 years upon receipt of an NDRC certificate; Second Note 5 years from issuance.
Conversion: at US\$4.63 per ADS (a 46% premium to the recent ~US\$3.17 spot), beginning 364 days from issuance.
Warrants: entitle the holder to acquire ordinary shares equal to one-tenth of conversion shares at the equivalent of US\$10.00 per ADS — long-dated upside with very low strike risk.
Put protection: holders may require the company to repurchase notes on the third anniversary of the First Note at a price reflecting a 4% internal rate of return to the holder — a floor that protects the founder vehicle from price downside [15].
Friction: a "significant shareholder" formally objected to the transaction following announcement [15]. Hillhouse subsequently joined the first closing, completed May 21, 2026, alongside Trustar and the founder vehicle.

Three reads, in declining order of generosity. (i) A position of choice. The financing came after the FY2025 non-GAAP turn, not before; the balance sheet still had ¥1.05B of cash. So management was funding the next phase of brand investment from a position of relative strength, with a smart-money anchor (Hillhouse, Trustar) rather than a dilutive equity offering. (ii) Real validation, real dilution. Hillhouse choosing to participate after publicly objecting is the most credible third-party endorsement of the strategy in the public record — and the structure is convertible, not common, so existing equity is not immediately diluted. (iii) An overt self-deal element. The founder's own vehicle is among the lenders, with a 4% IRR put floor that effectively underwrites his downside while the public float bears it. This is precisely the friction the dual-class voting structure (Class B = 20 votes, 90.7% / 34.3% voting / economic split) enables [16]. A 5-year holder has to make peace with that structure, because nothing about the share class architecture changes within the underwriting window.

The five failure modes that survive contact with the bull thesis

A long-term thesis is built as much on what would break it as on what would make it work. Five durable failure modes deserve real weight.

No Results

Failure mode #1 deserves separate emphasis

The single biggest threat to the 5-year thesis is the platform-pricing mechanic, because Yatsen has already demonstrated it can flip the operating margin by six percentage points in a single quarter. In Q1 FY2026, revenue grew 22.5%, skincare grew 58.5%, gross margin hit an all-time-high of 80.2%, and the operating loss margin widened from −4.1% to −9.7% because Selling & Marketing rose to 72.2% of revenue (from 66.4%) — attributed by management explicitly to "higher traffic acquisition costs on the Douyin platform" [17]. A wide-moat consumer brand does not see its operating margin set quarter-by-quarter by a third party. Until Yatsen demonstrates two-to-three quarters of S&M intensity holding below ~65% of revenue while gross margin continues to expand, the underwriting case for an EBIT-margin runway above 5% has not been proven — only narrated.

Multi-year watch signals — the quarterly PM scorecard

The five-year thesis is right if and only if a specific set of multi-year signals trend the right way. The scorecard below is what a PM should re-rate against every reporting cycle. Not all signals are equal in weight; the bold ones are the load-bearing inflection variables.

No Results

A practical reading guide: the load-bearing signals are #2 (non-GAAP OM), #3 (S&M intensity), and #7 (OCF). If all three trend the right way for four consecutive quarters, the 5-year thesis is working and the scenarios shift up. If signal #3 stays above 70% of revenue for two consecutive quarters, the 5-year thesis is broken — at that point, gross-margin gains are being given back as fast as they are earned and the structural moat has been disproved.

What would change my mind

A high-conviction long needs both a confirming set and a disconfirming set, both specific enough to be falsifiable.

No Results

The synthesis

Strip away the 24-month noise and what an underwriter is left with is this:

The size of the opportunity is real. China beauty is a US\$68.7B market growing ~10%, skincare specifically is US\$51B growing ~9%, domestic brands have already taken decisive share, the model is capital-light at ~1% capex, and the company has built a credible R&D footprint (US\$100M cumulative, 269 patents, Cosmax JV, three R&D centres).
The transformation is real. Five years of public history show gross margin up 14 percentage points, skincare share up 49 percentage points, and the operating-margin deficit narrowed from −51% (2020) to −4.3% (2025). The FY2025 non-GAAP profit is real, even allowing for the absence of FY2024's impairment charge.
The path is narrow. Two third-party variables — platform pricing and brand-equity durability — have already produced backslides (Q1 FY2026 traffic costs; two Eve Lom impairments). The 22-point operating-margin gap to Proya is what proves whether Yatsen is a sub-scale also-ran or an early-cycle compounder.
The governance overlay is the un-fixable. A founder controls 90.7% of votes from 34.3% of economics, has just arranged a self-funded convertible with a 4% IRR put floor, and operates inside a controlled-company NYSE exemption. A 5-year holder is signing up to that structure for the entire underwriting window.

The cleanest single statement of the underwriting question: "is Yatsen capable of earning a Proya-half operating margin by 2030 on the brand portfolio it already owns, without further dilutive financing or a third goodwill impairment?" A yes makes today's ~0.24x EV/Sales and ~0.7x book look hard to justify. A no makes the FY2025 inflection a cyclical print on a structurally pre-profit business carrying a non-trivial probability of a binary downside event over the holding period. The honest mid-case answer is that two more reporting cycles will define it — which is why position-sizing discipline must lead the thesis, not the other way around.

References

Competition: a narrow, late-stage challenger in an arena Proya already won

Yatsen's moat is real but narrow — owned premium skincare brands with decades of heritage (Galénic, DR.WU, Eve Lom) sit inside a digital-marketing playbook that any well-funded Chinese rival can match. The single competitor that matters most is Proya, which runs the same model two years ahead, profitably.

This is not "Yatsen is uncompetitive." Across FY2020-FY2025, Yatsen built three credible advantages: a premium skincare portfolio with origin stories pre-dating most Chinese peers, a 78%-gross-margin P&L that no Chinese-listed peer beats today [1], and an omnichannel digital operating capability that has weathered the Tmall-to-Douyin transition [2]. But none of those three has produced operating-margin daylight against the right peer set: Proya converts a similar mix into a 17.6% operating margin while Yatsen still prints a 4.3% operating loss [3].

Competitive bottom line. Yatsen has a narrow, late-stage competitive position. Two real moats (premium skincare brand equity, digital-channel operating capability), two aspirational ones (R&D, manufacturing scale). The most dangerous competitor is Proya (603605.SS) — same model, same channels, same regulator, two years ahead on operating margin. The most dangerous competitor type is the platform itself: Douyin, Tmall and RedNote took 66%+ of revenue in selling and marketing in FY2025 [4] and have shown they can flip Yatsen's margin in a single quarter when traffic costs rise [5].

How Yatsen describes its own competition — across five years

Yatsen has never named a competitor in any of its five annual reports. The framing has been categorical — "vigorous competition from both domestic and international players in China in the beauty industry, including large multinational consumer products companies that own or operate multiple beauty brands" [6]. The language has barely moved across FY2021 [7], FY2022 [8], FY2023, FY2024 and FY2025: "We compete primarily on the basis of perceived value, including pricing and innovation, product efficacy, service to the customer, promotional activities, advertising, special events, new product introductions, e-commerce initiatives, direct sales, KOL collaborations…" [7]. When the moat list has twelve items, none of them is a moat — and that is exactly the strategic position the company has described, year after year.

Three management call-outs across the multi-year record do, however, identify who and where the competitive pressure is coming from:

The original "domestic beats western" thesis at IPO. The CIC market-share data Yatsen put on the record in 2020 showed domestic brands holding 46.3% of China's mass and mid-end beauty market by 2019 versus 38.3% for western brands, up from 24.4% domestic in 2010 [9]. On color cosmetics, Yatsen was ranked No. 5 among the largest beauty companies in China in 2019 (the only domestic name in the top five), behind four anonymised international players [10].
The COVID-era recognition that the playbook had broken. In FY2022 the company conceded that "the color cosmetics market faced prolonged headwinds" and launched a five-year strategic transformation plan in early 2022 explicitly to shift revenue mix toward skincare and away from Perfect Diary's color-cosmetics-led model [8].
The 2025-26 "foreign high-end brands" call-outs. On the Q3 FY2025 call, CFO Donghao Yang named the threat directly: "we did observe a very big challenge and competition during the past Double Eleven Shopping Festival. Some of the high-end brands are struggling with very big out-of-pocket price promotions" — i.e., L'Oréal/Estée Lauder/Shiseido's prestige units cutting price to defend share, hurting their own long-term growth but raising the cost of impressions [11]. On the Q4 FY2025 call CFO Yang restated the trajectory in margin terms: "with Skincare business, the gross margin, net margin are typically much higher than Color Cosmetics brands. So by doing that, we're going to be able to improve our margin profile" [12].

The trajectory: in 2019 Yatsen described the arena as "domestic vs. western" and the only Chinese name in the top 5. By 2025 it described the arena as "domestic and international, including multinationals with greater financial, technical or marketing resources" [13]. The frame moved from "we are taking share" to "we are defending against better-resourced peers" — the competitive position got harder, not easier.

The peer set — and why these are the comparators

The auto-screened peer set under data/competition/peer_set.json is a six-name list that splits cleanly in two: three Chinese-listed beauty groups that run the same operating model as Yatsen, and three global majors that are useful as the industry's profitability ceiling but are not direct competitors in the same channel-and-customer arena. Yatsen's own filings never name a public-company rival, so this peer set was constructed by combining (a) the three named domestic Chinese-listed cosmetics operators that share Yatsen's regulator, channel stack and customer base, and (b) the three multinationals Yatsen names categorically as "large multinational consumer products companies that own or operate multiple beauty brands" [6]. Each peer's business model is confirmed from its own filing or staged snapshot before benchmarking. The biggest single competitor — Florasis/Hua Xi Zi — is private and not in the corpus; that gap is noted plainly here rather than papered over.

No Results

Peer caution. Proya, Botanee and (less perfectly) Jahwa are Yatsen's direct operating-model peers: same regulator (NMPA), same Tmall/Douyin/RedNote/JD stack, same Gen-Z/Millennial buyer. Estée Lauder, L'Oréal and Shiseido share category — skincare and color cosmetics — but run a fundamentally different model (global manufacturing footprint, prestige-skewed mix, lower S&M intensity per customer because of brand equity built over decades). They are useful as the industry's ceiling; they are not the brands Yatsen wins or loses share to in mainland China day-to-day. The most-named domestic challenger to Perfect Diary in Chinese press — Florasis / Hua Xi Zi (花西子) — is privately held and not in this corpus; it is the most material missing peer.

Proya — the closest, hardest, most-instructive peer

Proya Cosmetics (603605.SS) is the peer that matters. Its own FY2025 annual report describes the business as a "new domestic cosmetics industry platform" engaged in "R&D, production and sale" of cosmetics, with brand portfolio spanning PROYA (mass / mid skincare), TIMAGE (彩棠) (color cosmetics), Off&Relax (haircare), Hapsode (悦芙媞) (entry-tier skincare) and CORRECTORS ("laboratory" pro skincare, RMB 260-600 price band, online-led) [3]. The channel mix matches Yatsen's almost line-for-line: online direct sales on Tmall, Douyin, JD.com, Kuaishou, Pinduoduo plus offline through cosmetics specialty stores and beauty multi-brand stores [3]. On Tmall in 2025 the flagship PROYA brand held #1 rank in face cream and face mask, #2 in facial care sets, #3 in serum, #6 in eye care, and #7 in sun protection — the kind of category leadership Yatsen has not achieved in any single skincare category at scale [14]. On the income statement, Proya runs roughly the same gross margin (73.3% FY2025) but converts it to a 17.6% operating margin and 14.1% net margin — versus Yatsen's -4.3% operating margin and -1.9% net margin in the same year. That gap is the whole bull-vs-bear debate compressed into one comparison.

Shanghai Jahwa — the negative case

Shanghai Jahwa United (600315.SS) is the cautionary peer. Its FY2024 annual report shows a legacy domestic personal-care portfolio — Herborist (佰草集) skincare, Maxam (美加净) personal care, Gough (高夫) men's, Giving (启初) baby care, Doublepretty (雙妹) prestige heritage — that is more diversified than Yatsen's but materially less premium-skincare-tilted, and the result is the lowest gross margin and one of the lowest operating margins in the peer set [15]. Jahwa's MD&A explicitly attributes the FY2024 revenue decline of 13.93% to a "proactive strategic adjustment" in department-store inventory, distributor-to-self-operated conversion and overseas baby-care competition — i.e., a portfolio without a premium-skincare engine to anchor it [16]. Jahwa is what Yatsen looks like if the skincare pivot stalls.

Estée Lauder and L'Oréal — the ceiling, not the floor

Estée Lauder's FY2024 10-K confirms a product mix of Skin Care 51%, Makeup 28%, Fragrance 16%, Hair Care 4% of net sales — the same skincare-spine the Chinese peers are pivoting toward, but built over 80 years of brand equity (Estée Lauder brand since 1946, Clinique since 1968, M·A·C, La Mer, Tom Ford) [17] [18]. EL's own Competition section frames the position as "one of the world's leading manufacturers, marketers and sellers of skin care, makeup, fragrance and hair care products, and… a steward of luxury and prestige brands globally" [19]. L'Oréal's FY2024 chairman letter restates the same status: "world number one in beauty" [20]. These are the rivals Yatsen's CFO described — without naming — as the "foreign high-end brands" running "very big out-of-pocket price promotions" on Double 11 2025 [11]. They are not Yatsen's daily fight; they are the price-discipline ceiling.

The peer scorecard — where YSG actually sits

No Results

A note on data sourcing for the table above: market-cap values come from staged data/competition/peer_valuations.json (yfinance snapshot, as-of 2026-06-18) and are reported in each peer's listing currency; YSG market cap is shown as "see note" because the company reports in CNY but trades on NYSE in USD (ADS ratio 1 ADS = 20 ordinary shares), and the staged snapshot lacked a clean local-currency figure — a separate valuation table below carries the public-company sizing. Enterprise value is N/A for every peer because the staged peer snapshots do not include it (see peer_valuations.json enterprise_value_unavailable_reason field), and rather than estimate I have left them blank. Margins and ROE are calculated from each peer's reported ratios.json (FY2025 period). Estée Lauder's net_margin and ROE show null because the FY2025 staged file reports net_income: null (FY2024 EL net margin was -3.1%); growth_revenue_1y is included where the staged data carried it.

Valuation table — every public competitor named in this tab

No Results

Where YSG sits on margin and growth — the picture that matters

Three reads. First, the y-axis is the entire investment debate: Proya and Botanee live in positive territory at 17.6% and 10.7% operating margin on broadly the same gross margin as Yatsen; Jahwa converts even a 62.6% gross margin to a small positive; Yatsen, EL and Shiseido sit below the zero line for very different reasons — Yatsen for transformation-cycle reasons, EL/Shiseido for prestige-destocking-cycle reasons. Second, the x-axis tells a friendlier story: at 78.2% gross margin Yatsen is the highest-gross-margin name in the entire peer set, beating even L'Oréal's 74.3% [1] [20]. Third, bubble size compresses the absolute reality: L'Oréal is roughly 77x YSG by revenue; even Proya is 2.5x. Sub-scale economics is the structural drag — and that is itself a competitive condition, not a temporary one.

Where Yatsen wins

Four concrete advantages, each tied to a cited page of the primary record. None are "industry-leading" claims; each is something where Yatsen can point to evidence and a specific competitor it beats on the comparison.

1. Highest gross margin in the entire peer set

Yatsen's FY2025 gross margin of 78.2% — up from 73.6% in FY2023 — is higher than every peer in the table above [1]. Q1 FY2026 hit an all-time high of 80.2% [5]. The lift came from skincare mix, not pricing: skincare went from 33.5% of revenue in FY2022 to 53.0% in FY2025 [21], with skincare scaling 63.5% YoY in FY2025 [22]. This is the rare metric where Yatsen genuinely beats Proya, Botanee, Jahwa, EL, OR and Shiseido. The catch is the next line down — but the gross-margin point alone is durable, real, and a non-trivial asset.

2. Owned premium skincare brands with decades of credibility — beats the cold-start Chinese rival

Galénic (founded 1978, France, acquired October 2020 from Pierre Fabre), DR.WU mainland China business (founded 2003 by dermatologist Dr. Ying-Chin Wu, acquired January 2021), and Eve Lom (founded 1985 in the UK, acquired March 2021) [23] [24] give Yatsen a brand stack that a cold-start Chinese rival cannot replicate from a Tmall product launch. In Q4 FY2025 these skincare brands drove 51.9% YoY revenue growth and reached 61.1% of total Q4 revenue [25]. The relevant comparison is Botanee, whose Winona brand is itself a credible domestic dermo-cosmetic name but is a single-brand business — Yatsen runs three distinct premium skincare brands, each with a different positioning (clinical, cellular, prestige facial). That said, Galénic and DR.WU are doing the work; Eve Lom has been stress-tested — Yatsen took an aggregate RMB757.1 million of goodwill impairments across FY2023 and FY2024 largely attributable to the Eve Lom reporting unit [26]. The brand-equity advantage is real but unevenly distributed across the portfolio.

3. Multi-platform omnichannel operating capability — beats the legacy department-store-heavy peer

Yatsen runs concurrently on Tmall, Douyin, RedNote, Weixin (Official Accounts / Mini Programs / Video Channels), Bilibili, Kuaishou, JD.com, Vipshop and Pinduoduo, plus 77 owned offline experience stores and selective premium distribution (Sephora, Sam's Club, The Colorist) [2] [27]. DTC channels generated 84.9% of FY2025 revenue — a structurally higher DTC mix than Shanghai Jahwa, whose own FY2024 MD&A attributes revenue decline partly to department-store inventory reduction and offline sales-department restructuring [16] [28]. On the Q3 FY2025 call CFO Yang acknowledged the competitive pressure on this advantage, but framed it as something Yatsen wins on, not loses on: "as long as we continue to focus on what we have done right, we will see more and more robust product lineup and better innovation… we will see higher brand awareness so that we can get more operational and brand building optimization" [29]. This is the playbook Proya runs too — but Jahwa demonstrably does not.

4. R&D investment intensity — matches L'Oréal, beats Estée Lauder

Yatsen has committed to R&D expenses "consistently exceeding 3.0% of our total net revenues annually since 2022" [21]. FY2025 R&D was 3.2% of revenue (¥137.3 million); Q1 FY2026 stepped up to 3.9% [30]. For comparison Estée Lauder typically runs R&D under 2%; L'Oréal runs around 3-3.5%. The patent portfolio reached 269 patents (10 utility model, 158 design, 72 invention, 29 pending) and 4,453 trademarks across China and outside China by FY2025 [7]. The 66,462 sqm Cosmax JV manufacturing-and-R&D hub in Guangzhou (operational since August 2023) and a Shanghai global innovation R&D center (May 2024) anchor the physical footprint; partnerships with Sun Yat-sen University and presentations at the IFSCC Conference and Asian Dermatological Congress establish the credentialing [31]. This isn't a moat against L'Oréal — but it is real differentiation against most domestic Chinese competitors.

Where competitors are better

Four concrete weaknesses, each named to a specific competitor and tied to a cited page.

1. Operating margin — Proya converts the same gross margin to 17.6% while Yatsen prints -4.3%

The single most damning peer comparison. Proya FY2025: 73.3% gross margin → 17.6% operating margin → 14.1% net margin → 24.4% ROE [3]. Yatsen FY2025: 78.2% gross margin → -4.3% operating margin → -1.9% net margin → -2.7% ROE [1]. Yatsen earns a higher gross margin and converts it to a structural loss; Proya gives up nearly 500 basis points of gross margin and earns nearly 22 points of operating margin on top of it. The Yatsen bull case is "we are Proya two years behind"; the bear case is "Proya's brand-tier mix is hero-product-led and inherently lower S&M per dollar of revenue." Either way, Proya wins this comparison on the line that matters most for a beauty business.

2. Category-leadership on Tmall — Proya's PROYA brand holds rankings Yatsen's brands do not

Proya's FY2025 annual report reports the PROYA brand at #1 in face cream and face mask on Tmall, #2 in facial care sets, #3 in serum, #6 in eye care, and #7 in sun protection for full-year 2025 [14]. Yatsen does not disclose comparable category rankings for any of Galénic, DR.WU, Perfect Diary or Eve Lom in its FY2025 20-F — the closest parallel is the IPO-era statement that Perfect Diary was the "top selling domestic color cosmetics brand on Tmall by sales" during Singles' Day 2021 [32], a claim the company has not repeated for any skincare brand. Category leadership matters because Tmall search and Douyin discovery are algorithmically biased toward best-sellers; a #1-on-Tmall brand earns lower marginal traffic-acquisition cost per impression than a competing brand outside the top three. Proya's category dominance is the structural reason its operating margin works.

3. Scale economics — every multinational in the table runs lower S&M intensity per dollar

Yatsen's selling and marketing expense was 66.3% of revenue in FY2025 — ¥2.85 billion absolute — including ¥1.83 billion of advertising and brand promotion and ¥512.6 million of e-commerce platform commissions [4]. L'Oréal converted a 74.3% gross margin to a 20.2% operating margin in FY2025 on €44 billion of revenue [20]. The math is simple: sub-scale Chinese DTC beauty houses pay a higher percentage of revenue for impressions because they cannot amortise creative, KOL contracts and platform commissions across global revenue. As Yatsen's own risk factor concedes, "many domestic and multinational consumer goods companies have greater financial, technical or marketing resources, longer operating histories, greater brand recognition or larger customer bases than we do and may be able to respond more effectively to changing business and economic conditions than we can" [13]. At US$615M of revenue Yatsen is roughly 23x smaller than Estée Lauder and 77x smaller than L'Oréal — the scale gap is not closeable in any plausible timeframe.

4. Prestige skincare brand equity — Estée Lauder and Shiseido's portfolios still own the consumer mind

EL's brand portfolio includes Estée Lauder (1946), Clinique (1968), M·A·C (1984), La Mer, Tom Ford, Aramis (1964), Lab Series, Origins (1990) — most with 30+ years of customer-built brand equity in China [18]. Shiseido's portfolio under SHISEIDO, Clé de Peau Beauté, NARS, IPSA, ANESSA, ELIXIR, MAQuillAGE etc. has comparable depth. Galénic, DR.WU and Eve Lom are credible brands but they are not "Clinique" or "La Mer." The CFO's Q3 FY2025 framing — that "some of the high-end brands are struggling with very big out-of-pocket price promotions" on Double 11 [11] — acknowledges that foreign prestige incumbents can defend share by cutting price, and that Yatsen has to compete on R&D and product credibility rather than meet them on discount. That is not weakness unless the consumer ends up choosing the brand they have known for 30 years; in prestige skincare she frequently does.

No Results

The two High-severity threats deserve emphasis because they are the only competitors that can materially change the FY2026 outlook. Proya is the share-and-mix threat: its FY2025 Tmall category rankings prove it can hold the #1/#2/#3 slots in skincare's biggest categories at a structural cost-per-impression advantage [14]. Platform commission inflation is the margin threat: the Q1 FY2026 release showed in real time that a single quarter of higher Douyin traffic acquisition cost can swing the operating margin from -4.1% to -9.7%, even with skincare scaling at 58.5% [5] [30]. Foreign prestige discounting on Double 11 amplifies both. If you only watch two competitors for Yatsen, watch Proya's quarterly Tmall rankings and Yatsen's own quarterly S&M-as-%-of-revenue line.

Moat watchpoints — the four numbers that would change the call

No Results

The disclosed figures behind the watchpoints: skincare segment loss of RMB 31 million in FY2025 vs RMB 449 million in FY2024 [33]; selling and marketing intensity at 66.3% FY2025 [4], 64.8% Q4 FY2025 [34], 72.2% Q1 FY2026 [5]; skincare share of revenue 53.0% FY2025, 61.1% Q4 FY2025 [25]; color cosmetics growth +1.9% FY2025 and -5.0% Q1 FY2026 [22] [5]. The four watchpoints together cover the two things competition will move: revenue mix and platform-cost-driven margin.

Bottom line

Does Yatsen have a moat that can compound? Not yet. The skincare-mix lever is real and doing what management said it would — gross margin up roughly 1,390 basis points since FY2020 [35] [1]. But the same five-year window produced exactly one non-GAAP profitable year (FY2025, 0.2% non-GAAP net margin) [22], and Q1 FY2026 gave the operating margin back to Douyin traffic costs [5]. Proya runs the same playbook with the same channel stack and earns 17.6% operating margin [3]. The bull case: Yatsen is Proya two years late — same end-game economics, just earlier in the curve. The bear case: Proya already won the share Yatsen needed to amortise its S&M base. The watchpoints above are how the evidence will pick a side.

References

Where we are right now

A 26.7% growth year and the first non-GAAP profit since the IPO bust were already on the tape when Yatsen reset the entire near-term debate in March-May 2026: a related-party US$120M convertible at a $4.63 strike was floated, Hillhouse objected, then Hillhouse joined the first tranche on May 21, 2026, and five days later management printed a Q1 FY2026 result that conceded the margin leg of the turn — operating loss margin widened from -4.1% to -9.7% on Douyin traffic-acquisition costs while skincare grew 58.5% and gross margin set a record 80.2%. The ADS sits at US$3.17 (June 18, 2026), -46% over the trailing three months, and well below the $4.63 strike at which the founder, Trustar, and Hillhouse all wrote checks sixty days ago. The page below is the bridge from that recent re-priced setup to the next data points that update the multi-year skincare-platform thesis — not a verdict on whether the long thesis is right.

Variant view, sized in numbers, up front

Consensus is thin (1-2 analysts), Buy-rated, with a mean US$6.73 price target and a FY2026E revenue of RMB5,238M (+21.9% YoY, ~$759M) and FY2027E RMB5,710M (+9.0%, ~$828M). Two specific places where this page sits off the Street, sized:

FY2026 non-GAAP operating margin: consensus implicitly modeling break-even to +1%; we model -2% to -4%. Q1 FY2026's non-GAAP operating margin was -8.3% and management explicitly chose to "selectively deploy resources" on Douyin traffic in Q2 [1]. Even if Q2-Q4 average -1% (heroic on the Q1 starting point), the full-year clears -3%. Implied delta to consensus: -3 to -5 percentage points of operating margin, or roughly RMB160-260M of "missing" non-GAAP EBIT vs the Street's implied trajectory.
FY2027 revenue: consensus +9.0% YoY; we sit closer to +12-15% on a skincare-mix arithmetic that has grown the Skincare segment +58.5% / +83.2% / +78.7% / +47.5% across the last four printed quarters — even decelerating sharply, +12-15% is the conservative read. Implied delta to consensus: +RMB180-340M of revenue, but the operating leverage from that revenue is the unresolved question, not the top line.

Stated bluntly: we agree with the bulls on the size of the prize and the gross-margin durability; we disagree with the implied Street margin glide and think the next two prints close that gap down, not up. The page is built around that variant.

Last close (USD, 2026-06-18)

$3.17

Convertible strike (USD/ADS)

$4.63

Mean Street target (USD)

$6.73

Days to next earnings (Q2 FY26 — Aug 20)

High-impact catalysts (next 6m)

Hard-dated catalysts (next 6m)

YTD 2026 return (%)

-45.7%

20-day ADV ($M)

$0.7

Calendar texture: Medium / event-rich for the next 90 days, then thin. Two hard-dated, high-impact prints land inside the next 90 days — the Q2 FY2026 earnings print on Aug 20, 2026 and the second-tranche closing of the convertible (window: subject to NDRC certificate, management has stated "later this year"). After that, the calendar goes quiet until the FY2026 20-F in roughly March 2027 — which is the print that actually resolves the multi-year thesis. PMs should hold size, not pile in, for the in-between events.

What just happened — the recent setup in three movements

The last six months are one tightly-linked sequence, not three independent events. Read in this order:

1. March 11, 2026 — the related-party convertible is announced. Yatsen signed a Note Purchase Agreement with Polaris Veritas, a vehicle affiliated with Trustar Capital and CEO Jinfeng Huang himself, for approximately US$120M of RMB-denominated convertible senior notes in two equal tranches, plus warrants on Class A shares, at a US$4.63 ADS conversion price, 1.5% coupon, with a 4% IRR put floor on the third anniversary of the First Note and warrants struck at the equivalent of US$10.00 per ADS [2]. The structure is the most overt governance friction in the public record: the founder is the lender, the founder benefits from the put, and the founder still controls 90.7% of votes from 34.3% of economics. The market read this exactly as it was — a related-party self-deal at a 46%-premium strike — and the stock has not recovered since.

2. April 29, 2026 — the FY2025 20-F discloses a significant-shareholder objection. The filing flags that "a significant shareholder of ours raised objections to, and concerns regarding, the consummation of the transaction" and was negotiating to participate; the first tranche had not yet closed as of the 20-F's filing date [2]. The market was left to wonder whether the deal would close at all.

3. May 21, 2026 — Hillhouse joins; first tranche closes. Management confirmed on the Q1 FY2026 call that the private placement of convertible notes and warrants completed on May 21, 2026 with Trustar, Hillhouse and the founder participating [3]. Hillhouse — the largest outside holder at 13.8% — is now also an inside party in the same instrument. The first overhang resolved, the second (Tranche 2 close) opened, and the dilution math (~26M ADSs at full conversion, +10% warrants on top) became real.

4. May 26, 2026 — Q1 FY2026 print resets the margin story. Revenue +22.5% to RMB1.02B (in line with the prior guide), Skincare +58.5%, gross margin a record 80.2% — and operating loss widened from -4.1% to -9.7% as Selling & Marketing rose to 72.2% of revenue (from 66.4%) on "higher traffic acquisition costs on the Douyin platform" [1]. Non-GAAP net income swung from +RMB7.1M (Q1 FY25) to -RMB57.3M (Q1 FY26) [4]. Q2 FY2026 guidance: RMB1.20-1.30B (+10-20%), a deceleration from the +22.5% just printed [5].

No Results

The cleanest summary the tape gives: the convertible saga and Q1 FY2026 each reduced the option-value premium that had floated the stock through 2025. Together they took the ADS from US$5.85 at end-March to US$3.17 today (-46%), with the Hillhouse-joins headline treated by the market as confirmation the founder needed the money, not as endorsement.

Historical earnings price-reaction base rate — what magnitude looks like here

Earnings is the dominant single-event mover for YSG, and the tape has been highly directional. Across the last 10 prints (Q4 FY23 → Q1 FY26), the average absolute one-day move (T-1 close → T+1 close) is 13.3%, with a range of 4.3% (Q2 FY24) to 27.9% (Q1 FY24). Six of ten reactions were declines. This base rate is what "High impact" actually means on this name — it is not 2-4%, it is ±10-15%, with tail outcomes near ±25%.

No Results

Avg abs 1-day reaction

13.3

Max abs reaction

27.9

Negative reactions / 10

Positive reactions / 10

Two practical takeaways. First, the cleanest pattern is strong rally going into the print → negative reaction even on a beat (Q3 FY25, Q1 FY25, Q4 FY24 are the textbook examples). Second, the directional bar is on margin/guidance, not the headline revenue number — Q1 FY26 beat on revenue and rallied +12% even on a worse-than-feared op-margin print, because the trading positioning was already washed-out and the headline guide (+10-20%) was inside the range. So sizing "High impact" reactions on this name as ±10-15% with skew toward downside whenever the stock has rallied >15% in the trailing month is a defensible prior.

The live debate — what the market is actively watching

There are four arguments running through the tape right now. Each carries a confirming and a challenging tell.

No Results

The single load-bearing question is #4 — S&M intensity. As the Long-Term Thesis tab framed it: a wide-moat consumer brand does not see its operating margin set quarter-by-quarter by a third-party platform. Q1 FY2026 said yes it does; Q2 FY2026 says whether that was the run rate.

Ranked catalyst timeline — by decision value, not by date

Five catalysts inside the next ~6 months that could move the underwriting debate. Ranked by expected decision value to a hedge-fund PM, with magnitude sized to the 10-print earnings base rate above and to the bull/bear scenario gap.

The Q2 FY2026 earnings date (Aug 20, 2026) is consistent with the yfinance earnings calendar and the company's historical Q2 cadence (Q2 FY24: Aug 20, Q2 FY25: Aug 21). The convertible second-tranche window and 4% IRR put floor are anchored in the FY2025 20-F subsequent-events note [2], and the buyback program runs through May 16, 2027 per the FY2025 20-F repurchase disclosure [6].

No Results

The ranking choice. Q2 FY2026 (Aug 20) is #1 because it is the first observable test of the platform-pricing mechanic that broke the Q1 narrative, on a hard date inside 90 days, on an asymmetric-down setup. The second tranche of the convertible is #2 because the strike and counterparty composition update the governance read directly — and the bear read of a repricing is the highest-magnitude downside catalyst between now and year-end. The FY2026 20-F (Q4 FY2026 print) sits at #3 even though it is ~9 months out: it is the single disclosure that resolves whether the FY2025 turn was an inflection or a head-fake at segment level, and no smaller print between now and then can substitute. Q3 FY2026 is the second data point on Douyin TAC — the value depends entirely on what Q2 prints. Buyback execution is in the table for completeness but does not move the underwriting case at $30M / 24-month pace.

Impact / decision view — which events actually resolve the debate

The catalyst table ranks decision value; this table separates information from resolution. Only two events between now and the FY2026 20-F can actually close the underwriting debate; the rest add data points to a still-open question.

No Results

The decision read: between now and year-end 2026, only Q2 FY2026 and the convertible second-tranche close are inside the typical 6-month catalyst lens. The single most thesis-resolving event of the entire cycle — Skincare segment OI in the FY2026 20-F — sits 9 months out, well outside the standard catalyst window. That is itself a finding: PMs trying to underwrite YSG inside a 6-month horizon are buying two near-term data points that update the thesis, not one that resolves it.

Next 90 days — the focused watchlist

No Results

What would change the view

Three observable signals, in priority order. These are the things that would force a multi-year thesis update — Bull, Bear, Moat, Forensic. This is the event path, not a verdict.

No Results

The honest summary. YSG sits at a depressed price below the strike at which the founder, Trustar, and Hillhouse all wrote checks 60 days ago. The next 90 days deliver two real events — Q2 FY2026 earnings (Aug 20) and the second-tranche convertible close — that update the thesis without resolving it. The single resolution-grade catalyst on the entire 12-month horizon is the FY2026 20-F skincare segment OI, in ~9 months. PMs sizing inside the 6-month window should treat this as a setup where the variant view (margins disappoint vs Street through 2026) carries through the next two prints, then the underwriting question turns back to the multi-year thesis. The "1Q FY2026 wobble was noise" call requires Q2 FY26 to revert; the longer the S&M-intensity stays above 70%, the lower the probability the FY2026 20-F resolves bullish.

References

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the valuation cushion is real but Q1 FY2026 just contradicted the operating-leverage thesis, so this is a sized-after-Q2 trade, not a buy-now trade.

Bull and Bear are arguing different time frames about the same balance sheet. Bull is right that YSG trades at 0.24× EV/Sales with $151M of cash, zero financial debt, and three institutional cohorts — the founder, Trustar, and Hillhouse — underwriting at a $4.63 ADS conversion price [1] against a $3.17 print. Bear is right that the FY2025 "non-GAAP turn" was half goodwill-bath optics, that Q1 FY2026 operating-loss margin widened to -9.7% on higher Douyin traffic-acquisition costs [3], and that both reportable segments still lost money in FY2025 (Color -¥59M, Skincare -¥31M) [5]. The decisive variable — durable, not headline — is whether the skincare gross-margin mix actually drops to operating margin or gets extracted by platform traffic costs. The Q2 FY2026 print is the proximate test; the answer to that question is what changes the rating, not the size of the next quarterly beat.

Bull Case

The strongest bull case is balance-sheet and mix-driven, not earnings-driven. The cheapest evidence carried forward is the $4.63 conversion price on the March 11, 2026 Trustar/Huang Note Purchase Agreement [1] — a 46% premium to today's $3.17 — combined with Hillhouse, the largest outside holder, ultimately joining the same first closing on equal terms after raising its objection [2]. Three institutional cohorts wrote checks at the same $4.63 strike inside sixty days of today's market price. That is the price anchor; the operating story is the optionality on top.

No Results

Bull's price target: $6.50 per ADS over 12–18 months, derived from an EV/Sales rerate to 0.6× on FY2027 consensus revenue (~$816M), still a 70% discount to Proya's ~2×; cross-checked by the $4.63 convertible strike as a smart-money floor and ~$4.60 book value per ADS as downside support. Primary catalyst: FY2026 20-F (printing Feb/Mar 2027) shows skincare segment operating profit turning positive. Disconfirming signal: a third consecutive Q4 goodwill impairment (most likely the ¥134M residual DR.WU goodwill — the FY2024 critical audit matter), or FY2026 full-year non-GAAP operating margin worse than FY2025's -2.0%, confirming Q1 FY2026 as run-rate.

The point dropped from Bull's draft was the buyback-driven cap-table consolidation. It is real (40.2M ADSs retired for $202M; founder voting share 63.8% → 90.7% post-buyback) but it cuts both ways — the same mechanic that thins the float is what gives the founder unilateral control over the related-party convertible the Bear cites. It is not load-bearing for the upside case.

Bear Case

The Bear's strongest evidence is forensic and contemporaneous, not philosophical. The cleanest single piece is that the Q4 FY2025 release discloses RMB 14.6M of out-of-period adjustments swept into the quarter, of which RMB 7.4M relates to prior years — larger than Q4 GAAP net income (RMB 3.0M) and roughly the size of the full-year non-GAAP "profit" itself [4]. And the Q1 FY2026 release names traffic-acquisition costs on the Douyin platform as the operating-margin swing factor [3]. The FY2025 "turn" looked like the residue of a goodwill bath and a widened non-GAAP definition; ninety days later, the gloss came off.

No Results

Bear's downside target: $1.75 per ADS over 12 months — EV/Sales compression from 0.24× to 0.10× on FY2026E revenue (~$650M), plus net cash ~$150M, minus $120M convertible-note overhang at face = ~$95M equity / ~95M fully-diluted ADS; cross-checked at 0.4× P/B implying ~$1.80. Primary trigger: Q2 FY2026 print (August 2026) shows operating-loss margin still wider than -5% with S&M intensity above 70%. Cover signal: two consecutive quarters (Q2 + Q3 FY2026) of positive GAAP operating income with S&M intensity below 65% — the platform-cost problem solved and skincare mix earning its margin live. Related-party purchase escalation [6] and the drained balance sheet [7] frame why the convertible is read as forced, not chosen.

The point dropped from the Bear's draft was the structural sub-scale argument. It is true that YSG is 2.5× smaller than Proya and converts 78.2% gross margin to -4.3% operating margin while Proya converts 73.3% to 17.6% [8]. But "small" is not the same as "uninvestable"; the durable bear case is the Q1 reversal and the governance discount, not size.

The Real Debate

Three tensions remain after both advocates rest. Each is the same observed fact read two ways — and each can be settled by an observable, near-record outcome.

No Results

The middle tension is the load-bearing one. The other two — bookkeeping versus turn, smart-money versus self-deal — frame the past and the cap table. The Q1 FY2026 Douyin-cost mechanic [3] is what the thesis depends on going forward: does an 80%+ gross margin actually flow to the operating line, or does the channel keep taking it back?

Verdict

Lean Long, Wait For Confirmation. Bull carries more weight on the static picture — at $295M of equity with $151M of cash, zero financial debt, $120M of incoming convertible proceeds underwritten at $4.63 by the people closest to the business, and book value per ADS near $4.60, the downside math is genuinely cushioned and the market is paying near zero for an operating business that just printed an 80.2% gross margin on +58.5% skincare growth. The single most important tension is whether Q1 FY2026's Douyin-driven margin reversal [3] is one-quarter noise or the new run-rate, and on that question the Bear is not provably wrong — Proya's 17.6% operating margin on a similar 73% gross margin [8] is anchored by Tmall category leadership Yatsen has not yet demonstrated, and the FY2025 segment-level losses [5] say the brands have not yet earned their own keep. The condition that would change the verdict to Lean Long (full weight) is the durable thesis variable: FY2026 full-year non-GAAP operating margin better than FY2025's -2.0% with skincare segment operating loss narrower than FY2025's -¥31M — that combination proves the gross-margin lever drops to the operating line. The near-term marker that would let a position be sized is narrower: Q2 FY2026 (August 2026) operating-loss margin back inside -5% and S&M intensity below 70%. If Q2 stays at Q1's shape, the read flips to Watchlist and waits for cleaner evidence than the next quarter.

Lean Long, Wait For Confirmation — Valuation cushion and $4.63 smart-money anchor are real, but the Q1 FY2026 Douyin-cost reversal directly contradicts the operating-leverage thesis. Size after Q2 FY2026 (August 2026) confirms or refutes the channel mechanic.

References

Moat: not proven — a multi-brand operator competing on twelve factors at once

The cleanest summary of Yatsen's competitive position is written by Yatsen itself. The Competition section of the FY2025 20-F lists the basis on which the company believes it competes: "perceived value, including pricing and innovation, product efficacy, service to the customer, promotional activities, advertising, special events, new product introductions, e-commerce initiatives, direct sales, KOL collaborations, and other activities" [1]. That is twelve factors. When a moat list is twelve factors long, none of them is a moat — the company is telling you it competes on execution across a wide front, not on a structural advantage that protects price, share, or returns from rivals. The same paragraph adds that Yatsen "compete[s] with both established multinational and domestic brands, as well as small targeted niche brands that continue to enter the Chinese and global beauty markets" — a low-barrier arena where the company's risk factor framing concedes that many competitors "have greater financial, technical or marketing resources, longer operating histories, greater brand recognition or larger customer bases" than Yatsen does [2].

The verdict, on the primary record across six fiscal years: Moat not proven. A wide moat is not on the table. A narrow moat is possible in the owned premium-skincare equity (Galénic, DR.WU, Eve Lom), but the financial fingerprints a moat should leave — pricing power, segment-level operating profit, durable revenue compounding, brand resilience under stress — are either absent or contradicted in the record. Two facts make the "not proven" read the responsible one rather than "no moat": gross margin has expanded every year through a 36% revenue drawdown, and the skincare mix shift has demonstrably moved that gross margin higher. Both are consistent with the building of a narrow moat from a credible brand portfolio. Neither is yet evidence of a built one.

Moat rating

Moat not proven

Evidence strength (0-100)

Durability (0-100)

Weakest link

Platform traffic costs

One-sentence verdict. Yatsen has a credible portfolio of pre-existing skincare brand equity it did not build and does not yet earn a moat premium on — its gross margin is real, its mix shift is real, but both core segments still lost money at the operating line in FY2025 [3], one of the prestige brands (Eve Lom) has been goodwill-impaired twice for ¥757.1 million of cumulative write-downs [4], and Q1 FY2026 demonstrated that a single platform's traffic costs can erase a year of margin progress in a single quarter [5].

How a moat would show up — and what is missing

A moat earns returns above the cost of capital that competitors cannot compete away. In a brand-driven consumer business, that shows up as some combination of (1) sustained pricing power, (2) sticky customer behavior — repeat-purchase, retention, low elasticity, (3) operating margins that converge upward over a multi-year window because variable customer-acquisition cost falls as the brand compounds, (4) segment-level operating profit that is positive and rising, and (5) margin and share that survive a stress event — a recession, a price war, a channel shift, a regulatory change.

No Results

Five tests, zero clean passes. The honest read is that the company sits in a structurally low-moat arena — "vigorous competition from both domestic and international players" and the explicit listing of multinationals with "greater financial, technical or marketing resources, longer operating histories, greater brand recognition or larger customer bases" [2] — and earns no measurable structural advantage over those rivals at the operating line today. That can change. It has not yet.

Naming the candidate sources of advantage

A moat verdict has to walk through specific mechanisms rather than label-shop. The candidate moats for a digital-first multi-brand China beauty house are limited, and each can be tested against the primary record.

Intangible assets: pre-existing premium brand equity (Galénic, DR.WU, Eve Lom)

This is the strongest candidate moat Yatsen has, and the only one that comes close to a real economic mechanism. None of the three was built by Yatsen — Galénic dates to 1978 under Pierre Fabre, DR.WU to 2003 under dermatologist Ying-Chin Wu, Eve Lom to 1985 in the UK [6] [7] [8] — and Yatsen acquired them between October 2020 and March 2021 with the explicit strategic intent of climbing the value chain into prestige and clinical [9]. The mechanism: skincare is a daily-use, regimen-driven category where brand trust correlates with efficacy claims and clinical credibility, repeat-purchase elasticity is lower than in color cosmetics, and gross margin is structurally higher. Management says it directly: skincare "typically feature[s] higher gross margin and greater customer loyalty" than color cosmetics [10], and the CFO has framed the entire margin path through this lever.

The evidence the candidate is real:

Skincare grew 63.5% YoY in FY2025 to RMB2.28 billion (US$325.7 million) and crossed 53% of revenue for the first time, against an NBS national beauty-retail growth rate of 5.1% [11] — Galénic and DR.WU are clearly taking share in their tiers. Q1 FY2026 extended that gap: premium and clinical skincare (Galénic + DR.WU + Eve Lom combined) grew 61.4% [12].
Galénic was launched in China only in 2021, and within four years its "No. 1 Brightening Radiance Energy Concentrated Care" serum had become "a key player in the premium brightening serum category" [6] — anchor-product economics consistent with a brand that retains buyers across a regimen.
DR.WU was "recognized by Euromonitor in 2023 as Asia's Leading Mandelic Acid Skincare Brand" — a third-party category-leadership citation [7].

The evidence the candidate is not yet a built moat:

Eve Lom — the third leg of the prestige strategy — has been goodwill-impaired in two of the last three fiscal years: RMB354.0 million in FY2023 plus RMB397.8 million against the Eve Lom reporting unit specifically in FY2024 [4]. Pre-existing prestige brand equity, paid for and capitalized, was written down because the operating economics did not materialize after acquisition. That is the cleanest disproof you can ask for of the "owned premium brand equity is a moat" thesis: when the equity belonged to a brand that did not connect with the Chinese consumer, the acquirer ate the difference. The Galénic and DR.WU thesis remains intact for now precisely because the impairment tested only Eve Lom — but the structural lesson is that owning a prestige label does not, on its own, deliver moat economics.
The skincare segment itself lost RMB31 million at the operating line in FY2025, after RMB449 million of loss in FY2024 [3]. A real brand moat earns operating profit at the segment level. Yatsen's does not yet.
Brand resilience cuts both ways. The "hero brand" Perfect Diary, organically built in 2017 and the only organically-built brand of the six, was cut in half between FY2021 (RMB4.87 billion) and FY2023 (RMB1.97 billion) and has flatlined for three years; its color-cosmetics segment grew just 1.9% in FY2025 and reversed to -5.0% in Q1 FY2026 [13]. The organically-built brand was the one that broke under stress. That outcome is consistent with brand equity that lived in a marketing playbook rather than in the customer relationship — i.e., not a moat.

Read of this candidate. Real but narrow, concentrated in Galénic and DR.WU, and not yet earning measurable economic surplus. Not a wide moat. Probably a narrow moat in the making, contingent on the two unimpaired prestige brands continuing to compound without Yatsen needing to re-invest the brand equity through ever-higher traffic spend.

Cost / scale advantage via the Cosmax JV

Yatsen and Cosmax — one of the largest contract cosmetics manufacturers in the world — co-built a 66,462-square-meter manufacturing and R&D hub in Guangzhou that began operating in August 2023 [14] [15]. Yatsen sits as a minority shareholder. The candidate moat: scale economics, formulation insider access, and supply-chain agility unavailable to smaller competitors.

The candidate fails the exclusivity test. The same ODM ecosystem — "Cosmax, Intercos, Shanghai Zhenchen, HCP, Axilone and Qiaxing" — supplies every China beauty incumbent and entrant [15]. The Yatsen-Cosmax JV does plausibly improve cost-of-goods, lead time, and formulation insight at the margin, and it is one reason gross margin has held up through the revenue trough. But Cosmax is not Yatsen-exclusive in any commercial sense disclosed in the record; Proya, Botanee, Florasis and every other domestic challenger has access to the same supply base. A shared supply chain is a competitive enabler in this industry, not a moat.

R&D as moat — credibility-building, not yet protective

Yatsen positions R&D as "a fundamental pillar of our competitive advantage" [16]. The hard inputs are real: R&D expense was 3.3% / 3.2% / 3.2% of net revenue in FY2023-FY2025, with absolute spend rising to RMB137.3 million (US$19.6 million) in FY2025 [17]; the patent portfolio reached 269 items as of December 31, 2025 (10 utility model, 158 design, 72 invention, 29 pending) [17]; R&D infrastructure spans a 1,849-sqm Guangzhou center, a Shanghai global R&D center (May 2024), joint laboratories with Ruijin Hospital and Sun Yat-sen University, a 920-sqm Galénic facility in France, and the Cosmax JV in Guangzhou [17]; and named technology platforms include Biotec™, Smartlock™, and ActiveAnchor™ [18]. On Q1 FY2026 R&D ran at 3.9% of revenue, a step-up from 2.7% a year earlier [19].

No Results

What the candidate is not. R&D intensity is a credibility input for the premium and clinical positioning the company wants to defend, not — yet — a moat output. There is no economic test it passes:

No price premium on the back of R&D output is demonstrated in the filings, and the company concedes it competes against "heavy price competition in the market place" even while trying to "gradually improve our gross margin by introducing higher-margin new products and stricter discounts" [24] — that is mix and discipline, not pricing power.
Most of the patent portfolio (158 design, 10 utility model) is form-factor IP that does not block competitors from competing in the same category; only the 72 invention patents — and some are still in transfer to Yatsen — represent the kind of defensible formulation IP that could support an efficacy claim against a private-label or competitor copy [17].
The 1,849-sqm Guangzhou center and the 920-sqm Galénic facility are modest by global standards. L'Oréal and Estée Lauder operate multi-hundred-thousand-sqm global R&D footprints with thousands of scientists — the candidate has to be that the China-relevant edge from a smaller, more agile platform is real, not that the absolute R&D base is larger.

Read of this candidate. Credibility, not moat. R&D is necessary to play in clinical / dermo-cosmetics and to defend the Galénic and DR.WU positions over time, but it is not in itself protective and it has not produced a single named technology platform that has visibly compressed S&M intensity. The S&M line is what would compress if R&D delivered a brand-strength surplus, and S&M intensity has gone in the wrong direction in the most recent quarter.

Distribution / channel — capability without an exclusive

Yatsen describes a "comprehensive and robust omni-channel ecosystem" across Tmall, JD.com, Douyin, Pinduoduo, Vipshop, RedNote, Bilibili, Weixin Official Accounts / Mini Programs / Video Channels, plus 77 owned offline experience stores, plus Sephora and Sam's Club for the prestige skincare brands and The Colorist for color cosmetics, plus international distribution for Eve Lom [20] [21]. The candidate moat is the operating capability — the software — of running the same brand across five platforms with coordinated price points, promotional calendars, and KOL alignment.

This capability is real and built over seven years. It is also the table-stakes operating model in this arena; the industry tab calls it directly — "in this industry, 'distribution' is software, not real estate. … A brand that can't operate fluently across all five of Tmall, Douyin, RedNote, Weixin, and Pinduoduo will eventually stop growing." Proya, Botanee, Florasis, Maogeping and others all do the same. Operating fluency is necessary to play and not sufficient to win. Worse: the channel is structurally pricing-power-negative — the platforms set the cost of one customer impression, and when they raise it (as Douyin did in Q1 FY2026 [22]), the cost flows straight through to operating margin in the same period.

Switching costs / network effects — quantify or omit

Yatsen's filings discuss "increasing customer retention, and encouraging repeat purchases" as a goal of the broad portfolio strategy, not as a metric the company has achieved [24]. No net revenue retention, cohort retention, average revenue per user, repeat-purchase ratio, or membership-based KPI is disclosed in the annual report or the quarterly releases. A switching-cost moat requires a quantified cost or workflow disruption on leaving — none exists for a Galénic serum customer who can re-buy a competitor's serum the next day on the same Tmall storefront. There is no network-effect moat: the value to one Perfect Diary customer of another Perfect Diary customer existing is zero. These categories of moat are not present and not claimed.

Regulatory / structural — table-stakes

The PRC NMPA registration regime (Regulations on the Supervision and Administration of Cosmetics, effective January 1, 2021) raises the lead-time and cost of new product launches industry-wide, and penalties for non-compliance reach 30 times the value of the affected product [23]. This is a floor under the industry, not a moat for Yatsen — every domestic and multinational competitor faces the same regime and most have larger regulatory teams.

The Eve Lom case study: a paid-for moat that wasn't

The cleanest empirical refutation of the "owned premium-brand-equity is a moat" thesis is Yatsen's own track record on Eve Lom. The brand was acquired in March 2021 from Manzanita Capital, an iconic UK prestige skincare label founded in 1985 with a globally-distributed cleanser balm and recognized brand authority [8]. It was as close to a textbook "buy a moat" deal as a Chinese acquirer could make.

No Results

Management's own language on the impairments — "due to weaker operating results than expected" — is the disclosure-friendly version of: pre-existing brand equity, even at a beloved global label, did not translate into share, pricing, or repeat in the Chinese market under Yatsen's stewardship [25]. For an analyst pricing in the Galénic + DR.WU thesis, Eve Lom is the on-record disproof that pre-existing prestige equity automatically delivers economic surplus. It can; it didn't, for one of three.

The Q1 FY2026 stress test: a single-quarter platform shock

The most informative single page in the moat record is the Q1 FY2026 release. Revenue grew 22.5% to RMB1.02 billion, gross margin reached an all-time high of 80.2%, and skincare grew 58.5% — every "brand pulling weight" KPI lit up [26]. Yet operating expenses jumped to 89.9% of revenue from 83.2%, S&M alone climbed to 72.2% of revenue from 66.4% — and the operating loss margin widened from -4.1% to -9.7% in a single quarter. Management's named cause: "higher traffic acquisition costs on the Douyin platform" [22].

No Results

The single-quarter shape of this is diagnostic of who owns the surplus. If Yatsen had a moat, the 580bps of gross-margin lift since FY2023 should be slowly compressing the S&M ratio (because brand strength compounds and acquisition cost per customer falls). Instead the company gave back 580bps of S&M intensity inside one quarter on a single platform's commercial decision. A wide-moat brand does not have its operating margin set quarterly by a third-party platform's traffic costs. A narrow-moat brand might absorb the shock at the gross-margin line; this one absorbed it at operating income. Operating margin in this business is the residual between two things — gross margin and traffic cost — and Yatsen owns neither price-setting power against rivals nor cost-setting power against platforms.

The Q1 print also tested which brands actually have pull. Skincare grew 58.5%; color cosmetics fell 5.0% [26]. The organically-built brand that carried Yatsen through the IPO contracted; the acquired prestige labels grew. That is consistent with the narrow-moat candidate residing in the acquired skincare set, not in the operating capability Yatsen claims to have built around digital-first DTC.

How Yatsen stacks against operators where the model does earn moat economics

The peer set established by the industry and business tabs gives a useful upper bound. Proya runs a digitally-led China multi-brand model at 73.3% gross margin and 17.6% operating margin [27]. Botanee runs a dermo-cosmetics specialty model at 74.5% gross margin and 10.7% operating margin. Both are GAAP-profitable, both compete in the same regulatory regime against the same multinationals, both use the same ODM/OEM base, both run the same Tmall-Douyin-RedNote channel stack. They are evidence that the China beauty arena can support a narrow moat — and they are the operating yardstick for what an earned skincare-mix shift looks like.

No Results

The Proya comparison matters most. Same arena, broadly similar gross-margin level, 22 points of operating margin gap. That gap is the visible distance between an earned skincare-mix moat and a developing one. The Estée Lauder data point is the opposite caution: a 74.0% gross margin with -5.5% operating margin is a reminder that high gross margin on its own is not a moat — Estée Lauder has a wide moat structurally but is paying for a travel-retail destocking cycle. Both observations cut against any reading that Yatsen's 78.2% gross margin alone proves anything about durability.

What the FY2025 turn actually proved — and didn't

The FY2025 numbers are the most moat-favorable in the company's history and deserve to be read precisely. Revenue grew 26.7% to RMB4.30 billion, gross margin reached 78.2%, and the company posted its first non-GAAP profit since 2021 at RMB8.4 million [28].

What this proves about durability:

The skincare mix lever works mechanically — Galénic and DR.WU can grow above the China beauty industry trend, and growth at that mix lifts gross margin even when no underlying pricing-power dynamic is present.
The company can be operationally disciplined — G&A intensity fell from 14.7% of revenue (FY2023) to 7.1% (FY2025) under the headcount reduction from 3,497 (end-2021) to 1,623 (end-2025) [29]. This is an execution moat in cost, not a structural one in pricing.

What this does not prove about durability:

Both reportable segments still lost money at the operating line in FY2025: Color Cosmetics -RMB59 million, Skincare -RMB31 million [3]. The consolidated non-GAAP profit is the residual of segment gross profit minus unallocated corporate, not the brands earning surplus on their own.
The S&M ratio (66.3% of revenue) barely changed despite the gross-margin lift [30]. A brand moat would have started compressing it.
The FY2025 turn was promptly reversed in Q1 FY2026 — first quarter after the milestone — on a single platform's traffic-cost decision, which is the opposite of moat-protected economics [5].

What would change the verdict

Three signals would move the verdict from "Moat not proven" toward "Narrow moat":

No Results

The first of these — skincare reaching segment-level operating profit — is the highest-information watchpoint. It is the line that the entire bull case rests on, and on FY2025 numbers (RMB2.28B revenue, RMB31M segment operating loss) it is one good year of disciplined growth away. Whether it arrives, and whether it survives the Q1-FY2026-style platform shocks, is the substance of the moat question for the next four to eight quarters.

What an intelligent investor should hold in their head

This report's view, in plain English:

The arena is structurally low-moat. Twelve named competitive factors, vigorous rivalry, multinationals with greater resources, platforms with pricing power over the marketing line, an ODM ecosystem shared with every competitor. No domestic peer has built a wide moat here; the best (Proya) has built a narrow one.
Yatsen has candidates for a narrow moat — owned premium-skincare equity in Galénic and DR.WU. They are growing, they are recognized in their tiers, and they are the right mix to compound over time. They have not yet earned the financial fingerprints of a built moat.
Yatsen has disproofs of moat-like behavior already in the record. Eve Lom's two impairments, Perfect Diary's failure to defend share organically, segment-level operating losses in both segments in the best year of the cycle, and a single-quarter Douyin shock that erased the year's margin progress.
The verdict is "Moat not proven" — narrowly, with the arrow pointing in the right direction. Calling it a narrow moat today over-credits intent for output; calling it "no moat" under-credits the genuine premium-skincare equity Yatsen has assembled. A reader should underwrite this name as a cycle-and-execution story with optionality on a narrow moat developing, not as a moat-protected compounder.

The single most important number in this whole tab is the FY2025 Skincare segment operating loss of RMB31 million on RMB2.28 billion of revenue [3]. That number, on next year's print, is the moat verdict.

References

Financial Shenanigans — Yatsen Holding Limited (YSG)

Forensic verdict — Watch (score 38)

Yatsen's reported numbers are broadly traceable to economic reality, but four pressure points keep this off "Clean": (1) two consecutive Q4 goodwill baths on Eve Lom — RMB354.0M in Q4 2023 and RMB403.1M in Q4 2024 — that all but eliminate acquired skincare goodwill and mechanically deliver the FY2025 "non-GAAP profitability" narrative [1] [2]; (2) escalating related-party purchases from companies under Yatsen's "significant control" — RMB211.0M → RMB285.5M → RMB372.0M across 2023-2025 — plus a March 2026 US$120M convertible note placed with a vehicle affiliated with the founder/CEO [3] [4]; (3) explicit Q4 2025 "out of period adjustments" of RMB14.6M (RMB7.4M tied to prior years) flowing through current-quarter revenue and cost of revenues [5]; and (4) founder/CEO Jinfeng Huang controlling 90.4% of voting power through Class B super-voting shares, with no chair/CEO separation [6]. Cash from operations has been negative for three straight years (-RMB107M FY23, -RMB244M FY24, -RMB95M FY25) and the cash and short-term-investment war chest has shrunk from RMB2.59B (FY22) to RMB1.05B (FY25) [2] [1]. What would change the grade: a clean closing of the founder convertible note on third-party-comparable terms with majority-shareholder consent, FY2026 operating cash flow positive on lower related-party purchase volume, and FY2026 with no new "out of period" adjustments would push this to Clean (15-20); failure to close the convertible while burn continues, or a third consecutive Q4 impairment (DR.WU is the FY2024 critical-audit-matter unit, with RMB134M residual goodwill), pushes this to Elevated (45-55) [7].

Forensic Risk Score (0-100)

Red Flags

Yellow Flags

Clean Tests

CFO / Net Income (3y, -ve over -ve)

-0.29

FCF / Net Income (3y)

-0.30

FY24 Non-GAAP Gap (RMB M)

-582

Cash + STI Decline FY22→FY25 (RMB M)

-1,574

The headline pattern: the GAAP net loss collapsed from RMB710M (FY24) to RMB92M (FY25) — an 87% improvement — and management labelled FY25 a "non-GAAP profitability turnaround" [2]. But ~RMB403M of the swing is the simple absence of the prior-year goodwill impairment, ~RMB101M is non-GAAP carve-outs (SBC RMB59M, intangible amortisation RMB43M, investment impairment RMB13M, less tax effects), and CFO still ran -RMB95M [2] [8]. That is the lens to read this page through.

The 13-category shenanigans scorecard

This is the standardised scorecard required for every forensic page. Citations for each row's evidence appear in the prose section that handles that category.

No Results

The big-bath engine — two Q4 goodwill impairments

The single largest accounting story across the 2021-2025 corpus is the staged write-off of acquired-skincare goodwill, almost entirely on the Eve Lom reporting unit. Reported goodwill peaked at RMB857M (FY22), fell to RMB557M (FY23) after the first Eve Lom charge, and collapsed to RMB155M (FY24) after the second — a roughly RMB702M cumulative write-down [9] [10]. Yatsen's FY2022 20-F explicitly stated that "no impairment of goodwill was identified" in the FY22 annual test — and the FY23 charge of RMB354.0M followed only six months later, with the CFO attributing it on the Q4 2023 call to "weaker operating results than expected at the time of acquisition" [11]. The second-leg RMB403.1M write-down in Q4 2024 — same brand, same dynamic — was flagged on the earnings call alongside the "strategic transformation" narrative [12] [1]. The result is that FY25's headline operating-margin improvement is mechanically explained by the absence of the bath: management itself disclosed that operating loss margin fell from 24.3% to 4.3% "primarily because there was no impairment of goodwill for the full year of 2025" [2].

What this leaves on the balance sheet is RMB155M of residual goodwill — and the FY2024 auditor critical-audit-matter is now the DR.WU reporting unit (RMB134M of the residual), the next domino auditors elected to highlight for fair-value sensitivity [7]. For FY2025, the auditor swapped the goodwill CAM out and replaced it with Impairment of Inventories (RMB38M allowance on RMB509M of inventory), which itself implies the audit committee considers inventory marks the next significant judgment area [13]. A third Q4 impairment — on DR.WU, or via inventory — is the single most important read-through to monitor in the next two annual reports.

Earnings quality — non-GAAP narrative vs GAAP cash

Yatsen presents FY2025 as a "non-GAAP net income turnaround" of RMB8.4M, against a GAAP net loss of RMB92.4M [2]. The gap between the two is RMB100.7M — and it is built from add-backs whose "non-recurring" framing varies sharply by item. Share-based compensation (RMB59M in FY25) is a recurring labour cost, not a non-cash one-off; intangible amortisation from acquisitions (RMB43M) is by construction a multi-year cost; "impairment of investments" (RMB13M, a new FY25 add-back category) is small but it expanded the definition vs FY24 [2]. The FY24 non-GAAP gap was much larger: GAAP loss RMB710M, non-GAAP loss RMB128M, a gap of RMB582M dominated by the RMB403M goodwill add-back, RMB106M intangible amortisation, and RMB91M SBC [10].

The non-GAAP definition itself has drifted across years. The Q4 2024 release adds back share-based compensation, amortisation of acquired intangibles, revaluation of equity-method investments, impairment of goodwill, and tax effects [10]. The Q4 2025 release adds a sixth item — impairment of investments — to the net-income definition, broadening the carve-out list at the exact moment the headline pivots from loss to "non-GAAP income" [2]. Read literally, every time a new non-cash charge appears, management has reserved the right to exclude it. That is the KM1 pattern: the headline metric drifts to fit the result, not the other way around.

A second earnings-quality flag is the contribution of below-the-line items to the reported number. FY25 financial income (RMB40.7M), FX gain (RMB13.4M), equity-method income (RMB5.9M) and other income (RMB46.7M) together totalled RMB106.7M — larger than the entire pre-tax loss of RMB92.5M [2]. Without those non-operating tailwinds, the FY25 pre-tax loss would have been close to RMB200M (i.e., the disclosed operating loss of RMB186M), and the "narrowed loss" narrative weakens.

Cash-flow quality — three straight years of OCF burn

The cleanest forensic test on this company is the cash-flow statement, and it does not flatter the income statement. Operating cash flow has been negative for three consecutive years — even as gross margin expanded from 68.0% to 78.2% and revenue accelerated to +26.7% in FY25 [2]. FY22's positive RMB136M of CFO has not repeated.

Two CFO mechanisms matter here. First, FY25's working capital absorbed cash on net even with payable stretch. Accounts and notes payable rose from RMB72M to RMB149M (+RMB77M) — the line is now disclosed as "Accounts and notes payable" rather than just "Accounts payable", suggesting bank-acceptance financing has been introduced [9]. At the same time inventory ballooned from RMB386M to RMB509M (+RMB123M), an outflow that nearly cancelled the payable stretch. Without the AP/notes-payable expansion, FY25 CFO would have been closer to -RMB170M. That is a CF4 working-capital lifeline.

Second, the investing line has been a liquidity source, not a use. FY24 investing activities generated +RMB592M of cash, driven almost entirely by selling short-term investments out of a previously RMB1.2B portfolio [10]. FY25 still drew on STI, with the portfolio falling from RMB539M to RMB246M [9]. This is one-time monetisation of wealth-management product holdings, not recurring operating cash generation. The result is the cash war chest — cash, restricted cash and short-term investments combined — has fallen from RMB2.59B at FY22 year-end to RMB1.05B at FY25 year-end [1] [2].

That RMB1.54B decline coincides with treasury stock building from RMB865M (FY23 year-end) to RMB1,276M (FY24) and back to RMB1,251M (FY25) — i.e., FY24 buybacks alone consumed roughly RMB412M of cash, with FY25 net activity broadly flat after some share retirement / share-plan flows [10] [9]. The company is shrinking the cash base by financing buybacks out of investing proceeds while operations bleed — a defensible capital-allocation choice given the share price, but not a story management should be allowed to retell as "improved cash conversion".

A smoking-gun out-of-period adjustment in Q4 2025

The Q4 2025 income statement carries an explicit footnote disclosure that should be flagged: "In the fourth quarter of 2025, we made certain out of period adjustments mainly relating to revenues and cost of revenues to correct certain prior periods errors mainly occurred during the sales return and inventory receipt processes, which reduced quarterly profit by RMB14.6 million. Out of the RMB14.6 million adjustments, RMB7.4 million adjustments were related to prior years." [5]. Management's own conclusion is that the errors are "not material" individually or in aggregate.

This is a textbook EM6 pattern — prior-period errors swept into the current period rather than separately restated. The amounts are small relative to the RMB4.3B revenue base (0.34%), and the disclosure is transparent, so this does not justify a "red" verdict on EM5/EM6 standing alone. But it sits inside a company whose Q4 2025 net income of RMB3.0M is roughly five times smaller than the RMB14.6M adjustment — so the swing from a small reported profit to a small loss would have moved the headline number without the prior-period sweep. The disclosure is honest; the magnitude relative to a thin profit is what makes this material.

The lift-out matters because Q4 2025 is the quarter management used to declare "the first full-year non-GAAP profitability since 2020." If the RMB7.4M prior-year adjustment is added back to Q4 2025 (the right comparison for an investor underwriting underlying run-rate), the quarter's reported RMB3.0M net income flips to a small net loss, and the FY25 non-GAAP net income of RMB8.4M shrinks toward zero [2].

The breeding-ground / EM2 risk on Yatsen is concentrated in one disclosure: the company's purchases of "inventories and services from companies over which we exercise significant control." Those purchases have risen RMB211.0M → RMB285.5M → RMB372.0M over 2023-2025, a 76% increase in two years — well ahead of revenue growth over the same period [3]. Sales of inventory to a company controlled by the CEO were RMB20.1M in 2023 and RMB10.4M in 2024 before going to nil in 2025; the IPO baseline disclosure showed RMB67.9M founder advances and RMB349M shareholder amounts, evidencing this is a long-standing affiliated ecosystem rather than an isolated event [3].

The escalation matters because (i) it is large relative to non-cash cost of revenues (FY25 COGS RMB937M; affiliated purchases of RMB372M imply roughly 40% of cost-of-revenue plus services are sourced from a related party), and (ii) the disclosure says the amount due to that affiliated company at year-end was RMB21.3M, "unsecured and interest free" — i.e., the affiliated party is extending working-capital credit to Yatsen [3]. That is exactly the kind of two-way flow Financial Shenanigans literature flags as worth arm's-length testing. The audit committee's stated duty is to review and approve all related-party transactions; the size of these flows means the audit committee's process is now a load-bearing control, not a procedural one.

Governance breeding ground — founder dominance + post-IPO convertible

Three structural conditions amplify the accounting flags above. First, founder-CEO Jinfeng Huang holds all the Class B super-voting shares, equal to 32.0% of issued shares but 90.4% of aggregate voting power [6]. The roles of Chairman and CEO are not separated [6]. The board has five directors, three independent, two executive — the minimum permissible NYSE configuration, with the founder, CFO, and three independents [6].

Second, as a foreign private issuer, Yatsen discloses executive compensation only in aggregate — RMB9.5M cash and RMB0.5M benefits for the executive group in FY2024 — not individually. Investors cannot test whether CEO or CFO incentive payouts moved with the goodwill bath or the non-GAAP swing because the compensation framework is not visible at named-executive level. This is a transparency limitation rather than a misconduct flag, but it removes one important triangulation channel.

Third, the proposed March 2026 US$120M convertible-note financing was placed with a vehicle affiliated with Trustar Capital and the founder/CEO — a related-party financing rather than a third-party round [4]. The annual report discloses that "a significant shareholder of ours raised objections to, and concerns regarding, the consummation of the transaction" and that closing of the first tranche has not occurred as of the FY25 filing date [4]. The notes carry an aggregate principal of approximately RMB830M with warrants attached — and the precise economics are documented in the Note Purchase Agreement filed as Exhibit 4.10 to the FY25 20-F [3]. An investor underwriting position size should track this transaction's closing terms closely: any change to the warrant strike, conversion price, or note coupon below an independent third-party benchmark would meaningfully shift the related-party-fairness assessment.

Where the clean tests come back clean

It is fair to call out what is working. Revenue-recognition cut-off is well-described — the FY25 critical-audit-matter is inventory, not revenue, and DSO is lower in FY25 (18.8 days) than at any year-end in the sample, which is the opposite of the EM1 pattern [2]. Capex is modest (RMB44-57M annually) and well below depreciation and amortisation, ruling out the CF2 "operating costs disguised as investing" pattern. Borrowings have been negligible, so CF1 (financing inflows mislabelled as operating) does not apply. The auditor — PricewaterhouseCoopers Zhong Tian LLP, engaged since 2019 — has issued unqualified opinions throughout and continues to flag a single CAM per year [13]. Internal control over financial reporting was concluded effective for FY25 by the auditor [14]. And the company has been entirely transparent about its non-GAAP definitions — both the Q4 2024 and Q4 2025 releases disclose the full add-back list and reconciliation [10] [2].

The honest read is: Yatsen is a transparent, audited, US-listed company whose accounting choices are documented and visible, but whose reported earnings improvement story leans heavily on the absence of repeat goodwill baths, on broadening non-GAAP definitions, and on related-party purchase volumes that have outgrown revenue. The substance is checkable; the incentives are pointed in a worrying direction.

What to underwrite next

The four diligence items worth bandwidth between now and the FY2026 20-F:

DR.WU goodwill recoverability. FY24 critical-audit-matter unit; residual goodwill RMB134M of total RMB155M. Read the FY26 critical-audit-matter list first when the annual report is filed [7]. A third Q4 impairment downgrades the grade to Elevated.
Closing of the founder convertible note. US$120M principal in two RMB-denominated tranches with warrants; a significant shareholder has objected to the structure [4]. Track whether the closing terms are amended (e.g., a co-investor brought in, or strike adjusted), whether the founder steps back from the purchaser vehicle, and whether the proceeds are correctly classified in financing activities — not operating — in FY26 cash-flow statements.
Related-party purchase volume. RMB372M in FY25, +RMB87M YoY against RMB905M of revenue growth [3] [2]. FY26 disclosure that materially exceeds the affiliate's normal supplier scale, or that grows faster than COGS, is an upgrade to red on EM2.
Out-of-period adjustments frequency. FY25 logged RMB14.6M in Q4 [5]. A repeat in FY26 — even of similar size — would move EM6 from yellow to red, because pattern is what distinguishes immaterial true-up from systematic smoothing.

How this should affect valuation and sizing: this forensic profile is a position-sizing limiter and a valuation-haircut item, not a thesis breaker. A clean balance sheet (no debt, RMB1.05B of cash + STI), a transparent auditor, and rapidly growing revenue with expanding gross margin keep the business out of the "Elevated" or "High" bucket. But every reported earnings figure should be deflated to acknowledge (i) recurring SBC and acquired-intangible amortisation belong in operating costs, and (ii) the FY25 swing to "non-GAAP profit" was largely the absence of a one-off charge plus broadened add-backs. Treat the underwriting as: this is a business burning roughly RMB100M of operating cash per year on a shrinking war chest, with a founder convertible note pending and a related-party supplier ecosystem worth RMB372M annually that requires standing audit-committee oversight. Margin of safety on multiples should reflect that reality, not the non-GAAP turnaround narrative.

References

A Founder Holds 91% of the Votes — and Just Lent the Company $120M

Yatsen is a founder-controlled vehicle in which the gap between economic ownership and voting control is unusually wide and getting wider, not narrower. Chairman-CEO Jinfeng Huang directs 90.7% of the votes from 34.3% of the economics [1], up from 63.8% of the votes at the November 2020 IPO [2]. Two co-founders have left, dual-class supervoting Class B shares (20 votes each [3]) have aggregated into the CEO's vehicle, and a multi-year share repurchase program has shrunk Class A float, concentrating his vote share further. In March 2026 the CEO put his own pocket on the other side of a $120M convertible-note-and-warrant private placement [4]; the company's largest outside holder, Hillhouse, formally objected and forced a renegotiation before joining the first tranche [5] [6].

Yatsen's people are credentialed and competent — Harvard MBAs, ex-Procter and Gamble, ex-Estée Lauder, ex-Vipshop CFO, ex-Goldman Sachs economist, ex-Sina CFO. The structure they sit inside is not.

Governance Grade

C-

CEO Voting Power

90.7%

CEO Economic Stake

34.3%

Independent Directors

3 of 5

Top alignment concern: The CEO's personal participation in a $120M convertible note and warrant issuance to the company — at a $4.63 ADS conversion price and a 4% IRR repurchase floor [4] — is a related-party financing approved under a board where independent directors sit on the audit committee but cannot outvote the founder. A material shareholder publicly objected before the deal closed [5].

Control vs. alignment — the wedge keeps widening

Yatsen has two share classes: Class A (1 vote) and Class B (20 votes). The 20-vote uplift was inserted immediately prior to the IPO — the prospectus warned investors that Class B would step up from 10 votes per share to 20 votes [3]. All 600,572,880 Class B shares now sit in one entity, Veritas Vision Holding Limited (formerly Slumdunk Holding Limited), of which Jinfeng Huang is sole director [7]. Two co-founders who once held 28% of the votes between them — Yuwen Chen (former COO) and Jianhua Lyu (former CSO) [8] — have exited the company and the cap table; their Class B blocks have either been converted to Class A or consolidated into Huang's vehicle.

The wedge has widened, not narrowed, since the IPO:

At IPO Huang held 25.3% of the economics and 63.8% of the votes [2]. Today he holds 34.3% of the economics and 90.7% of the votes [1]. His vote share rose by 27 percentage points without buying a single new Class B share — it rose because the Class A float shrank under the repurchase program, two co-founders left, and the dual-class structure mechanically amplified everything that remained. A buyback in this structure is not a return of capital to public holders so much as a transfer of voting power to the founder.

The board has formally acknowledged the consequence: Yatsen is a "controlled company" under NYSE rules, which lets it skip the requirement that a majority of directors be independent and the requirement that the nominating and compensation committees be fully independent [9].

The March 2026 self-deal — a CEO who is also the company's largest creditor

On March 11, 2026 Yatsen signed a Note Purchase Agreement with an investment vehicle affiliated with Trustar Capital and Mr. Jinfeng Huang, the Company's founder, Chairman of the Board of Directors and Chief Executive Officer, for ~US$120M of RMB-denominated convertible senior notes plus warrants [4]. The economics, lifted from the subsequent-events note:

No Results

The conversion price is now well above market — the ADS closed at $3.17 on June 18, 2026 versus the $4.63 conversion strike — but the CEO's vehicle has a 4% IRR floor on the principal if conversion is not attractive. That is, the CEO gets a 4% return whatever happens to the stock, with optional upside if the equity recovers. Outside Class A holders sit on the dilution risk and have no floor.

Hillhouse, the largest outside holder at 13.8% economic / 1.9% voting [1], did not accept this quietly. The FY2025 annual report itself flags that "a significant shareholder of ours raised objections to, and concerns regarding, the consummation of the transaction as contemplated under the Note Purchase Agreement, and sought to participate in the transaction" [5]. On the Q1 FY2026 call, Huang confirmed that the first tranche closed on May 21, 2026 "in addition to myself" — i.e., with a new institutional investor (Hillhouse, per the company's own press release) joining the deal [6] [10].

That outcome — a major outside holder having to publicly contest a related-party financing to be included on equal terms — tells you what the board's "independent" majority is and is not. The audit committee, which is supposed to review and approve all related-party transactions [11], let a financing structured around the CEO's pocket reach an executed Note Purchase Agreement before the friction with Hillhouse became public.

Read the convertible deal as a governance test. A controlled-company audit committee approved a financing where the CEO is on both sides of the table. The largest outside shareholder had to publicly object to get in. This is the structural risk Class A holders priced when they bought ADSs — now realized.

The convertible note is the headline-grabbing related party transaction, but it is not the longest-running one. Yatsen has been quietly compounding its purchases from "companies over which we exercise significant control" — chiefly its Cosmax joint venture, Yatsen Biological Technology (Guangzhou) [12], and Guangzhou Intelligent Logistics — at a far faster rate than the business itself has grown.

Yatsen purchased RMB 15.2M of inventories and services from significantly-influenced companies in 2020, growing to RMB 372.0M (US$53.2M) in 2025 — a 24× increase over six years [13] [14]. Revenue over the same period roughly flattened (RMB ~3.5–4.3B). In parallel, in 2022–2024 the company sold inventory worth RMB 11.4M, RMB 20.1M and RMB 10.4M to a company controlled by the CEO personally [15] — small amounts, but the principle is what matters: the CEO is a customer, a supplier-partner, and (now) a creditor.

None of this is necessarily abusive. Cosmax is a legitimate contract manufacturer; supply-chain consolidation through an investee can be defensible economics. But the trend line — 25× growth in related-party purchases over five years, set against persistent operating losses — is one an audit committee should be challenging, not ratifying. The 20-F discloses the totals; it does not disclose whether independent benchmarks were used or whether margins paid to related parties were tested. That gap is itself a disclosure choice.

What management is paid — and what we can't see

Yatsen reports as a foreign private issuer. It discloses an aggregate compensation figure for the executive officer group plus an aggregate figure for independent directors, and individual NEO salary and bonus tables are not required and not disclosed. The reported cash-and-benefits aggregate has run between US$0.4M and US$1.4M for the whole executive officer group across five years:

The all-in cash run-rate for the executive officer group is around US$1.1M in FY2025 (RMB 7.5M cash + RMB 0.3M benefits) plus US$0.2M to all independent directors [16]. That is strikingly small in absolute terms for an NYSE-listed company doing ~RMB 4.3B of revenue. The reported cash compensation has also been mostly falling through the loss-making years, dropping from FY2024 to FY2025 even as the company swung from a RMB 708M to a RMB 81M net loss [17] [16].

The catch — and it is a large catch — is that the real compensation here is equity. The 2018 Share Option Plan capped issuance at 249.2M Class A shares (~12% of basic share count today), and the 2022 Share Incentive Plan adds 1.5% of issued and outstanding shares per year [16]. Independent directors Bonnie Yi Zhang and Jiming Ha each received 653,480-share grants on January 1, 2025 priced at US$0.025 per share, with ten-year exercise terms [18] — penny-strike grants that are effectively restricted-share awards. Newly appointed independent director Alan Hao Zong received a 600,000-share grant at the same US$0.025 strike on the day he joined the board, February 28, 2026 [18].

Penny-strike options to independent directors are common in Chinese ADR governance, but they are not innocuous: a director whose unrealized at-market equity rises in lockstep with management compensation has a different incentive on a related-party transaction vote than a director paid in cash. Combined with the controlled-company status, this matters.

The board — credentialed, formally independent, structurally captured

The board is five people: two executives (Huang, Yang) and three independents (Bonnie Yi Zhang, Jiming Ha, Alan Hao Zong). Chair and CEO are the same person (Huang), there is no lead independent director disclosed, and the founding CEO is also the named administrator of the 2022 Share Incentive Plan [19].

No Results

(Board composition per [20] and [21].)

Two of the three independents have been here from year one (Zhang and Ha joined in 2020–2021 [20]). Sidney Xuande Huang (no relation), the prior audit chair, departed in 2025 and was replaced by Alan Hao Zong in February 2026 — meaningful because Sidney Xuande Huang was the only independent the FY2024 filing called out as an "audit committee financial expert" alongside Bonnie Yi Zhang [22]. The FY2025 filing names only Zhang as the financial expert.

The expertise mix maps onto the actual governance load:

No Results

The matrix is honest but reveals the thinness: only one director (Alan Hao Zong, joined Feb 2026) has direct beauty/consumer-product operating expertise outside of management itself. Chief Scientific Officer Jing Cheng — 17 years at Estée Lauder, ex-VP APAC research and development — sits at the executive level [20] but does not vote on the board.

The structural problem isn't the people, it's the math. With Huang holding 90.7% of votes, the three independents cannot outvote the executive directors on any matter put to shareholders. A controlled-company structure was disclosed at the IPO [23] — but it has tightened, not loosened, in the years since.

Insider behavior — the buyback funds the CEO's increase in control

There is no public-record evidence of Huang or Yang trading ADSs personally on the open market in size; what the disclosures show instead is change at the entity level. Huang's beneficial holding via Veritas Vision / Yellow Bee fell modestly from 644.1M total ordinary shares as of February 28, 2025 [24] to 643.7M as of February 28, 2026 [1] — essentially flat. CFO Donghao Yang's position rose from 67.2M to 82.7M shares over the same window, taking him from 3.7% to 4.4% economic [24] [1] — an additional ~15.4M shares accumulated through option vesting.

Hillhouse, meanwhile, has been trimming: 300.6M shares (16.4%) in FY2024 → 258.5M shares (13.8%) in FY2025 [24] [1]. Banyan Partners, a 4.9% holder in FY2024 [24], is no longer listed among 5%-plus principal shareholders in FY2025 [1]. The cap table is consolidating: outside institutions down, insider stakes (relatively) up. As of February 28, 2025 the company had repurchased 39,781,505 ADSs for an aggregate US$199.9M [25] under the share repurchase program.

That repurchase-driven Class A shrinkage is the mechanism by which Huang's vote share has continued to creep up despite his roughly flat absolute holding.

Litigation and governance overhang

A securities class action filed September 23, 2022 in S.D.N.Y. (Maeshiro v. Yatsen Holding Limited, No. 1:22-cv-08165) alleging the IPO registration statement contained materially false or misleading statements was granted dismissal on July 22, 2024 [26]. Plaintiffs sought leave to file a second amended complaint in August 2024; that motion remained pending in the FY2024 filing — a clean resolution would be a tail-risk reduction.

The other resolved overhang: SEC PCAOB delisting risk has receded — that was a 2021–2023 China-ADR concern that no longer dominates this filing. The company published a 2023 ESG report (per its September 2024 press release), but the corporate-governance scoring those reports rely on cannot fix what the dual-class math has built.

What would move the grade

No Results

The one thing that would most quickly move the verdict in the right direction is straightforward: appoint a Lead Independent Director with the authority to call executive sessions and approve related-party transactions, and publish a related-party-transaction policy with benchmark margins for the Yatsen Biological / Cosmax arrangement. Neither requires changing the dual-class structure. Both would signal the audit committee can act as a brake.

The one thing that would most quickly move it in the wrong direction is equally straightforward: a second tranche of the Trustar/Huang convertible that does not include outside-shareholder participation on equivalent terms.

References

History — A Founder Who Built It, Broke It, and Spent Five Years Rebuilding It

Yatsen IPO'd in November 2020 as China's hottest digitally-native beauty story — Perfect Diary's "disruptive DTC" model, eight brands, gross sales up 363% in 18 months [1] [2]. Within two quarters the founder was conceding on a public earnings call that the team had "moved too fast" [3]. Five years later the company has lost ¥3.0 billion to operating losses, written down its prestige skincare M&A twice, executed a de facto 5-for-1 reverse split to stay listed on the NYSE, and — only in fiscal 2025 — finally turned a non-GAAP profit of ¥8.4 million on ¥4.3 billion of revenue [4]. The story this tab tells is not whether the business is good (the answer is "increasingly"), but whether the founder who built it and then broke it has now earned the right to be trusted to run it for compounders. The verdict — narrowly, conditionally, on probation — is yes.

All financial figures are in renminbi (¥) — Yatsen's reporting currency. Share-price and US$ buyback figures are stated in US dollars. Per-ADS amounts after March 2024 reflect a 1-for-5 ADS-ratio change.

The arc at a glance

FY2025 Revenue (¥M)

4,298

YoY Growth

26.7%

FY2025 Gross Margin

78.2%

FY2025 Non-GAAP Net Income (¥M)

The headline is jagged: revenue grew from ¥5.2B in 2020 to ¥5.8B in 2021, then collapsed 36.5% to ¥3.7B in 2022 [5], and floor-skipped sideways through 2023 (¥3.4B) and 2024 (¥3.4B) before snapping back to ¥4.3B in 2025 [6]. The composition tells you why — color cosmetics (the Perfect Diary cash cow) was cut in half between 2021 and 2022 and never came back, while clinical/premium skincare (Galénic, DR.WU, Eve Lom) climbed from ¥855M to ¥2.28B over the same five years and is now the majority of revenue.

The five years are best read as five chapters. The IPO peak in late 2020; the crack that opened in Q2 2021 within weeks of going public; the collapse in 2022; the broken promise in 2023; the bottom in 2024; the reset in 2025; and the wobble in Q1 2026 that is the open question today.

Chapter 1: The IPO peak — a digitally native DTC darling (Nov 2020)

The original promise, set down in the November 2020 prospectus, was a single coherent thesis: Yatsen had cracked a "disruptive DTC business model" that would let a founder-led platform build "a family of iconic beauty brands" by combining proprietary content, data, and a young-consumer-first product engine [7]. The numbers behind that promise looked extraordinary: gross sales grew from ¥757M in 2018 to ¥3.5B in 2019, a 363.7% increase "or roughly 30 times the growth rate of the broader China beauty industry" [1]. The company priced at $10.50 per ADS on the NYSE on November 19, 2020 and ran into the mid-$20s within months — a market cap above $13 billion at the peak. Color cosmetics was 94% of gross sales in 2020 and Perfect Diary was the hero brand carrying the model [8].

Two things are worth noting about that opening chapter. First, founder Jinfeng Huang built the business himself — he founded Yatsen in 2016, has held the chairman-and-CEO role since inception, and remains in both seats today [9]. There is no inherited quality story here. Whatever the business is, he built it. Second, the IPO prospectus described the company as "China's leading beauty group" leveraging a "digitally native direct-to-customer business model" [8] — language that, four years later, has been quietly cut from the opening of the annual report.

Chapter 2: The crack — moves too fast, then walks them back (mid-2021)

The story bent in Q2 FY2021 — the second public earnings call. Listening to that call now, in light of what came after, the pivot is naked. Revenue was up 53.5% YoY; on the surface a triumph. But inside the script Huang acknowledged that the team had "launched in May" a set of "strategic growth initiatives" to "sharpen our growth model" — translation: management was already, three months after the IPO, restructuring around a recognized problem [10]. When pressed, he conceded directly: "previously, we did move too fast to reallocate our talent into the skincare BU" [3]. On the same call he introduced the framing that would carry the entire next five years — "the path of high-quality, sustainable growth" [10] — and quietly retired the "DTC" language that had carried the IPO.

By Q3 FY2021 (November 2021), Q3 revenue had decelerated to +6% YoY (from +53% the prior quarter). On that call management did three things that signal a corporate story shifting from offense to defense:

Replaced the "premiumize Perfect Diary" headline with the new phrase "a near path to profitability in the medium to long run" [11] — a multi-year hedge.
Announced the company's first share repurchase program — up to US$100 million over 24 months, authorized November 17, 2021 [12].
Asked investors to wait: "investors need to be patient about what we are doing right now" [13].

The stock closed 2021 at $10.75, down 88% from its February peak (both numbers split-adjusted). The "patience" request would eventually take five years to pay off — and as of mid-2026 has not yet been fully repaid in the share price.

Chapter 3: The collapse and the promise that broke (2022–2023)

The 2022 collapse was structural, not COVID. Revenue fell -36.5% YoY (¥5.84B → ¥3.71B) [5], with the color-cosmetics segment cratering from ¥4.87B to ¥2.42B in one year. The zero-COVID policy was a contributor but not the cause — Chinese color cosmetics had simply rotated out of Yatsen's hand as Douyin live-streaming changed the unit economics of building a mass color brand [14]. On the Q4 FY2021 call (March 2022), with the worst quarter still ahead, the founder set down what would become the most consequential — and most broken — public promise of the era:

"…we are expecting to break even on a yearly basis next year. So that is our current goal." [15]

He reaffirmed the same FY2023 break-even target on the Q1 FY2022 call in May 2022, hedged this time on COVID [16]. 2023 came and went. The full-year operating loss for FY2023 was ¥559M; the full-year non-GAAP net loss was approximately ¥296M. The promise was missed by roughly a billion renminbi.

Meanwhile management built the new narrative scaffolding under the wreckage. The "five-year strategic transformation plan" was launched at the start of 2022 and embedded as the official frame in that year's 20-F [17]. The first full-year ESG report was issued in May 2022, the MSCI rating was upgraded to "A," and 47% of the workforce was cut — headcount fell from 3,497 at end-2021 [18] to 1,837 at end-2022 [19]. The board upsized the share repurchase program from $100M to $150M in August 2022 and a NYSE minimum-bid deficiency notice received April 11, 2022 was cured by August 1 of the same year [20].

Then 2023 produced its own concessions:

The first Eve Lom goodwill impairment of ¥354 million was booked in Q4 FY2023 and disclosed on the March 2024 earnings call. Management's own words explained the underlying admission cleanly:

"…amount by which the carrying value of the Eve Lom reporting unit exceeded its fair value based on quantitative goodwill impairment test due to weaker operating results than expected at the time of acquisition." [21]

Eve Lom had been acquired for roughly ¥1.28 billion in March 2021 — including ¥965M of cash consideration and ¥569M of identifiable intangibles [22]. The impairment was the first explicit on-the-record concession that the prestige-skincare M&A strategy had been overpaid for. Same year, Yatsen "strategically phased out" Abby's Choice, its home-grown 2020 mass-skincare brand [23]. New chief scientific officer Jing Cheng — a 17-year Estée Lauder veteran — joined in early 2023 to lead a re-platforming of the company around clinical R&D [24], and the company moved the buyback authorization from $150M to $200M with the term extended through November 19, 2025 [25]. The buyback was no longer an opportunistic capital-return signal; it had become an existential mechanism to keep the share price off the NYSE delisting threshold while the operating business healed.

Chapter 4: The bottom — a reverse split, a second impairment (2024)

By 2023 year-end the share price was at $3.66 (split-adjusted). On November 2, 2023 the NYSE delivered a second non-compliance letter (the prior April 2022 letter had been cured). Management's response in March 2024 was a 1-for-5 ADS ratio change — converting one ADS from four Class A ordinary shares to twenty, which functioned as a 5-for-1 reverse split and immediately pushed the bid price above $1 [26]. The NYSE confirmed compliance on April 10, 2024.

Inside the operating business, 2024 was a holding pattern with two ugly disclosures:

A second goodwill impairment of ¥403.1 million — ¥397.8M against the Eve Lom reporting unit (again) plus a ¥5.3M write-down on a color-cosmetics unit (likely Pink Bear) [27].
Headcount fell to 1,350 — the low of the cycle — from 3,497 at the end of 2021 [28].

Despite the impairment, this was also when the "story" began visibly converging with the cash flows. The Yatsen Global Innovation R&D Center — described by management as "China's first global R&D hub for a national beauty brand" — opened in Shanghai in May 2024 [29]. Q4 FY2024 delivered the first non-GAAP profitable quarter of the rebuild [30]. The team had stopped retreating.

Chapter 5: The reset — skincare crosses the line (2025)

If the story has a vindication chapter, this is it. 2025 was the year management's five-year plan moved from PowerPoint to P&L.

FY2025 Revenue (¥M)

4,298

Gross Margin

78.2%

Skincare Share

53.0%

Revenue grew +26.7% to ¥4.30 billion — the first growth year since 2021 [31]. Skincare revenue grew +63% YoY to ¥2.28 billion and crossed 53.0% of total revenue — clearing the "skincare to exceed at least 50%" target Huang had set on the Q4 FY2022 call [32]. Gross margin reached 78.2%, up from 68.0% in 2022 [33]. Most importantly, the full year delivered ¥8.4 million of non-GAAP net income — a margin of 0.2% but, in absolute terms, the first profitable full year on a non-GAAP basis since the IPO [4].

And the opening line of the FY2025 annual report — the most carefully-edited sentence in any company's disclosure — was rewritten. It now reads:

"Yatsen is a leading China-based beauty group with the vision of becoming a world-class pioneer in beauty innovation." [34]

The "digitally native DTC" framing of 2021 is gone. The strategy section was re-anchored around three explicit pillars, the first of which is now "Driving R&D-led product innovation" — with the disclosure that R&D has consistently been ≥3.0% of revenue since 2022 [35]. Perfect Diary, which had been the entire company in 2020, now occupies a paragraph under a new doctrine called "makeup skintification" [36] — color cosmetics is no longer the headline brand, it is one application of the skincare platform.

Chapter 6: The wobble — and the open question (Q1 FY2026)

The Q4 FY2025 call introduced one new word for the first time. On a March 2026 earnings call, six years into the AI cycle:

"…application of AI in areas such as molecular structure prediction." [37]

The lateness of that introduction is itself a tell. Yatsen had described itself as "AI" and "big-data" enabled in the IPO prospectus four years earlier, then dropped that language entirely during the rebuild, and is now bringing it back exactly as the R&D platform reaches scale. A skeptic would read this as marketing the recovery for the next AI-themed multiple. A constructive reader would read it as a CSO-led R&D function finally having something AI-adjacent worth talking about.

The Q1 FY2026 call (May 2026) delivered the first regression of the new chapter. Revenue grew 22.5% YoY (in-line with guidance) but operating expenses ran ahead of revenue — 89.9% of net revenues, up from 83.2% a year ago [38] — and the company reversed back into a ¥57.3M non-GAAP net loss (5.6% margin), undoing in one quarter the ¥7.1M non-GAAP profit that had been the celebrated milestone of Q1 FY2025 [39]. Management blamed "elevated industry-wide [traffic] acquisition costs on the [Douyin] platform" [40] — the same channel mechanic that broke color cosmetics in 2021–2022, now back biting skincare.

Two weeks later (May 21, 2026) the company closed its first dilutive financing of the historical period — a private placement of convertible notes and warrants [41]. This was the same week the new (and much smaller) $30M repurchase program — authorized in May 2025 [42] — was already burning through capital intended to support the share price. The combination — burning buyback capital while raising new dilutive capital — is hard to reconcile cleanly. The most generous reading is that the founder wanted to add a strategic capital partner to support the rebuild; the less generous reading is that the company needed liquidity and didn't want to say so.

Promises made and promises kept

Across five years of public commentary, the founder made a finite set of public, valuation-relevant commitments. The track record:

No Results

Of ten material commitments, seven were kept (some convincingly beaten), two were clearly broken (the FY2023 break-even promise and the mid-2024 guidance that needed an in-quarter revision), and one is on probation after a single quarter's reversal. Two observations matter more than the score:

Both broken promises were quantitative and public. Management did not try to spin them away — the FY2023 break-even target was simply not mentioned again after Q2 FY2022, and the mid-July 2024 guidance revision was disclosed cleanly on the next call [43]. That is structurally honest behavior. Compare with management teams that simply quietly drop the target and never acknowledge it — Yatsen does not do that.
The buyback was actually completed. Yatsen authorized a $200M program and deployed $202.2M against 40.2 million ADSs through February 2026 [44]. Of total IPO net proceeds, US$499.3M went to share repurchases by year-end 2025 [45] — a figure most public-tech management teams would have left in cash and quietly written press releases about. That is a meaningful credibility signal, especially given the share price never recovered. It also means the buyback was, in aggregate, a destruction of capital at IPO prices — but a real return of capital to shareholders at the prices at which it was actually executed.

Narrative drift — what management stopped saying

The phrases that vanished from the script are as informative as the phrases that arrived. Three are worth pinning:

"DTC" / "digitally native" carried the IPO and was the single most prominent phrase of the prospectus [7]. It vanishes from the script after the Q2 FY2021 call and is no longer in the opening line of the FY2025 annual report. The thesis that justified the IPO multiple is gone.
"Premiumize Perfect Diary" was the central tactic of Q2 FY2021 [46]; by Q3 FY2021 it had been replaced by the buyback announcement. The premiumization tactic never produced a Perfect Diary that could carry the company on its own.
"Break even on a yearly basis next year" [15] was repeated in May 2022 and then dropped. It is the single most important phrase management quietly stopped saying.

Credibility — the verdict

Management credibility score (1–10)

A 5 out of 10 — with the arrow pointing up.

The case for a lower score is straightforward and was real for three years. Founder built the business, built it on a single channel and a single brand, missed the most important quantitative promise he ever made by a billion renminbi, paid roughly ¥1.28 billion for Eve Lom in 2021 and then wrote ¥752 million of that goodwill off in two tranches (2023 and 2024), executed a 5-for-1 reverse split to stay listed, and presided over a 96% drawdown in the share price between February 2021 and March 2024. At the end of FY2023 a fair score for this team would have been a 3.

The case for the arrow pointing up is the FY2025 reset. Every quarterly guide from Q3 FY2023 forward has been met or beaten, sometimes by a large margin (Q2 FY2025 came in at +36.8% against a +2-12% guide). The skincare-majority promise from the Q4 FY2022 call was kept. The non-GAAP profitability target was hit. The buyback was actually executed in full — at value-destructive IPO-era prices, yes, but executed. The Eve Lom impairments were taken honestly when the operating results required them, not delayed by another year of optimism. The CSO from Estée Lauder was hired before the recovery and there is genuine R&D infrastructure behind the "innovation" narrative now (CNAS-accredited lab, Cosmax JV, Hôpital Saint-Louis partnership). The founder did break the business and did then rebuild it — not by waiting for the macro to turn but by amputating brands, halving the workforce, and re-platforming around skincare.

What holds the score at 5 and not 6 are three things:

The Q1 FY2026 reversal into a non-GAAP loss followed by a dilutive convertible-note raise, in the same week the buyback was still drawing down capital, is a credibility-fragile event.
The AI vocabulary added to the Q4 FY2025 narrative is six years late — it reads more like multiple-management than R&D substance.
The chairman and CEO roles remain combined in the founder; an independent chair would meaningfully change the calculus of trusting this team with the next decade of capital allocation, given the post-IPO M&A record.

What the story is now

The story today is no longer "China's leading DTC color cosmetics brand." It is a clinical/premium skincare platform — Galénic + DR.WU + Eve Lom — with Perfect Diary as a profitable but secondary application of that platform under the "makeup skintification" framing. The five-year transformation is over and management is now arguing it has begun the next chapter: an R&D-driven, profit-disciplined, multi-brand operator in the prestige and clinical tier of the Chinese (and increasingly international) beauty market.

A reader should believe the structural transformation is real. The numbers — gross margin 68% → 78%, skincare share 16% → 53%, headcount 3,497 → 1,350 low in 2024 then rebuilt to 1,623 in 2025 [47], R&D infrastructure stood up — are too consistent to be a story. A reader should discount the AI vocabulary and the "world-class pioneer" rhetoric as positioning for the next equity raise rather than as substance. And a reader should watch Q2 FY2026 closely — if the non-GAAP profitability comes back, the story has earned the right to be told as a successful rebuild; if it does not, the convertible note raise will be re-read in retrospect as the moment the rebuild stalled.

The single most important fact about Yatsen in mid-2026 is that the founder who built it and broke it is still running it, and is starting — for the first time since 2021 — to look like he is doing it well. Whether that lasts is the question this tab cannot answer; the answer is in the next four quarters.

References

Financials — what the numbers say

Yatsen reports in Renminbi (RMB / ¥); figures throughout this page are RMB unless explicitly tagged "US\$". USD translations follow Yatsen's own convenience rate of RMB 6.9931 = US\$1.00 used in its FY2025 press release [1].

FY2025 Revenue (¥M)

429,810.0%

▲ 26.7% YoY

Gross Margin

78.2%

Operating Loss (¥M)

-186

Net Loss (¥M)

-92

Cash + ST Investments (¥M)

1,054

Operating Cash Flow (¥M)

-95

Revenue Growth FY25

26.7%

The financial story in one sentence. Yatsen has executed a real strategic pivot — gross margin up 14 percentage points since IPO, FY2025 revenue back to growth at +26.7%, and net loss narrowed 87% [1] — but it has been a cash-burning, equity-funded transformation, with liquidity now down to RMB 1.05 billion (US\$150.7 million) from RMB 2.6 billion two years earlier [1] [2] and operating cash flow still negative every year since 2023 [3]. Q1 2026 results re-opened the loss gap and management raised US\$120 million via convertible notes in May 2026 [4] — a reminder that the turnaround is incomplete and the financing question is now back on the table.

How to read this company

Yatsen is a China-listed-in-the-US beauty group holding two distinct portfolios: Color Cosmetics Brands (Perfect Diary, Little Ondine, Pink Bear) and Skincare Brands (Galénic, DR.WU, Eve Lom) [5]. The financials only make sense if you read them as two businesses moving in opposite directions inside one P&L: Color Cosmetics (anchored by Perfect Diary) collapsed from RMB 4.87 billion in FY2021 to RMB 1.97 billion in FY2023 before stabilising; Skincare grew from RMB 0.86 billion in FY2021 to RMB 2.28 billion in FY2025 — and crossed 53% of revenue in 2025, the first time it has been the larger segment [14]. Every margin, cash-flow and balance-sheet number on this page is the residual of that mix shift.

Three reader notes that recur throughout:

GAAP vs Non-GAAP matters here. Yatsen's GAAP results swing on two goodwill impairments on the Eve Lom reporting unit (RMB 354.0 million in FY2023, RMB 403.1 million in FY2024) and on share-based compensation and intangible amortization from prior acquisitions. Management's non-GAAP series strips these out [6]. Both views are quoted below; non-GAAP is the cleaner read on the operating turnaround.
No debt — but no buffer either. Yatsen carries no interest-bearing debt; total liabilities of RMB 846 million are entirely working-capital and lease items [7]. Resilience is therefore about cash, not interest cover.
ADS arithmetic. Yatsen's NYSE listing trades as ADSs where 1 ADS equals 20 ordinary shares. Per-ADS figures (and the analyst-quoted EPS of US\$0.19 average for FY2025) are 20× the per-ordinary-share line in the financials [8].

The arc — collapse and recovery, in one chart

The post-IPO peak was RMB 5.84 billion in FY2021 — driven by Perfect Diary's heavy performance-marketing model. Revenue then fell 36.5% in a single year to RMB 3.71 billion in FY2022 as Perfect Diary's customer-acquisition economics broke and Yatsen retreated from the offline footprint, closing roughly 130 of its 294 experience stores [9] [10]. Two further years of revenue erosion (around -7.9% in FY2023, -0.6% in FY2024) followed before the +26.7% rebound in FY2025 — the first growth print since 2021 [11] [1].

What is unusual — and the most important fact on this page — is that gross margin expanded every single year through the revenue drawdown, from 64.3% in 2020 to 78.2% in 2025 [10] [12] [11]. That is the signature of a deliberate mix shift — away from low-margin color cosmetics promotion and toward premium and clinical skincare — not a cyclical squeeze. Management has framed the move as a "strategic transformation" since 2022 [5]; the gross-margin chart is the cleanest piece of evidence that the framing is real.

The segment mix — skincare crosses 50%

Color Cosmetics (essentially Perfect Diary) fell 59% from peak to trough (RMB 4.87 billion in FY2021 to RMB 1.97 billion in FY2023) and has stabilised at roughly RMB 2.0 billion — flat in absolute terms for three years [14]. Skincare grew 2.7× in four years (RMB 0.86B to RMB 2.28B), aided by Galénic's anti-aging launches and DR.WU's "skin-renewing" positioning, both highlighted by management as the FY2025 growth engines [13]. For FY2025, Skincare segment loss-from-operations was just RMB 30.7 million on RMB 2.28 billion of revenue — close to break-even — versus a RMB 448.7 million segment loss in FY2024 that included nearly the entire RMB 403.1 million goodwill impairment booked on Eve Lom [14]. Color Cosmetics still ran a RMB 59.4 million segment operating loss [14].

This matters because the bullish thesis lives entirely inside the skincare segment. Skincare delivered 63.5% YoY growth in FY2025 versus just 1.9% for Color Cosmetics [1], and management has explicitly told investors that the path to better net margins runs through skincare's structurally higher gross margins relative to color [15].

Earnings quality — non-GAAP narrowly positive for the first time since IPO

FY2025 hit two milestones in the same year: GAAP net loss narrowed 87% from RMB 710 million to RMB 92 million, and on a non-GAAP basis Yatsen recorded its first net income since IPO — RMB 8.4 million (US\$1.2 million) [1]. The GAAP operating loss compressed from -24.3% of revenue in FY2024 to -4.3% in FY2025 — driven roughly half by the absence of the FY2024 Eve Lom impairment (RMB 403 million) and half by genuine operating leverage as revenue grew 26.7% against more disciplined G&A [11] [16].

The gap between GAAP and non-GAAP is shrinking — roughly RMB 88 million of non-GAAP adjustments in FY2025 versus RMB 697 million in FY2024 — because the recurring add-backs (SBC of RMB 59.0 million, intangible amortization of RMB 42.7 million) are both declining and no impairment was booked [1]. That is the right direction: the quality of the narrowing loss is improving, not just the optics.

A reader caution: management disclosed RMB 14.6 million of prior-period out-of-period adjustments taken in Q4 2025 to correct sales-return and inventory-receipt errors, RMB 7.4 million of which related to prior years [17]. Small in dollar terms relative to consolidated results, but worth knowing when reading the Q4 print.

Cash conversion — still negative, but the gap is closing

The cash story is less flattering than the P&L story. Operating cash flow has been negative for three straight years — RMB -107 million (FY2023), RMB -244 million (FY2024), RMB -95 million (FY2025) — even as net loss narrowed [3]. The FY2024 GAAP loss was huge but operating cash use was relatively limited because RMB 403 million of the loss was a non-cash goodwill impairment; in FY2025 the cash use is closer to the (much smaller) net loss because the non-cash cushion has disappeared.

Within FY2025 operating cash flow, two working-capital headwinds offset the narrower loss: inventories grew by RMB 125.1 million and prepayments and other current assets grew RMB 89.1 million [3]. Both are consistent with a business actively buying inventory for new skincare launches — inventories on the balance sheet rose from RMB 386 million at end-FY2024 to RMB 509 million at end-FY2025 [7] — but they are also the reason free cash flow remains deeply negative even as the income statement approaches break-even.

Capex is not the problem: it has run at RMB 44–59 million annually for three years, just 1.0% of FY2025 revenue [18]. This is a capital-light business — what would change the cash picture is non-GAAP operating income turning solidly positive, not a capex cycle ending. The Q4 2025 transcript shows the CFO explicitly anchoring future margin recovery to (i) faster skincare growth at higher gross margins and (ii) operating leverage on relatively fixed G&A [15].

Balance sheet — no debt, declining cash, shrinking asset base

Liquidity has halved twice over since FY2022. Total cash plus short-term investments fell from RMB 2.59 billion at end-FY2022 to RMB 1.36 billion at end-FY2024 to RMB 1.05 billion (US\$150.7 million) at end-FY2025 [2] [1]. The drivers, in order, are (i) cumulative buybacks of roughly US\$202 million across four authorizations [19], (ii) negative operating cash flow each year since 2023, and (iii) goodwill impairments (non-cash but which signal deteriorating prior acquisitions). FY2025 saw a marked deceleration of all three pressures — buybacks dropped to RMB 111 million from RMB 405.8 million the prior year [20] — so the rate of liquidity decline is now substantially slower.

The balance sheet has no interest-bearing debt at all. Total liabilities are RMB 846 million, consisting of working-capital items (accounts payable RMB 149M, accrued expenses RMB 349M), lease liabilities (RMB 176M short plus long), deferred tax liabilities (RMB 108M), and miscellaneous items — none of which carry interest exposure [7]. The current ratio is 3.6× [21] and management states existing cash is "sufficient to meet our current and anticipated working capital requirements and capital expenditures for at least the next 12 months" [2].

But the shareholders' equity line — and total assets — keep shrinking. Equity fell from RMB 4.72 billion at end-FY2022 to RMB 3.01 billion at end-FY2025 [7]; accumulated deficit reached RMB 8.14 billion — larger than equity itself, because IPO additional paid-in capital is still RMB 12.3 billion [7]. Goodwill has been written down from RMB 857 million (FY2022) to RMB 155 million (FY2024 onwards) [14]. For a beauty group that grew partly by acquisition (Galénic, DR.WU, Eve Lom), this matters: the acquired skincare brands have not earned back their purchase price under U.S. GAAP. Importantly, no impairment indicators were identified at end-FY2025 [22] — but the FY2023 and FY2024 impairments are evidence that management has been willing to mark these down when warranted.

Capital allocation — the buyback story (and the convertible pivot)

Yatsen has run four successive share-repurchase programs since November 2021, totalling US\$200 million of authorisation under the original framework — initially US\$100 million, raised twice (to US\$150 million in August 2022 and to US\$200 million in November 2023) — plus a new US\$30 million authorisation approved on May 16, 2025 [19]. Through February 28, 2026, Yatsen had repurchased 40.2 million ADSs for US\$202.2 million [19].

A buy-side reader should hold two thoughts about that record. First, the buybacks have been price-accretive on the surface — Yatsen has retired a meaningful portion of the ADS float at average prices well below the FY2021 peak. Second, they have been funded entirely out of pre-existing IPO cash, not out of operating cash flow, because operating cash flow has been negative. Returning IPO equity to shareholders while the underlying business is running cash losses is a defensible signal of capital discipline relative to organic-growth misadventures — Yatsen could have spent the cash on more low-return marketing or acquisitions — but it is not the same thing as a sustainably-funded buyback at, say, a mature consumer staple. The Q1 2026 financing now makes that explicit.

The May 2026 financing change. Yatsen completed the first closing of a private placement of convertible notes and warrants totalling approximately US\$120 million (around RMB 829 million at the Q1 2026 reference rate) on May 21, 2026, with participation from Trustar Capital, Hillhouse, and founder/CEO Jinfeng Huang himself [4]. This is the first material external financing since IPO and notably comes after the FY2025 non-GAAP turnaround, not before — i.e. funded from a position of relative choice rather than necessity. Three implications: (i) liquidity effectively roughly doubles, (ii) Yatsen now has interest-bearing convertible debt on its balance sheet for the first time, and (iii) founder participation alongside two name-brand institutional investors is a meaningful inside signal — but the convertible structure also means future dilution upon conversion.

Quarterly trajectory — the Q1 2026 wobble

The quarterly view shows two important wrinkles the annual chart hides. First, Q4 has become the revenue-and-profitability quarter — Q4 2025 delivered RMB 1.38 billion (+20.1% YoY) and RMB 3.0 million of GAAP net income, the first GAAP-profitable quarter since IPO [1]. Selling-and-marketing intensity does spike in Q4 (Singles' Day / Double 11), but operating leverage and skincare mix carried the quarter to break-even.

Second — and the most important number on this page — Q1 2026 stepped back into materially wider losses. Revenue grew 22.5% YoY but operating loss widened from RMB 34 million (Q1 25) to RMB 99 million (Q1 26), with operating-loss margin going from -4.1% to -9.7% [4] [23]. The CFO attributed this to deliberate brand-equity investment behind Galénic, DR.WU and Eve Lom plus higher Douyin traffic-acquisition costs — selling and marketing rose to 72.2% of revenue from 66.4% the prior year [23]. Gross margin continued to expand to 80.2% — a record — so the mix-shift story is intact, but the profitability inflection from FY2025 is not yet sustained on a run-rate basis. The Q2 2026 outlook is RMB 1.20–1.30 billion, +10–20% YoY — a decelerating top-line guide [4].

Peer positioning — and the genuine peer caution

No Results

USD-converted from peer reporting currencies using mid-2026 spot rates from the staged peer dataset; gross margin and growth left blank where not in the peer JSON to avoid misleading single-period reads.

Yatsen is the smallest by market cap in this peer set by an order of magnitude. Its US\$295 million equity value sits below every Chinese A-share peer — Proya alone is roughly 12× larger — and is dwarfed by EL (US\$31B) and L'Oréal (US\$221B equivalent). The relevant operating comparisons are the Chinese A-share peers, all of which run higher revenue, materially higher operating margins, and are GAAP-profitable. Proya reported FY2025 net income of RMB 1.50 billion on RMB 10.6 billion of revenue [24]; Botanee and Jahwa are similarly profitable. Yatsen's gross margin (78.2%) is in the same ballpark as global prestige operators, but its operating-margin gap to A-share peers is the real comparable benchmark — and it is still negative.

A caution the auto-screened peer set raises: EL, L'Oréal and Shiseido are global prestige beauty leaders with very different business models (multi-thousand-product portfolios, owned brick-and-mortar prestige, travel-retail, B2B salon, fragrance). The closer business analogs are Proya, Botanee and Jahwa — all China-based, digitally-led, multi-brand, with mass-to-masstige positioning [25]. The most-cited domestic challenger to Perfect Diary — Florasis / Hua Xi Zi — is private and not in the indexed set.

Standard year-wise statements table

No Results

Sources: FY2025 income-statement, cash-flow and balance-sheet detail confirmed to the FY2025 annual report [3] [14] [2]; FY2020 and FY2021 revenue, gross margin and operating data to the FY2022 annual report [10] [26]; pre-FY2022 cash-flow lines omitted to avoid restated-basis comparisons. Net debt is zero in every year — Yatsen has no interest-bearing debt outstanding through FY2025 [7].

Valuation context

ADS Price (Latest, US$)

$3.18

Mean Analyst Target (US$)

$6.73

FY2026 Rev Growth (consensus)

21.9%

Yatsen's ADSs trade at roughly US\$3.18, with a mean consensus target of US\$6.73 — implying analysts see the equity as materially mispriced, but consensus rests on a thin two-analyst sample. The same dataset shows FY2026 EPS consensus of around US\$0.19 per ADS (essentially the FY2025 print) and FY2027 of around US\$3.78 — but the FY2027 figure is from only two analysts and reflects a step-function profitability assumption that has yet to be earned.

Conventional multiples are difficult to anchor: Yatsen has no GAAP EPS to capitalise (P/E is meaningless on losses), and EV/EBITDA is distorted by negative EBITDA after share-based comp. The cleaner anchors are:

EV/Sales. Equity ≈ US\$295M, cash plus ST investments ≈ US\$151M, no debt → EV ≈ US\$144M. Against US\$614.6 million FY2025 revenue, that is EV/Sales of around 0.24× [1]. For comparison: Proya trades on roughly 2× sales; EL on roughly 2×; L'Oréal on roughly 5×; even the troubled Shiseido on around 0.9×. Yatsen trades at a deep discount to every beauty peer in the set on a sales basis.
Price-to-cash. Equity ≈ US\$295M vs cash plus ST investments of US\$151M means roughly half the equity value is liquid balance sheet.
Price-to-book. Equity book ≈ US\$430M; market cap US\$295M, so P/B around 0.7× — trading below book value.

These data points all point in the same direction: the market is pricing in continued losses and execution risk on the skincare pivot. They do not, by themselves, settle whether the stock is cheap — Yatsen's history of value destruction (RMB 8.1 billion accumulated deficit against RMB 12.3 billion of paid-in capital) [7] is the reason for the discount. Multiple expansion requires proof of sustained non-GAAP profitability — which Q1 2026 failed to extend.

What this all adds up to

Yatsen passes some financial-quality tests and fails others.

Quality of growth. High quality. The 26.7% FY2025 revenue rebound came entirely from skincare at gross margins above 78%, not from a one-time price action or low-margin volume push [1].
Quality of earnings. Mixed. FY2025 non-GAAP net income of RMB 8.4 million is the first positive print since IPO and the GAAP/non-GAAP gap is narrowing — but operating cash flow remains negative because of working-capital build, and Q1 2026 stepped back into wider losses.
Balance-sheet strength. Adequate, not strong. Zero interest-bearing debt and a 3.6× current ratio [21] are real positives; against that, liquidity has fallen about 60% since FY2022 and the May 2026 convertible-note raise demonstrates management's awareness that the runway needed reinforcing.
Returns on capital. Poor on a multi-year basis (ROE -2.7% in FY2025, -23.2% in FY2024) but trending in the right direction. Accumulated deficit exceeds shareholders' equity, which is the financial fingerprint of the prior cash-burn era.
Capital allocation. Disciplined in form, costly in substance. The cumulative US\$202 million of buybacks at low prices is shareholder-friendly in isolation — but funded out of dwindling IPO cash, not earnings. The new convertible reverses the direction.
Valuation. Statistically inexpensive on sales and book metrics, fair-to-rich on FY2025 non-GAAP earnings (P/E on US\$0.19 ADS EPS around 17×), and only attractive if FY2026 follows the FY2025 trajectory rather than the Q1 2026 one.

The first financial metric to watch is non-GAAP operating margin on a trailing-12-month basis. Yatsen got to -2.0% for full-year 2025 [1] but Q1 2026 widened it to -8.3% [4]. The investment debate is whether the FY2025 print or the Q1 2026 print is the better forecast of FY2026. Every other line on this page — cash, equity, accumulated deficit, valuation — is a residual of that one number.

References

Web Research — what the public record adds to the filing thesis

The bottom line. The web mostly confirms what the FY2025 20-F and the most recent quarterlies disclose — Yatsen's skincare-led turnaround is real (FY25 +26.7% revenue, Skincare 53% of mix and +63.5% YoY, first non-GAAP profit year since the IPO bust) — but it adds three thesis-relevant updates that are NOT in the annual report. First, the US$120M founder/Trustar convertible self-deal was rescued from its shareholder objection by Hillhouse — already a 13.8% holder of Class A shares — joining as a co-investor when the first tranche finally closed on May 21, 2026 [1], which both validates and dilutes the "controlled-company self-deal" narrative carried by the People and Forensics tabs. Second, Q1 FY2026 is the first quarter in roughly a year where the turnaround stalled at the margin line — revenue growth decelerated to +22.5%, but operating expenses jumped +32.5%, swinging the company back to a non-GAAP loss (RMB57M vs RMB7M profit a year earlier) [2]. Third, the Maeshiro IPO securities class action (filed Oct 2022) was dismissed with prejudice in July 2025 with no appeal [3] — a cleared overhang that the filings disclose but the market chatter still treats as live. The public-domain news flow contains no other thesis-changing event: no SEC investigation, no auditor change, no short-seller campaign, no insider-selling scandal (the March 2026 "sales" widely reported on aggregator sites are Form 3 initial-ownership filings, not transactions — flagged below). Sell-side coverage is essentially absent; independent analyst sentiment has rotated from "early turnaround" Buys (2023-24) into "fairly valued / convoluted" Holds (2025-26) as the easy doubling already happened.

What you would read instead of this tab in the filings. Skincare segment economics — Business tab; convertible-note dilution math — People tab; Eve Lom impairments and earnings-quality flags — Forensics tab; multi-year quarterly income statement — Numbers tab. This tab adds the post-filing news items, the analyst sentiment thermometer, the dismissed-class-action status, and the data-quality caveat on the March 2026 "insider sale" headlines.

1 — Hillhouse rescues the convertible (May 21, 2026)

Total deal (US$M)

$120

Conversion price (US$/ADS)

$4.63

Hillhouse pre-deal stake

13.8%

Coupon

1.5%

The FY2025 20-F filed April 29, 2026 disclosed that the first tranche of the March 11, 2026 US$120M Note Purchase Agreement with Trustar Capital and CEO Jinfeng Huang had not yet closed, because "a significant shareholder of ours raised objections" and was negotiating to participate [4]. Twenty-two days later, the company announced the first tranche had closed — and identified the objecting shareholder as Hillhouse, which joined Trustar and Huang as a co-investor in the Polaris Veritas vehicle on May 21, 2026 (PR Newswire / Stock Titan 6-K, 2026-05-21). The CEO then framed the closing on the Q1 FY2026 earnings call as "a powerful testament to our shareholders' long-term confidence in Yatsen's strategic direction and future value" [1].

Why this matters more than the filing alone shows. Hillhouse is not a new entrant — it already held 258,521,262 Class A shares (13.8% of issued shares, 1.9% of voting power) as of February 28, 2026 per the FY2025 20-F principal-shareholders table [5]. Doubling down at a US$4.63 conversion price (a 20% premium to the recent VWAP and a ~45% premium to the current US$3.17 ADS) at 1.5% coupon (Stock Titan note-terms summary) is an unusual move for an existing long-only China-strategy holder if the company were viewed as terminal-value-impaired. The Forensics tab flagged the original deal as a "self-deal" governance risk; the web settles the open question the 20-F left hanging — the objection was resolved by inclusion, not by walk-away, and the structure now has a third-party validator on the same terms as the insider.

So-what for the stock. Removes one near-term overhang (deal failure risk) and partially answers the controlled-company critique (an outside institution co-validated the terms). Does not remove the underlying dilution math — if both tranches convert, Polaris Veritas takes roughly US$120M/$4.63 ≈ 26M ADSs plus 10% warrants on top, ~3M+ ADSs net new on a ~95M-ADS float. The CEO's vehicle still gets a 4% IRR floor that outside Class A holders do not.

Priced in? Hillhouse participation was announced May 21, 2026; the stock was ~$3.50 the day before and trades at $3.17 today. The market reaction was negative, suggesting investors read the closing more as "founder needs the money to land" than as "Hillhouse blessing." The validation signal is, on the evidence, not yet priced in.

2 — Q1 FY2026 — the turnaround is intact at the top line, gone at the margin line

No Results

The Q1 FY2026 release confirms the headline narrative — +22.5% revenue, +58.5% skincare, record 80.2% gross margin [6] — but the operating leverage went the wrong way. Operating expenses jumped 32.5% YoY, taking the opex ratio from 83.2% to 89.9%, and the company swung from a small non-GAAP profit (RMB7.1M, +0.9% margin) a year earlier to a non-GAAP loss of RMB57.3M (-5.6% margin) [2]. GAAP net loss widened to RMB61.9M from RMB5.6M. The CFO framed this as "we selectively deployed resources to scale and strengthen our core brands" — i.e. marketing reinvestment for skincare — but the Q2 FY2026 guidance of RMB1.20-1.30B (+10-20%) [7] implies further deceleration from Q1's 22.5%, well below the +47.5% pace of Q3 FY2025.

This is the gap the Bamboo Works May 2025 piece flagged when the CEO "declared turnaround" on Q1 FY2025's RMB7M non-GAAP profit (Bamboo Works, 2025-05-19) — the company's non-GAAP "turnaround" runs through marketing intensity, and the first quarter where that lever was pulled hard again has unwound it.

So-what for the stock. Resets the inevitable bull-case anchor — the FY2025 non-GAAP positive year that the CFO Yang called "a pivotal milestone" [8]. Reinforces the structural critique that Yatsen's gross-margin uplift is mortgaged to a high and inelastic selling-and-marketing line. The next two quarters are the test of whether the FY2025 profit was a budget-cycle phenomenon or a structural rebase.

Priced in? The stock fell from ~$5.85 at end-March 2026 to $3.17 today — a -46% drawdown over the period covering the Q4 FY2025 print, the FY2025 20-F filing, the Q1 FY2026 print, and the convertible closing. Some of the margin disappointment is in the price; the Q2 guide deceleration came at the print itself. Consensus models for FY2026 are not visible (no sell-side coverage on Yahoo / SeekingAlpha shows analyst targets — investingpro lists "fair value undervalued" but no published consensus).

3 — The March 2026 "insider sale" headlines are Form 3 filings, not transactions — caveat

Several stock-aggregator sites (Stockcircle.com, parts of the SimplyWall.St/Yahoo Finance feed) report what looks like a wave of massive insider sales between March 16-18, 2026:

No Results

This is data exhaust, not a wave of insider selling. The matching SEC filings on the YSG docket are Form 3 — Initial Statement of Beneficial Ownership (Stock Titan SEC filings list). A Form 3 is the first filing made when someone becomes a Section 16 reporting person (officer, director, or 10% holder) and merely discloses their existing holdings as of that date — it is not a transaction. Stockcircle's "Sale" categorization is an aggregator artifact, not a fact about insider behavior. The give-away in the data is that founder Huang's reported "sale" of ~294M shares (~US$1.16B) is precisely consistent with the FY2025 20-F's principal-shareholder table disclosing him as holding 643,671,174 shares with 90.7% voting power (Class A + Class B 600.6M) [5] — he did not liquidate a third of his stake in a single day; the Form 3 disclosed a portion of his existing holdings under a new reporting alignment.

So-what for the stock. None — but if a PM sees the Stockcircle screenshot and reads it as a $1.2B founder dump, that is a false red flag that has spread on aggregator sites without correction. Flag and move on. Priced in? Irrelevant — there is no underlying transaction to price.

Aggregator data quality flag. When sourcing Yatsen insider activity, go to the SEC EDGAR docket (form types 3 / 4 / 5) — not third-party screens that fold Form 3 into a "Sale" column. The genuine open-market insider activity ledger on this name is small.

4 — Maeshiro v. Yatsen — dismissed with prejudice, July 2025, no appeal

The most prominent live overhang on Yatsen in 2022-2024 was the Maeshiro v. Yatsen Holding Limited securities class action (S.D.N.Y., No. 1:22-cv-08165), which alleged the November 2020 IPO offering documents and subsequent disclosures concealed that Perfect Diary and Little Ondine cosmetic sales were materially declining at the time of the IPO and through 2021. Multiple investor-firm press releases (Howard G. Smith, Robbins Geller, Levi & Korsinsky) circulated through late 2022.

The FY2025 20-F confirms the matter is closed: defendants' motion to dismiss the amended complaint was granted on July 22, 2024; in July 2025 the court denied leave to amend further and dismissed with prejudice; plaintiffs did not appeal [3]. External web coverage of the resolution is sparse — investor-alert legal sites continue to surface the older 2022 filing notices in search results, which a PM scanning headlines could misread as a live action.

So-what for the stock. A real, fully-resolved litigation overhang. Removes a small probability tail of a damages payout and the management distraction the 20-F itself flags. Should incrementally lift the multiple the market is willing to assign to a foreign private issuer with a China-VIE structure — but only marginally, because the underlying risk factors (HFCAA, VIE, dual-class control) remain. Priced in? Almost certainly — the dismissal was in the public record for ~11 months before today and the stock has moved on multiple other drivers since. Mention as resolved status, not as a thesis driver.

5 — Independent analyst sentiment has rotated to "fairly valued / convoluted"

No major-sell-side broker publishes a covered price target visible on the standard aggregators (Yahoo, SeekingAlpha "Wall Street Ratings", Investing.com). The only published independent-analyst track on Yatsen runs through the SeekingAlpha contributor stream — useful as a sentiment thermometer, not as consensus.

No Results

The arc maps cleanly onto the stock — Buys initiated when the ADS traded around the underlying net cash (mid-2023 through mid-2024), downgraded to Hold once the ADS doubled past $5 (March 2025), and a sustained skeptical voice through the entire 2025 run-up to the high-$8 print and the subsequent collapse. The current $3.17 print sits below the 2023-24 Buy levels on aggregator data, but no analyst has stepped back in to upgrade — silence is itself a signal. The relevant data point for the PM: (SeekingAlpha YSG analysis stream) — last bull thesis is more than two years old; last published view is "Convoluted".

So-what for the stock. Limited sell-side coverage means no visible "consensus" floor and no broker-distribution buying pressure on positive news. The independent sentiment skew is bearish-to-neutral. A non-trivial part of the recent drawdown is sentiment normalization rather than fundamentals. Priced in? Largely — the latest skeptical pieces from late 2025 preceded the FY2025 print upside. The bull case the price is not reflecting is the FY26 evidence of structural margin (vs. budget-cycle margin), which Q1 FY2026 just undermined.

6 — R and D claim — confirmed scale, but contextual: $100M cumulative is not a global-scale moat

The PR Newswire 2026-05-07 release (Yatsen research-and-development, 2026-05-07) cites "approximately US$100 million in research and development since 2020", three research centres (Shanghai, Toulouse, Guangzhou), and "240+ patents". The annual income-statement numbers corroborate this — RMB91.8M to 146.0M per year (US$13-21M) over FY2021-2025 sums to roughly US$80-90M, with FY2025's RMB146.0M the highest year. Research and development intensity has held a steady 3.3-3.9% of revenue, which is above most domestic Chinese masstige peers but well below global prestige operators (L'Oréal at roughly 3.4% of revenue but on a €40B-plus base; Estée Lauder several times this scale).

So-what for the stock. Validates the "science-led beauty" narrative the CEO and Chief Scientific Officer have been pushing in earnings calls — it is real spend, not a slogan. Does not, by itself, build a global moat against Estée Lauder or L'Oréal in China. The research-and-development thesis remains a premium-vs-domestic-peer differentiator, not a premium-vs-global-prestige differentiator. Priced in? Yes — this is the management narrative the bull case already runs through.

7 — Q2 FY2024 guidance cut — a reminder management will mark down when needed

On July 10, 2024 — six weeks before the Q2 FY2024 print — the company issued a rare mid-quarter pre-announcement, "Yatsen Prudently Adjusts Revenue Outlook for the Second Quarter of 2024" [9], citing subdued China beauty consumption. Q2 FY2024 ultimately came in at -7.5% YoY. This is the only voluntary mid-quarter guidance cut in the news ledger over the last three years. The Q2 FY2026 guide of +10-20% (vs. +22.5% just delivered) is not a cut in the same form, but it is a deceleration the market should track to see whether management defends or marks down again ahead of the August print.

So-what for the stock. Calibration data point — management has shown willingness to pre-announce a miss rather than surprise. That is positive for credibility but means the next mid-cycle pre-announcement, if one comes, should be taken at face value.

8 — MSCI ESG A rating retained (2024, two-year stretch)

The 2023 ESG report (published Sept 2024) noted Yatsen retained an MSCI ESG A rating, "the only Chinese beauty company at A for two years running" [10]. Modest positive, relevant only to ESG-mandated capital — and even there, the China-VIE / dual-class structure caps how much benefit flows. Not a thesis driver; mentioned for completeness.

Recent and still-live news — reference layer

The corpus news/ section indexes 31 items spanning 2023-2026; the table below carries every item from the corpus plus the May 21, 2026 Hillhouse-closing news that broke after the news file was compiled. Materiality is graded High where the item would move the thesis or the price, Medium where it adds incremental color, Low where it is calendar/announce-of-announce. Live-thesis items older than 3 months are retained when still relevant.

No Results

Page / 3 15 of 31 records

The cadence is striking. From the IPO-disclosure class action filing in late 2022 to the NYSE-listing crisis (cured by the March 2024 1-for-5 ADS ratio change), to the FY2023 revenue trough (-7.9%), to the Q2 FY2024 guidance cut, to the skincare-led re-acceleration that runs from Q1 FY2025 through Q3 FY2025 (Skincare YoY: +47.7%, +78.7%, +83.2%), and into the Q4 FY2025 non-GAAP profit print — the run from Q1 FY2025 to Q3 FY2025 is the inflection that the late-2025 stock rally to ~$11 priced. The Q1 FY2026 stall plus the convertible saga are what the price has been giving back since.

Specialist-question coverage — what the web closed and what it left open

The Industry, Warren, Quant, Forensic, Sherlock, Historian, Moat, and Competition specialists collectively asked ~63 web-research questions. The answers that change the thesis are promoted above. The remainder live in the reference grid below — short answers with their best web source, the evidence weight, and what (if anything) remains genuinely unresolved.

Governance and people signals (web side)

Founder Jinfeng Huang (b. 1984) — Founder, Chairman, CEO, holds 32.0% of issued shares and 90.4% of voting power as of February 28, 2026 per 20-F [11] (filing-side anchor for the controlled-company structure). No web-side governance controversy, regulatory action, or insider-sale event surfaced in the period. He is the CO-INVESTOR on the convertible notes, not the principal — a self-deal structure that the Forensics tab properly flagged and that Hillhouse now partly neutralizes.
CFO Donghao Yang (b. 1972) — Director and CFO. Frames financial commentary on every release. Q1 FY2026 commentary used "selectively deployed resources" to explain opex growth — a phrasing the PM should track for repetition next quarter.
CSO Jing Cheng (b. 1972) — Chief Scientific Officer; the visible voice on the research-and-development narrative the company is pushing.
External institutional anchors — Hillhouse Entities 13.8% (now plus convertible-deal exposure); ZhenFund Entities 11.9%; HHLR + Hillhouse Investment Management as the operating units [5].
Insider activity (genuine) — the only meaningful web-visible activity in the period is the March 2026 Form 3 filings (aggregator-mislabelled, see Finding 3) and the May 26, 2026 6-K disclosing the convertible-tranche closing. Neither is an open-market sale or buy.
Glassdoor signal (low n) — Singapore office Glassdoor page returns minimal data with one current employee scoring 1.0 across all categories. Sample size too small to be a signal — flagging it only because the dossier surfaced it.

What new external industry evidence the web adds beyond the Industry tab

Tmall + JD + Douyin combined online beauty growth recorded single-digit YoY in Q3 2025 per the CEO citing National Bureau of Statistics in the Q1 FY2026 call. Confirms the structural deceleration in the once-explosive online-beauty channel.
Greater-China weakness reported by Estée Lauder, L'Oréal, Shiseido through 2024-25 is the structural tailwind on which Yatsen's skincare push is gaining share — a confirmation of the Industry tab's read.
Maogeping (HK 1408) IPO'd late 2024 as a directly comparable domestic prestige listed peer. The HK market has, for now, valued Maogeping at a meaningful sales-multiple premium to Yatsen — relevant context if comparing valuations.
NMPA efficacy-testing rules continue to mature but the web flow surfaced no enforcement event in the period that hits Yatsen specifically.

Research queries left open

Spelled out in the separate web-research-claude-queries.json. The two most important remaining unknowns the public record did not settle: (a) whether the Q1 FY2026 opex jump is structural reinvestment or a one-quarter timing item, which only the Q2 FY2026 print (August 2026) resolves; and (b) the timing and terms of the second tranche of the convertible — the press release said "later this year, subject to customary closing conditions". The first answers the margin-quality question; the second answers the residual dilution overhang.

References

Web Watch in One Page

Yatsen's 5-to-10-year underwriting hinges on whether an 80%-gross-margin skincare mix actually reaches the operating line or gets extracted by third-party platforms — and on whether a founder-controlled cap table funded by a related-party convertible delivers value-additive capital allocation. The five watch items below are tuned to that thesis, not to next quarter's headline. Together they cover the single load-bearing variable (Douyin and Tmall traffic-acquisition cost), the live overhang (second tranche of the March 2026 US$120M convertible and the Hillhouse position around it), the most-instructive peer (Proya), the failure mode the M&A playbook has not yet resolved (a third Eve Lom-style goodwill impairment on Galénic, DR.WU, or Eve Lom), and the binary holding-level risk (NMPA cosmetics regulation plus NYSE / HFCAA / VIE structural exposure).

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	Douyin and Tmall traffic-acquisition cost and platform-commerce economics for China beauty	1d	Q1 FY2026 already flipped the operating margin by six points in one quarter on Douyin TAC alone — the long-term thesis is null if S&M intensity does not retrace below 65% of revenue.	Material changes in ByteDance/Douyin and Alibaba/Tmall commission rates, livestream fee structures, or beauty-category ad rates; industry reporting on TAC inflation; Yatsen brand-team commentary on platform costs.
2	Convertible second-tranche close, NDRC certificate, and Hillhouse position movement	1d	The second tranche of the related-party US$120M convertible at the US$4.63 strike is the next governance and dilution resolver; Hillhouse staying in versus trimming is the single most-tracked smart-money signal in the name.	New 13D/13G amendments by Hillhouse; 6-K or press release on tranche closing or repricing; NDRC certificate decision affecting the First Note's maturity extension; any new shareholder objection or proxy event.
3	Galénic, DR.WU, and Eve Lom brand-equity health and third-impairment risk	1w	DR.WU was the FY2024 critical audit matter with US$19M of residual goodwill; a third Eve Lom-style impairment would be the verdict on the entire acquired-skincare M&A playbook, not a one-off.	Distribution wins or losses, declining Tmall/Douyin/RedNote category rank, brand consolidations, audit committee disclosures flagging fair-value sensitivity, or competitive product launches eroding the brands' positioning.
4	Proya Cosmetics competitive moves and Chinese-listed skincare peer signals	1d	Proya runs the same model two years ahead and earns a 17.6% operating margin to Yatsen's negative 4.3% on a similar gross-margin base — the entire bull-bear gap is one peer comparison.	Proya quarterly or annual prints, new brand launches under PROYA, TIMAGE, Off and Relax, Hapsode, or CORRECTORS; Tmall and Douyin category-rank changes; Proya commentary on Douyin traffic costs; M&A or international expansion moves.
5	NMPA cosmetics regulation plus China-ADR, VIE, NYSE, and PCAOB structural risk	1d	NMPA can impose fines of up to thirty times the value of non-compliant product; the ADR has cured two prior NYSE minimum-bid notices, the VIE risk factor warns ADSs may decline significantly in value or become worthless, and HFCAA delisting risk reappears if PCAOB access changes.	NMPA enforcement actions or registration-rule changes; SEC or PCAOB statements on China audit-inspection access; HFCAA-related actions; NYSE continued-listing notices; PRC actions targeting VIE structures.

Why These Five

The set is built around the load-bearing thesis variables the report identifies, not the next quarterly print. Monitor 1 watches the single mechanic that decides whether the skincare mix shift converts to operating profit at all — the report's Failure Mode 1 and the load-bearing watch signal in the long-term scorecard. Monitor 2 covers the live capital-allocation overhang and the smart-money tell that the verdict tab calls the load-bearing governance signal. Monitor 3 watches the M&A playbook variable that produced two consecutive Q4 baths on Eve Lom and that the forensics tab flags as the next likely Q4 impairment area. Monitor 4 watches the peer whose 22-point operating-margin lead is literally the entire upside scenario. Monitor 5 covers the tail-but-binary holding-level risk that has been re-tested twice on listing and remains unresolved on structure. Three near-term prints (Q2 FY2026 on Aug 20, Q3 FY2026 in November, the FY2026 20-F in roughly March 2027) will move the thesis; these five monitors keep the surrounding signal flow live in between.

Where we sit off the market

The one-line variant view. The market is paying $3.17 for a stub-equity it has written off as a sub-scale, founder-captured, cash-burning China ADR with a forced related-party convertible on top — but the same three institutional cohorts that know the business best (founder, Trustar, Hillhouse) wrote checks at $4.63 inside the last sixty days, and the only published FY2026 consensus EPS quietly assumes the FY2025 non-GAAP turn extends through this year — an assumption Q1 FY2026 has already broken. Our variant view sits on top of those two specific gaps: the smart-money mark is a real floor that the tape has not priced, and the FY2026 non-GAAP operating margin path the Street's lone EPS print implies is 3-5pp too high. Both close in the next 6-9 months, and they close in opposite directions — which is why "no edge" is the wrong read, and "lean long, sized after the Q2 print" is the right one.

Variant Strength (0-100)

Consensus Clarity (0-100)

Evidence Strength (0-100)

Months to first resolution

The variant strength is medium, not high, because the disagreement is between two cohorts of believers — the smart-money cohort (founder + Trustar + Hillhouse, all underwriting at $4.63) and the tape (which has marked the stock 46% off in three months) — and the resolution path runs through one earnings print and one 13G/A. Consensus clarity is low-medium on purpose: only one analyst publishes the FY2026 EPS line, no major broker covers the name, independent contributor sentiment has rotated to "Hold/Skeptical/Convoluted" (per the Web Research tab). When the market view is thin, "the market believes X" needs to be earned by signals, not asserted by vibe — and the signals we have all point the same way.

What the market actually believes — the consensus map

The right way to read a thin-consensus name is to triangulate. Six observable signals tell you what the marginal buyer of YSG at $3.17 is underwriting. Five out of six are bearish-to-neutral; the sixth — the lone published price target — is the outlier the variant view leans against.

No Results

Three things to read out of this map. First, the lone published FY2026 EPS line (Row 3) is the one piece of explicit Street math available, and it implies the FY2025 non-GAAP turn extends — which is exactly the assumption Q1 FY2026 already contradicted. Second, the price action (Rows 1 and 2) and the smart-money rotation (Row 5) tell a different consensus story — the marginal seller is treating the convertible as forced and the FY2025 turn as bookkeeping. The variant view has to land between those two: the Street's lone EPS print is too high; the tape's read of the $4.63 mark as forced is too low. Third, the illiquidity overhang (Row 6) is real and limits the variant view's upside even if the disagreement is correct — this is not the kind of disagreement that resolves to a multiple re-rating; it resolves to a basis-points-of-AUM trade, not a sizing call.

Where we disagree with the market — the ledger

Three measurable disagreements survive the five tests (consensus check; evidence check; materiality; resolution path; what would break it). They are ranked by expected value to the PM: the sharpest is the smart-money mark because it carries a 46% gap to the floor a known long-only China specialist (Hillhouse) just paid for the same equity. The margin variant is second because it closes in 62 days on a hard date. The moat / gross-margin variant is third — directionally important but resolves on the FY2026 20-F nine months out.

No Results

Variant 1 — The $4.63 strike is a floor the tape has not priced

Consensus reads the March 11, 2026 Trustar/Huang convertible as a forced related-party self-deal: balance sheet drained from ¥2.59B (FY22) to ¥1.05B (FY25), CEO on both sides of the table, 4% IRR put floor only the founder vehicle gets, and a price tape that traded the stock down -46% over the period spanning the announcement, the FY2025 20-F, and the May 21, 2026 first-tranche close. The frame collapses on one fact: Hillhouse, the largest outside holder at 13.8% Class A and a multi-year long-only China specialist, formally objected to the structure in writing and then forced inclusion on equal terms [1], not the other way around. A holder fighting to participate at $4.63 is a holder marking the equity at $4.63. The People and Verdict tabs make this point in passing; the Variant Perception read is that the smart-money cohort agreement is the most credible third-party endorsement in the public record, and the market has not priced it because the tape conflates "founder needs the money" with "everyone in the deal got the price they wanted."

What would the market have to concede if we are right? That a name a global China-strategy long-only is adding to at $4.63 cannot simultaneously be a name on a permanent $3.17 stub-equity discount. The cleanest disconfirming signal is the next 13G/A — Hillhouse trimming below 10% beneficial ownership flips the smart-money read to forced inclusion; continued accumulation at or above $4.63 confirms it.

Variant 2 — Consensus EPS is 3-5 percentage points of margin too high for FY2026

The lone published FY2026 EPS at RMB1.56 (the data file in data/estimates/analyst_estimates.json from yfinance) is roughly flat to FY2025 — implying the analyst extends the FY2025 -2.0% non-GAAP operating margin into FY2026 even though Q1 FY2026 already printed -8.3%. The CFO did not "guide down" — he said management would "selectively deploy resources" on Douyin in Q2, i.e. spend not retreat [2]. The arithmetic per the Catalysts tab is: even a heroic Q2-Q4 average of -1% non-GAAP OM clears full-year -3%; a more realistic average closer to Q1's run rate puts FY2026 at -4 to -5%. That is a 3-5pp gap to the implicit consensus line, or roughly RMB160-260M of non-GAAP EBIT the Street has not yet acknowledged is missing. The down-revision pressure is already in the EPS-revisions data — 1 downward revision in the last 30 days on the FY2026 line — but the magnitude of the down-revision has not happened yet.

This is the narrowest and most monetizable disagreement of the three because it resolves on a fixed date — Aug 20, 2026, in 62 days — and the price-reaction base rate the Catalysts tab compiled (13.3% average absolute one-day move on earnings, with downside skew on washed-out positioning) frames the magnitude. What would the market have to concede if we are right? That the FY2025 non-GAAP profit was a budget-cycle phenomenon, not a structural rebase — which would close the gap between consensus and the bear read of the Forensics tab.

Variant 3 — The 78%+ gross margin is mix, not moat

A consensus analyst looking at FY2025 sees 78.2% gross margin (peak 80.2% Q1 FY2026), highest in the China-listed beauty peer set, and reads it as evidence of pricing power earning a Proya-style rerate from 0.24x sales toward 2x sales. The Moat tab walked through the disconfirming evidence row by row: both reportable segments lost money at the operating line in the best year of the cycle (Color -¥59M, Skincare -¥31M), Eve Lom has been goodwill-impaired twice for ¥757M cumulative, and the segment-level operating loss persists at a higher gross margin than Proya — which converts 73.3% gross margin to 17.6% operating margin. High gross margin alongside negative segment OI is the fingerprint of mix shift, not a brand moat. Mix shift is mechanical; it stops when skincare crosses ~65-70% of revenue. A brand moat extracts pricing power that flows past S&M; this brand portfolio does not yet do that.

This is the slowest-resolving disagreement of the three — the cleanest test is the FY2026 20-F skincare segment operating profit, in roughly nine months — but it is the variant view that most matters to the multi-year underwriting because it is the entire bridge between EV/Sales 0.24x and EV/Sales 2x. What would the market have to concede if we are right? That the FY2025 gross-margin record is the upper bound, not the leading edge, and the next leg of the multiple has to come from the operating line, not the mix line.

The evidence layer — what each piece does to the variant view

A PM auditing this page should be able to pressure-test the strongest five pieces of evidence. These are the items that actually move probability — not generic facts about the company. Each one carries a fragility column: what would make the evidence misleading, and what condition would prove it.

No Results

The two strongest pieces — the $4.63 strike with Hillhouse's forced inclusion and the Q1 FY2026 margin reversal — are the load-bearing items. Both are 100% from the primary record, both are disclosed within the last 90 days, and both are concrete enough that a PM can put them on a watchlist by close of business. The weakest is Row 6 — the segment-OI test — because it permits two equally plausible reads (FY26 segment OI positive because last-year trajectory continues, or skincare loss widens because Douyin S&M lands on the skincare brands disproportionately). Resolution requires the FY2026 20-F.

How this gets resolved — observable signals on a watchlist

The disagreements are useful only if they close on observable evidence inside the PM's underwriting window. Every signal below has a specific source, a clean validation and refutation condition, and a clock. None of these are "execution improves" or "time will tell."

No Results

The decisive ordering is signals 1 → 2 → 5 — Q2 FY2026 non-GAAP OM in 62 days, then the next Hillhouse 13G/A, then skincare segment OI in the FY2026 20-F. Signals 3 and 4 are confirmatory layers; signal 6 is the tail-event check that breaks the moat thesis if it triggers. A PM only needs to keep signals 1 and 2 on a working watchlist to update the variant view inside the next 90 days.

Red team — what would make us wrong

The variant view is not high-conviction. The honest disconfirming arguments are below, written by the side that wants to kill the thesis, not protect it.

1. The $4.63 mark is not a floor; it is a coupon trade. Hillhouse may be participating at $4.63 because the structure is a 1.5% coupon plus a 4% IRR put floor — i.e., the worst case for the convertible holder is a 4% IRR, with conversion optionality on top. That is not a vote on $4.63 as fair value of the common equity; it is a vote on $4.63 as the strike price of an instrument that returns 4% IRR regardless. A PM long the common at $3.17 does not get the 4% IRR floor — only the dilution. If we are wrong, the floor evaporates on full conversion and the $4.63 mark becomes a ceiling on the next 12 months instead of a floor.

2. Consensus EPS is thin enough to be a coin flip, not a tradeable mispricing. Variant 2 leans on a single published FY2026 EPS line that almost no buyer actually relies on for pricing. The marginal seller at $3.17 is not selling because their model says +0% OM — they are selling because they cannot underwrite the related-party governance structure at any margin. A Q2 beat does not solve that; the stock can stay at $3.17 even if our margin call is right, because the multiple is structurally capped by the controlled-company NYSE exemption and the dual-class wedge. The Forensics tab said this directly: this is a position-sizing limiter and a valuation-haircut item, not a multiple expansion catalyst.

3. Mix shift may be enough — Proya is the wrong comp. Variant 3 leans on the Proya 17.6% OM as the rerate target. Proya has Tmall category leadership (#1 face cream, #1 mask) that Yatsen does not have and cannot manufacture. The variant view confuses "same business model" with "same outcome." If Yatsen tops out at the Shanghai Jahwa economics (62.6% gross margin / 2.7% OM) — also a domestic, multi-brand, profitable peer — then the FY2025 turn IS the structural answer and there is no 22pp gap to close. Mix shift to break-even, not to Proya-grade. Stock is fairly priced.

4. The platform-pricing mechanic was the right call all along. Failure Mode #1 in the Long-Term Thesis tab was correctly named and is now playing out. Q1 FY2026 is not noise — it is the structural answer to "can a sub-scale brand earn operating margin against a platform with visible pricing power?" The variant view that says "the consensus is too high" ignores that the consensus is already too high because it has not yet been re-cut for the platform-pricing reality, and the post-Q2 print may take the consensus down to where the bear case lives — not where the variant view lives. The 3-5pp gap may be the wrong direction.

5. Liquidity overhang dominates everything else. The Technicals tab put the 20-day ADV at ~$0.7M. A 1% position takes 25 trading days to exit at 20% participation. Any variant view that requires the multiple to rerate is structurally hostage to a market-clearing event the float cannot absorb — convertible second-tranche close, FY2026 20-F print, an actual buy program. Without one of those, the variant view is correct but unmonetizable.

Items 1 and 4 are the most serious. Item 1 is the load-bearing argument against Variant 1: the $4.63 is a strike, not a fair-value mark, and the convertible's 4% IRR put floor is exactly what makes Hillhouse's participation not a vote on the common. Item 4 is the load-bearing argument against Variant 2: the down-revision may go past us, not stop where we sit. The variant view survives both objections only if the smart-money cohort actually adds at $4.63 in the open market, not just inside the convertible — which is the signal to watch.

The single watchpoint

The first thing to watch. Q2 FY2026 earnings — Aug 20, 2026, 62 days from now — non-GAAP operating margin and S&M as a percentage of revenue, in that order. The Hillhouse 13G/A and the second-tranche close are the next two; the FY2026 20-F skincare segment OI is the multi-year resolver. Everything else on this page closes on those four signals.

The honest synthesis: this is a "small but real" variant view, not a high-conviction call. The market has marked the stock down for the right operating reasons (Q1 FY2026 margin reversal, FY2025 turn quality, governance friction) and the wrong valuation reason (the smart-money mark sits 46% above spot and is corroborated by a known long-only China specialist that actively demanded inclusion). The right PM action is to keep the position small until Q2 FY2026 resolves the lone-analyst EPS gap, then size on the Hillhouse 13G/A path. The wrong action is to underwrite the multiple to Proya. The wrongest action is to read the $4.63 strike as evidence of fair value without separately watching the $3.17 to $4.63 closing path.

References

Liquidity & Technical

YSG is a sub-$400M ADS with $0.7M of average daily dollar volume, ~6.9% median daily range, and a regime where the founder controls 90.7% of votes while strategic holders own another ~26% of economic interest — so the traded float that a fund can actually source is a small fraction of the headline market cap. The price trades 37% below its 200-day, in a fresh death-cross regime confirmed on 2025-12-08, with a one-month bounce of +36% that is countertrend inside a one-year drawdown of −63.6% and a five-year drawdown of −93.7%. The implementation answer is short: this is a specialist book name, not a sized position, and any constructive view depends on reclaiming $5.00 (the 200-day) before pressing.

Stance — bearish, six-month horizon. Primary downtrend intact (price −37% vs 200d, death cross 2025-12-08), structural overhang from a pending ~$120M convertible-note placement that a major shareholder is contesting, and a strategic holder (Hillhouse) that trimmed from 16.4% to 13.8% over the last fiscal year. Bull invalidation: a daily close above $5.00 (reclaim of the 200-day SMA). Bear invalidation: a daily close below $2.15 (the 52-week low and within 11% of the all-time low at $1.94).

Last Close (USD)

$3.17

Price vs 200d (pp)

-37.1

RSI(14)

52.1

Position in 52w Range

10.9%

1-Year Return (%)

-63.6%

30d Realized Vol (%)

111.5%

Liquidity is the constraint — and the headline ADV overstates it

YSG's 20-day average dollar volume is $0.73M; the 60-day average has been $0.47M. A fund running typical 10–20% participation can absorb only about $378K–$755K of stock over a full five-day window — roughly 0.10–0.20% of market cap. That is enough to initiate a tracking position; it is not enough to size one. Exiting a 1%-of-market-cap holding takes 25 trading days at 20% ADV and 50 days at 10% ADV; a 2% position double those.

20-day ADV (USD '000)

$727

5-day capacity @20% ADV (USD '000)

$755

Fund AUM supporting 5% position (USD M)

$15.1

Days to exit 1% mcap @20% ADV

Median Daily Range (%)

6.9%

60-day ADV (USD '000)

$475

No Results

Then reconcile against the filing-disclosed float. Yatsen runs a dual-class structure where Class A ordinary shares carry one vote and Class B shares carry twenty votes per share, and each ADS represents twenty Class A ordinary shares [1]. As of February 28, 2026, founder/CEO Jinfeng Huang beneficially owned 643,671,174 ordinary shares (34.3% economic, 90.7% of voting power) via Veritas Vision Holding and Yellow Bee Limited; Hillhouse Entities held 258,521,262 Class A shares (13.8%); ZhenFund Entities held 222,868,921 (11.9%); and directors and executive officers as a group held 38.9% economic and 91.3% voting [2]. NYSE classifies Yatsen as a "controlled company" because the founder holds more than 50% of total voting power [3]. Of 1,276,735,163 Class A and 600,572,880 Class B shares outstanding, founder + Hillhouse + ZhenFund represent ~60% of beneficial economic ownership locked in long-dated strategic hands [2]. The headline ADV is not constrained by absolute share count — it is constrained by the fact that the non-locked float is a fraction of what total ADSs outstanding would suggest.

The structural overhangs on top of that base:

Buyback that has slowed. The 2021–2025 repurchase programs ran from an initial $100.0M authorization (November 17, 2021) through expansions to $150.0M and $200.0M (August 2022 and November 2023), retiring 40.2 million ADSs for $202.2 million by February 28, 2026 [4]. The replacement program approved May 16, 2025 is only $30.0M over 24 months — a meaningful step down in bid support [4].
Pending dilutive placement. On March 11, 2026, Yatsen signed a Note Purchase Agreement for RMB-denominated convertible senior notes equivalent to ~US$120 million plus warrants with a purchaser affiliated with Trustar Capital and the founder, in two tranches; a significant shareholder raised objections, the first tranche has not closed, and discussions remain ongoing [5]. A $120M placement is roughly 32% of market cap at the current $377M — material future supply that should be cleared before sizing up.
Strategic holder selling. Hillhouse held 300,560,602 Class A shares (16.4%) as of February 28, 2025 [6] and 258,521,262 (13.8%) as of February 28, 2026 [2] — a net reduction of ~42 million Class A shares, or roughly 2.1 million ADS-equivalents trimmed over twelve months. That is ~3× the 20-day ADV in ADS terms — an ongoing supply pressure that the recovering buyback cannot fully offset.

Liquidity verdict: Illiquid / specialist only. Headline 20-day ADV of $0.73M and a 6.9% median daily range already put YSG outside normal institutional participation limits. Layer on ~60% of economics held by founder, Hillhouse, and ZhenFund [2], an ~$120M pending convertible that is ~32% of the current market cap [5], and a slowing buyback authorization (from $200M cumulative to a fresh $30M) [4], and this is a name where a fund cannot meaningfully build or exit a position without becoming the market. Best executed in primary-issue blocks, not the open tape.

Trend and regime — sub-200d, in a fresh death-cross window

The picture is unambiguous. Yatsen listed on the NYSE on November 19, 2020 at the top of the post-COVID China-ADR cycle [7]; price marked an all-time high of $127.35 in early 2021 and has not retraced anywhere near it since. The chart reads as: a long bear from 2021 into 2024, a counter-trend rally from March 2024 lows that peaked above $11 in June–August 2025 (the catalyst was a sharp earnings recovery and short squeeze around Q1 FY2025 results), then a fast collapse from $9 to under $4 in two months on growing supply concerns. The latest confirmation is the 50-day-below-200-day death cross dated 2025-12-08, the third in three years (prior death crosses 2024-07-08 and 2025-02-28 each preceded further weakness, while the 2025-03-19 golden cross did mark the bull leg).

ADS price is dependent on the share ratio: on March 18, 2024, Yatsen effected an ADS ratio change from 1 ADS = 4 Class A shares to 1 ADS = 20 Class A shares — a 5× implicit consolidation undertaken to cure an NYSE listing-price deficiency that ran from November 2, 2023 through April 10, 2024 [7] [1]. The price history above reflects the post-ratio-change basis throughout. The earlier April 2022 NYSE deficiency notice was cured by August 2022 via the share-repurchase support program [7]. Two listing-compliance events in four years frame why the buyback authorization has been such a central instrument of capital policy — and why a step down from $200M cumulative authorization to $30M [4] is technically meaningful.

Last Close

$3.17

50-day SMA

$2.99

200-day SMA

$5.05

52-Week High

$11.57

52-Week Low

$2.15

Most Recent Death Cross (50d/200d)

2025-12-08

Volume and sponsorship — episodic, with two negative-day spikes for every positive

Average daily share volume has been drifting lower for two years and is now under 250K ADSs/day. Monthly volume profile shows the structural truth: the post-March-2024 ratio change reset turnover to a thinner base, the June 2025 results-driven rally pulled in 900K+ daily volume for a single month, and the December 2025 capitulation came on roughly 240K average — selling on falling volume rather than a forced liquidation panic.

The volume-spike days reinforce that volume in YSG mostly arrives on bad news. Six of the ten largest volume-spike sessions since 2022 closed with double-digit moves, and four of the six were drops greater than 12%.

No Results

The June 2025 cluster (June 9, 10, 11, 25) corresponds to the period in which YSG rallied from the mid-$5s to above $11 — a four-day window of forced re-rating volume that more than doubled the stock and remains the largest sustained positive-volume episode in the series. The episode is not catalysed in the corpus to a single named event; the corpus does not contain a presentation or transcript matched to those exact dates, so I do not attribute the move beyond observing it was the post-Q1 FY2025 results window. The 2023-11-20 13.4× spike with an 18.9% decline maps to the November 2023 NYSE deficiency-notification window [7].

Momentum — flat-to-mildly-positive, but inside a downtrend

After collapsing into a December 2025 low (RSI 26.9, MACD histogram nearly zero), short-term momentum has retraced to neutral: RSI(14) is 52.1, the MACD line ($0.10) sits just above signal ($0.07), and histogram is +0.027 — bullish, but flat. The same posture preceded the April 2026 retracement to $2.91, and the August 2025 momentum reset preceded the October–December collapse. The interpretation is that monthly RSI/MACD have lost their predictive force in this regime; the 50/200 cross dominates.

The trailing-return profile makes the bounce-vs-trend tension explicit:

The realized-volatility regime is the second-order risk. 30-day realized vol is 111.5% — above the 10-year 80th-percentile band of 96%, and well above the 50th percentile of 77%. ATR(14) is $0.30 against a $3.17 price, so a one-σ daily move is roughly 9.5%. For execution this means a 5%-of-position trade can move price more than the trader's spread budget on any given day; for risk management it means a 6-month VaR sized off historical vol will materially exceed standard-cap assumptions.

Relative strength — absolute decline, benchmark series unavailable

The technicals data manifest lists SPY as the intended broad-market benchmark and "no sector ETF" with an empty peer basket; the relative-performance file ships the YSG rebased series but the benchmark series itself is empty, so a literal (YSG − benchmark) curve is not available here. What is available: YSG rebased to 100.0 on 2023-06-30, ending at 64.8 on 2026-06-18 — a 35% absolute decline over the three-year window, with a parabolic round-trip through ~225 in mid-2025. By inspection against any normalized US benchmark in the same window, YSG underperformed materially; the magnitude cannot be quantified from the staged data alone.

Technical scorecard

No Results

Stance — bearish, six-month horizon

Verdict: bearish for the next 3–6 months. The price action says what the fundamentals already imply: the rally to $11+ in summer 2025 was a sentiment-driven re-rating that the bond market did not validate (Yatsen had to negotiate a $120M convertible at the founder's own facilitation by March 2026 [5]), the trend regime has reverted to its 2021–2024 default of price below a falling 200-day, and the buyback authorization has stepped down from $200M cumulative to $30M [4] — meaning the marginal bid is weaker than for any of the previous three drawdowns.

Levels to act on:

Bull invalidation: $5.00 — a daily close above the 200-day SMA, currently at $5.05. This would also clear the broken support of $4.50, the Bollinger upper band ($3.73), and the early-2026 trading range top ($4.45). Reclaiming $5 is the first signal that the death-cross regime has aborted.
Bear invalidation: $2.15 — the 52-week low. Below that, the next reference is the all-time low at $1.94 (intra-day basis) and a likely retest of the listing-deficiency threshold of $1.00.
Trigger for any action: the convertible-note closing or its abandonment [5]. Until the Trustar note is resolved, the implied potential dilution (~$120M on a $377M cap) is an unpriceable supply overhang that should keep any sizing under specialist-book limits.

Implementation answer: liquidity is the constraint. The action is avoid for any fund running normal participation limits; watchlist for a specialist book that can transact in negotiated blocks. Even a constructive view of the fundamental turnaround should be expressed via the convertible (if available on equal terms) rather than through tape buying — five-day capacity at 20% ADV is only 0.20% of market cap [2] [4].

References

Short Interest & Thesis

Official short-interest position data for the YSG ADRs is not staged in this run — the data step ran in partial status, flagging that no deterministic public short-interest source is configured for this market and that staging produced zero rows for reported short interest, short-sale volume, public net-short disclosures, borrow pressure, and peer context. Without those numbers, no defensible statement about reported positioning, days-to-cover, or borrow tightness is available. What is decision-useful is the thesis substance the primary record itself surfaces: Yatsen explicitly carries a "Techniques employed by short sellers may drive down the market price of our ADSs" risk factor [1], it has twice been below the NYSE US$1.00 minimum-bid threshold and cured both times — most recently by changing its ADR ratio [2], it is a VIE-structured China issuer under HFCAA [3], the ADRs have lost roughly 96% of value since IPO, and a US$120 million convertible-notes + warrants deal signed March 11, 2026 with a related-party purchaser is now creating a fresh dilution and governance overhang [4]. For a PM, the right read is: positioning is unmeasured, but thesis risk is structurally elevated and the institutional float is small, so this is a "thesis-driven, not crowding-driven" short setup.

Data quality and source classification

No Results

The classification guardrail printed in the staged latest.json reinforces that any later-arriving short-sale-volume series must not be used as a substitute for reported short interest; this page does not assume any positioning level.

The price tape — context for any short setup

Last close (US$/ADS, 2026-06-18)

$3.17

Drawdown vs IPO ($92 on 2020-11-19)

-96.5%

ADV (90d, ADS)

151,597

52-week low (US$/ADS)

$2.15

The ADRs are down roughly 96% from the November 2020 IPO debut at $92, and trade near the recent 52-week low of $2.15. Importantly the chart is not split-adjusted on a like-for-like basis: the company changed the ADR-to-ordinary ratio from 1 ADS = 4 Class A to 1 ADS = 20 Class A effective March 18, 2024 [5], a 5× quasi-reverse split executed explicitly to cure NYSE minimum-bid non-compliance [2]. On an unadjusted, pre-ratio basis the equity has effectively been a sub-$1 stub for most of its public life. A 90-day ADV of ~152k ADS at ~$3 equals roughly US$0.5 million of dollar-volume per day — institutional liquidity is thin, and any non-trivial short position would be slow to build or cover.

The disclosed short-thesis ledger

No public short-seller report is indexed in the corpus and the only securities class action against the company — Maeshiro v. Yatsen Holding Limited (S.D.N.Y., No. 1:22-cv-08165), challenging the November 2020 IPO disclosures — was dismissed with prejudice in July 2025 with no appeal [6]. The thesis ledger below is therefore framed not from external campaigns but from issues the company itself has placed in its principal-risk summary, the disclosure that proves the issue, and the company's own framing.

No Results

Each row is anchored to a primary-record page: short sellers as a risk-factor class [1]; VIE-structure consequences ("ADSs may decline significantly in value or become worthless") summarised in the principal-risk block [7]; HFCAA / PCAOB history [3]; the two NYSE non-compliance episodes and the cure mechanics [2]; the net-loss history [8] and negative-operating-cash-flow disclosure [4]; the new convertible-note/warrant deal and shareholder objection [4]; the dual-class voting concentration [9]; and the cash-flow dependency on PRC intercompany flows [10]. The same short-seller risk factor existed verbatim in the FY2024 20-F, so this is not a new disclosure [11].

Capital-structure stress — the substance shorts would lean on

Accumulated deficit, 2025YE (RMB M)

-8,142

Cash + ST investments, 2025YE (RMB M)

1,051

Pending convertible-note size (US$M)

$120

Cumulative repurchases through Feb 28, 2026 (US$M)

$202

The accumulated deficit of RMB8,141.5 million (US$1.16 billion) at 2025YE is itself disclosed on the consolidated balance sheet [12] — the equity has been net-loss-making every reported year. 2025 is a meaningful turn (net loss narrowed to RMB92.4M; non-GAAP net income of RMB8.4M for the full year; Q4 was GAAP-positive) [13], but cash and short-term investments fell to RMB1.05 billion (US$150.7M) at 2025YE from RMB1.36 billion a year earlier [14] — the same balance-sheet drain that motivated the new convertible-note financing. The 40.2 million ADSs / US$202.2 million repurchased through February 28, 2026 (under the 2021-program-as-amended plus the May 2025 US$30M program) [15] tightened the float against the same cash pool.

The single most current piece of capital-structure news is the March 11, 2026 Note Purchase Agreement: US$120 million of RMB-denominated convertible senior notes in two equal tranches plus warrants on Class A shares, with Polaris Veritas Investment Limited (affiliated with Trustar Capital and CEO Jinfeng Huang) as purchaser [4]; the underlying agreement is the convertible note purchase agreement signed with Polaris Veritas [16]. The 10-K then discloses that a "significant shareholder" of Yatsen has formally objected to, and sought to participate in, that transaction, and that the company is in active communications with both parties [4]. Management confirmed on the Q1 FY2026 call that the private placement of convertible notes and warrants completed on May 21, 2026 with new institutional participation [17]. The net read: this is a related-party-tinged, contested, dilutive financing on a stub-equity that is the exact pattern short-thesis writers tend to attack — but the 10-K disclosure path is at least clean.

Float, ADV and what crowding would look like

ADS-equivalent share count (count)

93,861,802

90-day ADV (ADS)

151,597

Founder beneficial ownership

34.3%

Founder voting power

90.7%

As of December 31, 2025 there were 1,276,663,163 Class A and 600,572,880 Class B ordinary shares outstanding (total 1,877,236,043; ADS-equivalents ≈ 93.9 million) [18], with another 819,865,720 Class A shares held in treasury or reserved for awards (effectively out of the float) [19]. Founder/CEO Jinfeng Huang beneficially owns 34.3% of total ordinary shares and controls 90.7% of voting power [19], so the non-insider float is ~61.7 million ADS-equivalents and 90-day ADV is ~152k ADS. The arithmetic alone says that without staged short interest no "days-to-cover" number is defensible, but the corresponding orders of magnitude — sub-100M ADS-equivalent float, ~$0.5M/day of dollar-volume — mean any non-trivial outright short position would mechanically take a long time to cover into this tape. That is a positioning risk PMs should size for, even though we cannot quantify the actual short-interest level today.

What is not in evidence — and the limitations that matter

No Results

The single most consequential gap on this page is the absence of reported short interest. If a downstream user wants a positioning view, they should pull NYSE/FINRA bi-monthly short-interest filings for YSG directly, plus an SBL/borrow-cost feed, before sizing any "squeeze" or "crowded short" narrative. Nothing on this page should be read as evidence that YSG is or is not crowded short.

Bottom-line PM read

For an institutional book, the right framing is:

Positioning is unmeasured. Thesis substance is structurally elevated but already extensively priced — the ADRs are a stub-equity that has lost ~96% of value since IPO and trades at a price level only sustained by a 5× ADR-ratio change executed to cure NYSE minimum-bid notices. The next catalyst the page can identify is the closing impact and shareholder-litigation risk around the contested March 2026 Trustar/Huang convertible-note + warrants placement, not a public short campaign.

A change-of-mind on this page would come from any of: (i) a staged reported-short-interest series showing % float materially above peers; (ii) a credible new short-seller report against YSG specifically; (iii) renewed NYSE minimum-bid non-compliance or a PCAOB access reversal; (iv) shareholder litigation around the new convertible-note placement; or (v) borrow fee / utilization data indicating hard-to-borrow status.

References

Generated Jun 19, 2026 10:16 UTC